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Abstract
Discovering Novel Regulators of Nucleolar Form and Function
Lisa Ogawa McLean
2021

Nucleoli are dynamic nuclear condensates in eukaryotic cells that originate
through ribosome biogenesis at loci that harbor the ribosomal DNA. These loci are
known as nucleolar organizer regions and there are 10 in a human diploid genome. While
there are 10 nucleolar organizer regions however, the number of nucleoli observed in
cells is variable. Furthermore, changes in number are associated with disease, with
increased numbers and size common in aggressive cancers. In the near-diploid human
breast epithelial cell line, MCF10A, the most frequently observed number of nucleoli is
2-3 per cell. While ribosome biogenesis is an essential biological process that is common
among all life forms, studies that elaborate on the complexities of ribosome biogenesis in
higher eukaryotes, like humans, are few. In this dissertation, to identify novel regulators
of ribosome biogenesis in higher eukaryotes, I used quantitative imaging of MCF10A
cells to perform a high-throughput siRNA screen for proteins that, when depleted,
increase the percentage of nuclei with ≥5 nucleoli. Unexpectedly, this screening approach
led to the identification of proteins associated with the cell cycle. Functional analysis on a
subset of hits further revealed not only proteins required for progression through S and
G2/M phase, but also proteins required explicitly for the regulation of RNA polymerase I
transcription and protein synthesis. Thus, results from this screen for increased nucleolar
number highlight the significance of the nucleolus in human cell cycle regulation, linking
RNA polymerase I transcription to cell cycle progression.

i

In this dissertation, I also applied this high-throughput screening approach to
cancer drug discovery. Because ribosome biogenesis is essential for cell growth and is
linked to the pathogenesis of cancer, targeting the nucleolus has become an attractive
target for the development of novel therapies. Screening a library of ~4,000 FDAapproved drugs revealed over 100 compounds that regulate nucleolar number, with
antineoplastic agents being the most common identified. Expanding the search to a
library of ~25,000 novel, synthetic compounds also revealed additional regulators of
nucleolar number that are structurally distinct from the FDA-approved drugs and harbor
promise as putative new cancer therapies. The discoveries described herein broaden our
understanding of nucleolar biology in higher eukaryotes and will provide a foundation for
the development of novel and more effective therapeutics for the treatment of cancer.
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Chapter 1

Ribosome biogenesis, the nucleolus, and disease
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INTRODUCTION
The nucleolus has fascinated scientists since it was first observed in the eighteenth
century by bright-field microscopy. While scientists had studied this “nucleus within a
nucleus” throughout the nineteenth century, these studies were largely observational and
the function of this discernible nuclear body remained a mystery until the mid-1900s
(Montgomery Jr., 1898; Pederson, 2011; Raška et al., 2006). An early discovery that
contributed to the advancement of our current understanding of nucleolar function was
that the nucleolus is associated with a specific chromosomal site (McClintock, 1934). It
was not until after the discovery of the ribosome in the 1950s (Palade 1955), however,
that the function of the nucleolus was finally ascertained. Here, several studies
contributed to this landmark discovery, including one that found that Xenopus embryos
lacking a nucleolus also failed to synthesize ribosomal RNA [rRNA; (Brown and
Gurdon, 1964)]. Other studies concluded that RNA in the nucleolus was identical to the
rRNA in the cytoplasm and hybridized specifically to repeat DNA loci within the
nucleolus (Birnstiel et al., 1963; Chipchase and Birnstiel, 1963; Ritossa and Spiegelman,
1965). Thus, these discoveries and others during this same period began the decades of
research that have gone towards understanding how ribosomes are synthesized within the
eukaryotic nucleolus (Pederson, 2011; Raška et al., 2006). Today, it is well-established
that the nucleolus is a dynamic, subnuclear compartment in which the essential process of
ribosome biogenesis takes place.
Ribosome biogenesis is a modular process in which the ribosome, a megadalton
cytoplasmic ribozyme, is synthesized and assembled as two distinct subunits comprised
of RNA and protein. In eukaryotic organisms, the biogenesis of ribosomes initiates in
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large membraneless nuclear organelles known as nucleoli (Figure 1-1). Nucleoli form
around tandemly arrayed ribosomal DNA (rDNA) loci, also known as nucleolar organizer
regions (NOR), upon initiation of transcription by RNA polymerase I (RNAPI)
(Bersaglieri and Santoro, 2019; Grob et al., 2014; Hernandez-Verdun, 2011; McClintock,
1934; Potapova and Gerton, 2019). In mammals, the products of RNAPI transcription are
precursor rRNAs (pre-rRNA) that harbor 3 of the 4 mature rRNA species (18S, 5.8S, and
28S), along with external and internal transcribed spacer sequences that are removed by
numerous accessory factors (Aubert et al., 2018; Henras et al., 2015). The 18S is
assembled into the small subunit of the ribosome (SSU; 40S) and the 5.8S and 28S are
assembled into the large subunit of the ribosome (LSU; 60S), along with the RNA
polymerase III-transcribed 5S rRNA from an extra-nucleolar locus. Additionally, prerRNAs undergo nucleotide modification guided by small nucleolar RNAs (snoRNA) and
subunit assembly with the ~80 RNA polymerase II-transcribed SSU and LSU ribosomal
proteins [r-proteins; (Bassler and Hurt, 2019; Kiss, 2002)]. As a consequence of these
functions, nucleoli exhibit a tripartite substructure when observed by electron microscopy
comprising a (1) fibrillar center (FC), (2) dense fibrillar component (DFC), and a (3)
granular component (GC), each associated with different steps in ribosome biogenesis
(Brinkley 1965; Pederson, 2011; Sugihara and Yasuzumi, 1970). Thus, while scientists
have observed and studied this large and charismatic organelle for centuries, advances in
microscopy and the development of molecular tools have led to a comprehensive
understanding of nucleolar form and function, and continues to reveal novel complexities
of ribosome biogenesis and its connection to human disease.
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This dissertation will focus on several novel discoveries I have made surrounding
nucleolar form and function in higher eukaryotes. The nucleolar function of ribosome
biogenesis is an essential biological process that is common among all life forms and can
therefore be studied in any number of model systems. As such, many of the early studies
to define the process and factors involved were carried out in the single-celled budding
yeast, Saccharomyces cerevisiae (Woolford and Baserga, 2013). While studies in S.
cerevisiae have established a solid foundation of how ribosomes are synthesized in
eukaryotic organisms, they are unable to probe any added layers of regulation that may
occur in more complex, multicellular organisms, like humans. Here, I asked whether
novel factors governing ribosome biogenesis could be identified by investigating
regulators of nucleolar number in the human breast epithelial cell line, MCF10A. In
Chapter 1, I provide the necessary background for the research presented in the remaining
chapters. In Chapter 2, I report on the results from a genome-wide small interfering RNA
(siRNA) screen that was carried out to identify proteins that, when depleted, cause an
increase in the number of nucleoli per nucleus. In Chapter 3, I tested several proteins
identified in the siRNA screen for functional roles in ribosome biogenesis. In Chapter 4, I
adapted our screening approach to screen for small molecule regulators of nucleolar
number and to identify putative new nucleolus-targeting drugs for the treatment of
cancer. In Chapter 5, I conclude by sharing my current perspective on the field of
nucleolar biology and ribosome biogenesis and suggest future research directions
stemming from this dissertation. Some of the text, tables and figures that appear in this
dissertation have been published in (Farley-Barnes* and Ogawa* et al., 2019; Ogawa and
Baserga, 2017; Ogawa et al., 2021).
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Figure 1-1. Ribosome biogenesis is a complex, stepwise and modular process that
initiates in the membraneless nuclear organelle called the nucleolus. Previously published
in (Ogawa and Baserga, 2017). (Left) Flow chart of the general steps of ribosome
biogenesis. (Right) Simplified schematic of ribosome biogenesis. Ribosome biogenesis
initiates with the transcription of the precursor-ribosomal RNA (rRNA) by RNAPI from
an array of tandemly repeated rDNA loci. Following transcription, the pre-rRNA
undergoes processing to release the mature rRNAs (18S; 5.8S; 28S). The 18S is
assembled into the small subunit (SSU; 40S) of the ribosome, and the 5.8S and 28S are
assembled into the large subunit (LSU; 60S) of the ribosome. Additionally, nucleotide
modification, assembly with ribosomal proteins (r-proteins) and the 5S rRNA, and rapid
nuclear export occur. Final maturation of the SSU and LSU occur in the cytoplasm,
where they join on messenger RNA to perform their function in translation. Blue=SSU;
Orange=LSU. Small circles=r-proteins. 5’ETS, ITS1, ITS2, and 3’ETS=transcribed
spacer sequences in the precursor-rRNA. Black ball and sticks=nucleotide modifications.
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Nucleolar assembly and the cell cycle
The nucleolus is a nuclear organelle “formed by the act of building a ribosome
(Mélèse and Xue, 1995).” In humans, nucleoli arise from the tandemly arrayed rDNA
loci that are present on the short arms (p arms) of the 5 human acrocentric chromosomes
[chr 13-15, 21 and 22; (Floutsakou et al., 2013; Henderson et al., 1972). Although highly
variable, approximately 300-400 copies of the ~45 kb rDNA locus are present in a human
diploid cell (Gibbons et al., 2015; Gonzalez and Sylvester, 1995; McStay and Grummt,
2008; Schmickel, 1973). Interestingly, however, only around 50% of these loci are
actively transcribed (Conconi et al., 1989). These sites of rDNA arrays are aptly named
nucleolar organizer regions [NORs; (McClintock, 1934), and while there are 10 NORs in
a human diploid cell, studies in diverse model systems reveal that the actual number of
nucleoli per cell varies. Some of the variability in nucleolar number may be dependent on
cell cycle stage (Anastassova-Kristeva, 1977). A more recent survey, however, in
populations of asynchronized cells reveals that the average number of nucleoli also
differs depending on the cell line observed (Farley et al., 2015). Indeed, while not all
NORs may be competent or actively transcribed by RNAPI (Roussel et al., 1996), it is
also known that nucleoli fuse and will often comprise multiple NORs (AnastassovaKristeva, 1977; Floutsakou et al., 2013; Savino et al., 2001; van Sluis et al., 2016).
Additionally, a recent study also suggests that not all acrocentric chromosomes may
actually harbor rDNA (van Sluis et al., 2020). These data thus complicate the
reconciliation of the number of NORs with the observed number of nucleoli. Taken
together, the nucleolus is a dynamic host to the rDNA loci and embodies a complexity
that is best highlighted by the coordinated remodeling of nucleoli during mitosis.
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Nucleolar dynamics during mitosis
The nucleolus disassembles and reassembles every mitosis. Since Barbara
McClintock first observed the disappearance of chromosomally-tethered nucleoli in late
prophase and their re-emergence in telophase [Figure 1-2; (McClintock, 1934)], efforts to
understand the mechanisms underlying these dynamic changes have been made. It is now
well-established that the breakdown and reformation of nucleoli is a highly ordered
process that establishes reservoirs of pre-rRNA and processing factors to be recruited to
competent NORs following mitosis (Hernandez-Verdun, 2011). First hints that nucleolar
formation did not require de novo transcription of the rDNA came from studies in the
1970s that observed nucleolar assembly upon mitotic exit even in the presence of the
RNAPI inhibitor, actinomycin D [AMD; (Phillips and Phillips, 1973; Phillips, 1972)].
Later research elaborated on these early discoveries and observed, beginning in prophase,
the ordered relocation of pre-rRNA and processing factors to the chromosome periphery
that then migrates with the chromosomes during anaphase [Figure 1-2; (Gautier et al.,
1992; Savino et al., 2001)]. A recent high-throughput survey to define the nucleolar
proteins localized to the mitotic perichromosomal compartment identified a total of 65
such proteins (Stenström et al., 2020). Furthermore, it has recently been discovered that
pre-rRNA localization to the perichromosomal compartment is dependent on the marker
of proliferation, Ki67 (Hayashi et al., 2017). In telophase, nucleolar proteins at the
chromosomal periphery condense to form prenucleolar bodies (PNBs) from which
ribosome biogenesis factors are then recruited to the competent NORs where, with early
processing factors and pre-rRNA, promote nascent nucleolar reassembly (Muro et al.,
2010). Finally, in early G1, the nascent nucleoli fuse, which leads to nucleoli that are
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comprised of multiple NORs, both active and inactive (Anastassova-Kristeva, 1977;
Savino et al., 2001; Sullivan et al., 2001). Nucleolar disassembly and reassembly during
mitosis is therefore a complex and highly ordered processes that requires the coordination
of numerous factors to successfully propagate functional nucleoli from one generation of
cells to the next.
Nucleolar breakdown and reassembly, however, does not occur in a vacuum and
requires coordination with the cell cycle by cell cycle regulators. Beginning in prophase,
activation of the CDK1-cyclin B kinase leads to the inhibition of RNAPI transcription,
which coincides with the disappearance of nucleoli [Figure 1-2; (Sirri et al., 2002)]. The
repression of RNAPI likely occurs in part through phosphorylation of selectivity factor 1
(SL1), which impairs association with upstream binding transcription factor (UBTF) and
the formation of the RNAPI pre-initiation complex (Heix et al., 1998; Kuhn et al., 1998).
RNAPI transcriptional repression is then reversed in anaphase through the inhibition of
CDK1-cyclin B activity by PP1 phosphatases, which allows for nucleolar assembly to
initiate by telophase (Heix et al., 1998; Sirri et al., 2000). Together, these data are
consistent with the observations that nucleolar formation requires transcription by
RNAPI, even though initial assembly is driven by the recruitment of early processing
factors and PNBs at mitotic exit (Dousset et al., 2000). Furthermore, essential to the reinitiation of transcription is the expression of UBTF. In simple yet elegant studies using
engineered pseudo- and neo-NORs, UBTF binding was shown to be required for the
maintenance of competent NORs through mitosis and for the recruitment of RNAPI;
however, in the absence of an rDNA array, transcription did not initiate and nucleoli did
not form (Grob et al., 2014; Mais et al., 2005). The dynamic changes to the nucleolus
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during mitosis are thus highly coordinated and tightly regulated by cell cycle regulators
in order to ensure faithful cell duplication and viability.
While details surrounding the disassembly and reassembly of nucleoli in mitosis
have been established, there is much left to be determined. In the recent survey
identifying nucleolar proteins associated with the mitotic perichromosomal compartment,
65 proteins were identified, but 36 were not previously known to localize to
chromosomes (Stenström et al., 2020). Furthermore, the nucleolar proteins that localize
to the perichromosomal compartment are enriched in proteins with intrinsically
disordered regions (IDR), and this is intriguing given that IDRs are reported drivers of
nucleolar assembly through a biophysical process known as liquid-liquid phase
separation [LLPS; (Hyman et al., 2014; Lafontaine et al., 2020)]. The role of LLPS in
driving nucleolar organization has gained significant attention over the past decade and
establishing the contribution of this biophysical process will be important to gaining a
more comprehensive understanding of nucleolar form and function. Thus, while decades
of research have led to significant insights into nucleolar dynamics, particularly during
mitosis, many details remain to be uncovered.

Liquid-liquid phase separation in nucleolar assembly
Nucleoli are membraneless nuclear bodies that display biophysical properties
associated with liquids. Currently, there is significant momentum surrounding the study
of nucleolar organization as a product of the phenomenon of LLPS (Hyman et al., 2014;
Lafontaine et al., 2020). This body of research initiated with a study that observed liquid
droplet-like behavior of nucleoli in Xenopus oocytes, followed by a study that observed
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purified nucleolar proteins (FBL and NPM1, respectively) with rRNA from wheatgerm
form distinct liquid droplets that are immiscible when mixed and crudely mimic nucleolar
organization (Brangwynne et al., 2011; Feric et al., 2016). Although Xenopus nucleoli are
not tethered to chromosomes as in mammals, these studies and others suggest that
concentration-dependent physical properties of proteins, like fluidity and surface tension,
may explain higher order organization and coalescence events observed among nucleoli.
More recent studies have elaborated on these initial findings in human cells with
observations of coalescence in chromosomally tethered nucleoli and through the use of
super resolution microscopy (Caragine et al., 2018, 2019; Yao et al., 2019). In the latter,
the authors substantiate the involvement of IDRs in promoting self-association and liquid
droplet formation, identifying the FBL GAR domain as necessary to promote LLPS of
FBL (Yao et al., 2019). Additionally, when self-association of FBL was impaired by
mutants with a truncated GAR domain, so was the localization and processing of the prerRNA (Yao et al., 2019). There is, however, still some skepticism surrounding the broad
applicability of LLPS to explain the organization of membraneless cellular bodies, and
thus the field would benefit from a set of standards for testing the hypothesis in living
systems (Alberti et al., 2019; McSwiggen et al., 2019; Peng and Weber, 2019).
Furthermore, because nucleoli in higher eukaryotes are tethered to multiple different
chromosomes, additional factors like chromosomal movement and positioning within the
nucleus are likely to also play a contributing role in nucleolar fusion and organization
(Mangan and McStay, 2021; van Sluis et al., 2020). In conclusion, this new body of
literature suggests that in combination with other processes, like pre-rRNA transcription
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and higher-order chromosome organization, LLPS may contribute to the assembly of
nucleoli.
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Figure 1-2. Nucleolar dynamics during mitosis. In every mitosis, the nucleolus
disassembles in late prophase and reassembles in telophase. In prophase, pre-rRNA and
processing factors relocate to the chromosomal periphery, also called the
perichromosomal compartment. Activation of CDK1-cyclin B inhibits RNAPI
transcription by metaphase (red). Inhibition of CDK1-cyclin B by PP1 phosphatases reinitiates RNAPI transcription by telophase (green). In telophase, nucleolar proteins in the
perichromosomal compartment condense into prenucleolar bodies (PNB) from which
ribosome biogenesis factors are recruited to the competent nucleolar organizer regions
(NORs) and, with early processing factors and pre-rRNA, promote nascent nucleolar
formation. In early G1, nascent nucleoli fuse to from mature nucleoli. FC=fibrillar center
(green); DFC=dense fibrillar component; GC=granular component. Created with
BioRender.com.
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The nucleolar response to cellular stress
The nucleolus is more than just a ribosome factory. Although the primary
function of the nucleolus is to synthesize ribosomes, extra-ribosomal functions have also
been attributed to this organelle. These additional functions include cell cycle regulation,
and the processing and maturation of mRNA, snRNA, and the RNA components of
telomerase and the signal recognition particle (Boisvert et al., 2007; Pederson, 1998).
However, and arguably the most striking, is that it has also been defined as a sensor of
cellular stress that results in the stabilization of the tumor suppressor protein, p53. In
2003, Rubbi and Milner observed that common among all p53-inducing stressors is
nucleolar disruption (Rubbi and Milner, 2003). They proceeded to define how impaired
nucleolar function stabilizes p53 (Rubbi and Milner, 2003), which modulates
transcriptional networks that regulate diverse cellular processes (Boutelle and Attardi,
2021). The regulatory effects of p53 stabilization include the suppression of RNAPI
through direct disruption of the RNAPI pre-initiation complex (Zhai and Comai, 2000).
In subsequent studies, it was identified that p53 stabilization is mediated through the
interaction of the p53 E3 ubiquitin ligase, MDM2/HDM2, with the 5S ribonucleoprotein
(5S-RNP), which includes unassembled r-proteins, primarily RPL5 (uL18) and RPL11
(uL5), and HEATR3 (Calviño et al., 2015; Dai and Lu, 2004; Fumagalli et al., 2009;
Hannan et al., 2021; Lohrum et al., 2003; Russo and Russo, 2017). Furthermore, new
research further supports that the nucleolus senses diverse cellular stresses, including
stress caused by inhibition of RNA polymerases, nuclear export inhibition, and DNA
damage, but not proteotoxic stress (Hannan et al., 2021). Additionally, since the
discovery of the p53-mediated nucleolar stress response, several additional nucleolar
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stress pathways independent of p53 have also been described (James et al., 2014). The
identification of these stress response pathways has therefore positioned the nucleolus not
only as essential in producing ribosomes, but also as a hub in the coordination of the
cellular response to stress.

Crosstalk between the nucleolus and the DNA damage response
Discoveries made by studies employed to define the nucleolar proteome in higher
eukaryotes have contributed substantially to our understanding of the nucleolar response
to DNA damage. The Nucleolar Proteome Database (NOPdb3.0) is by far the most
comprehensive attempt at defining a complete proteome. In its latest update, it included
the identification of more than 4,500 proteins that localize to the nucleolus based on mass
spectrometry of purified nucleoli from several experiments in different human cell lines
(Ahmad et al., 2009; Andersen et al., 2005; Andersen et al., 2002; Leung et al., 2006;
Scherl et al., 2002). Two other published proteomes include another mass spectrometrybased proteome from T-cells (Jarboui et al., 2011), and a nucleolar proteome based on
immunofluorescence microscopy (Thul et al., 2017; Thul and Lindskog, 2018). One
analysis of nearly 700 nucleolar proteins revealed that among the functional classes
represented were not only r-proteins, RNA-binding proteins, and RNA helicases, but also
cell-cycle proteins, splicing related factors, and DNA replication and DNA repair
proteins (Andersen et al., 2005). I also performed an analysis of all the nucleolar
proteomes and uncovered a total of 166 DNA repair proteins among the datasets using
the Gene Ontology (GO) Consortium categorization for protein identification
[GO:0006281; Table 1-1; Appendix I; (Ogawa and Baserga, 2017). Data from these
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studies thus support a plurifunctional role for the nucleolus in higher eukaryotes and
lends support to the idea of the nucleolus as a sensor of DNA damage.
Beyond the localization of DNA repair proteins to the nucleolus, several studies
suggest a role for the nucleolus is the sequestration of DNA repair proteins until required
for DNA repair. In support of this proposed mechanism of coordinating the DNA damage
response, several studies have observed large changes in the nucleolar proteome when
treated with DNA damaging agents, like AMD (Andersen et al., 2005; Andersen et al.,
2002). In one study, treatment with UV and ionizing radiation revealed the mobilization
of proteins associated with non-homologous end joining (NHEJ) from the nucleolus to
the nucleoplasm (Moore et al., 2011). Similar observations have been made with the base
excision repair (BER) enzymes APEX1 (Lirussi et al., 2012) and ALKBH2 (Li et al.,
2013a), and the Werner syndrome protein [WRN; (Blander et al., 2002; Lee et al., 2015)].
It is also possible, however, that DNA repair proteins that localize to the nucleolus are
not just sequestered, but actually have yet to be defined roles in ribosome biogenesis.
Indeed, I explored this hypothesis and identified several DNA repair proteins with roles
in ribosome biogenesis and vice versa (Ogawa and Baserga, 2017); thus, it is likely that
both these explanations may be accurate. Taken together, the nucleolus is a dynamic
organelle that responds to DNA damage through the redistribution of nucleolar localized
proteins.
The nucleolus also responds to DNA damage through transient inhibition of
RNAPI, although the precise mechanism underlying the response remains incomplete.
First reported in 2007, Kruhlak and colleagues identified an ATM-mediated
transcriptional repression of RNAPI upon DNA damage by ionizing radiation that also
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depended on NBS1 and MDC1 (Kruhlak et al., 2007). Further, by using laser microirradiation the authors also observed that RNAPI repression was locally restricted to
nucleoli nearest the damaged chromatin (Kruhlak et al., 2007). Since this first study there
have been several additional studies that not only validated the ATM-mediated RNAPI
transcriptional repression, but that also further defined the mechanisms underlying this
response [Figure 1-3, A; (Calkins et al., 2013; Ciccia et al., 2014; Korsholm et al., 2019;
Larsen et al., 2014; Mooser et al., 2020)]. One clear discovery from these studies is the
central role that the ribosome biogenesis factor, treacle (TCOF1), plays in mediating the
response. TCOF1 is not only required to recruit NBS1 and possibly the rest of the MRN
complex (MRE11 and RAD50), but has also been shown to recruit TOPBP1 which is
required to activate ATR for the repression of RNAPI transcription [Figure 1-3, A;
(Ciccia et al., 2014; Korsholm et al., 2019; Larsen et al., 2014; Mooser et al., 2020)].
Other discoveries include in one study the observed absence of RNAPI transcriptional
repression with ionizing radiation (Moore et al., 2011), and in another the global
silencing of nucleoli upon micro-irradiation (Larsen et al., 2014), both in contrast to
initial findings and that suggest there are nuances in the nucleolar DNA damage response
that remain to be elucidated. What is certain, however, is that RNAPI transcriptional
repression upon DNA damage requires ATM-mediated recruitment of NBS1 and
TOPBP1 by TCOF1 that triggers RNAPI repression in an ATR-dependent manner.
DNA damage also leads to nucleolar reorganization into cap-like structures on the
nucleolar periphery. Observed over half a century ago, treatment with DNA damaging
agents like 4-nitroquinoline N-oxide and AMD led to nucleolar disruption and the
formation of nucleolar “caps” (Reynolds et al., 1964; Reynolds et al., 1963). Several
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decades later, recent studies on DNA damage specifically in the rDNA by the I-Ppol
endonuclease have finally made progress towards defining these intriguing structures.
Like DNA damage in nuclear chromatin, ATM-dependent RNAPI silencing is also
observed when damage occurs in the rDNA (Franek et al., 2016; Harding et al., 2015;
Kruhlak et al., 2007; van Sluis and McStay, 2015; Warmerdam et al., 2016).
Interestingly, however, it was RNAPI silencing and not DNA damage specifically that
led to the formation of nucleolar caps (Figure 1-3, B). This was ascertained because,
remarkably, treatment with AMD at doses that inhibited RNAPI that do not cause DNA
damage also led to cap formation, but that was independent of ATM (Harding et al.,
2015; van Sluis and McStay, 2015). Furthermore, probing the composition of caps caused
by DNA damage suggest that damaged rDNA from the nucleolar interior retreats to the
caps to be repaired. This is supported by the colocalization of caps with the rDNA, FC
and DFC ribosome biogenesis proteins, γH2AX, and DNA repair factors [Figure 1-3, C;
(Franek et al., 2016; Harding et al., 2015; Larsen et al., 2014; van Sluis and McStay,
2015; Warmerdam et al., 2016). Taken together, these data support an ATM-dependent
mechanism of RNAPI inhibition upon DNA damage in the rDNA; however, the purpose
of nucleolar reorganization may differ depending on the type of damage.
It is clear from this recent body of literature that there is a substantial crosstalk
between the nucleolus and the DNA damage response. Questions, however, still remain
including why the DNA damage response includes repression of RNAPI. For damage in
the nucleolar chromatin it may be an adaptation to preserve genome integrity. As the
most highly transcribed region in the human genome, repression of transcription during
DNA repair would limit collision between transcription and repair machinery (Lindstrom
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et al., 2018). Furthermore, as a highly repetitive region, prevention of double strand
breaks is important to limit homologous recombination (HR)-mediated gain or loss of
rDNA repeats, which has been associated with human disease (Lindstrom et al., 2018;
Warmerdam and Wolthuis, 2019). In the nuclear chromatin, repression of RNAPI may
represent a mechanism to coordinate DNA repair with cellular growth or with the p53
nucleolar-mediated stress response if damage is too severe, given that ribosome
biogenesis is an energetically costly process (Antoniali et al., 2014; Hannan et al., 2021;
Kruhlak et al., 2007; Warner et al., 2001).
Another outstanding question is, “What is the primary mode of DNA repair in the
nucleolar chromatin?.” A few well-supported studies have arrived at conflicting
conclusions regarding the predominant pathway for repair. In one study, HR-mediated
repair was concluded (van Sluis and McStay, 2015), whereas in two others, NHEJ was
shown as the primary mode of repair in the rDNA (Harding et al., 2015; Warmerdam et
al., 2016), with HR actually delaying repair and leading to the loss of rDNA repeats
(Warmerdam et al., 2016). Taken together, the nucleolus is highly responsive to cellular
DNA damage and occupies a central role coordinating the DNA damage response.
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Table 1-1. Human nucleolar proteomes include proteins involved in DNA repair. Three
databases exist on proteins that localize to the human nucleolus. Within each database, a
subset of proteins are classified as DNA repair proteins based on Gene Ontology (GO)
Consortium categorization (GO: 0006281).

NOPdb (Ahmad et

T-cell nucleolar

Human Protein

al., 2009; Leung et

proteome (Jarboui

Atlas subcellular

al., 2006)

et al., 2011)

proteome (Thul et
al., 2017; Thul and
Lindskog, 2018)

Total proteins

2717

872

1153

DNA repair

136

38

40

89

30

23

proteins
DNA repair
proteins with a
yeast ortholog
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Figure 1-3. Nucleolar response to DNA damage. The nucleolus is a cellular stress sensor
that responds to DNA damage. DNA damage in the nucleolar and nuclear chromatin both
result in the transient inhibition of RNAPI and the formation of nucleolar caps. Created
with BioRender.com.
(A) Model of ATM- and ATR- dependent inhibition of RNAPI upon DNA damage.
ATM-dependent TCOF1 recruitment of NBS1 and TOPBP1 results in the ATRdependent silencing of RNAPI in the nucleolus. TCOF1 may recruit the entire MRN
complex (MRE11-RAD50-NBS1). Black lightning bolt=DNA damage. Grey=RNAPI;
Red=silenced RNAPI.
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(B) Nucleolar caps. The nucleolar stress response results in the transient inhibition of
RNAPI. When RNAPI is silenced, dense nucleolar caps form on the nucleolar periphery.
The boxed nucleolar cap is defined in C.
(C) Nucleolar cap composition. When DNA damage, specifically double strand breaks,
occur in the rDNA, RNAPI is silenced and nucleolar caps are formed. The caps comprise
individual nucleolar organizer regions (NORs), γH2AX (a marker of DNA damage),
nucleolar proteins from the fibrillar center (FC) and dense fibrillar component (DFC),
and DNA repair proteins.

21

Ribosome biogenesis and disease
Nucleolar dysfunction is associated with a wide range of diseases. Because the
nucleolus is essential for growth and the cellular response to stress, it is not surprising
that dysfunction may contribute to disease. Today, a large body of evidence implicates
nucleolar dysfunction in a subset of congenital disorders, known as the ribosomopathies.
The nucleolus, however, has also been linked to aging, including neurodegenerative
diseases, and the pathogenesis of cancer. Gaining a broader understanding of the
connection of the nucleolus and ribosome biogenesis to disease will serve to improve our
ability to develop more targeted and effective therapeutics. While research has amassed
in understanding the connection of the nucleolus to disease, many questions remain to be
answered.

Ribosomopathies
The ribosomopathies are a diverse subset of congenital disorders caused by
mutations in genes associated with ribosome biogenesis. While all ribosomopathies share
defects in ribosome production, not all are caused by defects at the same step in the
process (Farley-Barnes* and Ogawa* et al., 2019). Perhaps the most studied of the
ribosomopathies are the bone marrow failure syndromes, including Diamond-Blackfan
anemia (DBA), Shwachman-Diamond syndrome (SDS), and Dyskeratosis Congenita
(DC), which can be caused defects in ribosome assembly (Ellis and Gleizes, 2011;
Ruggero and Shimamura, 2014; Warren, 2018). The association of ribosome biogenesis
with bone marrow failure was first identified in DBA (Draptchinskaia et al., 1999). DBA
can be caused by mutations in one of at least 19 r-proteins, however, the most common
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mutation among DBA patients is in RPS19 (Aspesi and Ellis, 2019). The consequence of
these mutations is r-protein haploinsufficieny, which results in a reduction in the
concentration of mature cytoplasmic ribosomes (Khajuria et al., 2018). Another wellstudied ribosomopathy is the mandibulofacial dysostosis Treacher Collins syndrome
(TCS). In most cases TCS is caused by mutations in TCOF1, however, it has also been
identified in patients with mutations in RNAPI subunits, POLR1B, POLR1C and
POLR1D (Bowman et al., 2012; Dauwerse et al., 2011; Sanchez et al., 2020; Splendore et
al., 2000; Teber et al., 2004). A related disorder, acrofacial dysostosis, Cincinnati type,
has also been identified and is caused by mutations in POLR1A (Weaver et al., 2015).
TCOF1 is a multifunctional protein with roles in pre-rRNA transcription, modification,
and the nucleolar response to DNA damage (Gonzales et al., 2005; Larsen et al., 2014;
Mooser et al., 2020; Valdez et al., 2004). However, because RNAPI subunits share the
pathophysiology of TCS, it is likely that a reduction in pre-rRNA levels observed with
TCS is the causative mechanism. Among the ribosomopathies, mutations have been
identified in factors required not only for ribosome assembly and transcription, but also in
pre-rRNA processing (Farley-Barnes* and Ogawa* et al., 2019; Warren, 2018). There are
currently at least 21 suspected and defined ribosomopathies (Farley-Barnes* and Ogawa*
et al., 2019; Warren, 2018), and new ribosomopathies continue to be discovered.
One of the most fascinating aspects of the ribosomopathies is the tissue specific
clinical manifestations of the diseases. While tissue-specificity in disease is not unique to
the ribosomopathies (Hekselman and Yeger-Lotem, 2020), the diversity of unique tissue
types effected by defective ribosome biogenesis has intrigued scientists. At this time, the
clinical manifestations of the ribosomopathies range from bone marrow failure and
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craniofacial abnormalities to intellectual disability and cardiac deficiencies [Figure 1-4;
(Danilova and Gazda, 2015; Farley-Barnes* and Ogawa* et al., 2019; Warren, 2018)].
Interestingly, however, a unifying feature of several ribosomopathies are defects in the
tissues that arise from the neural crest cell lineage (Trainor and Merrill, 2014; Watt and
Trainor, 2014). Neural crest cells are migratory progenitor cells that arise during early
embryonic development and differentiate into several unique cell types including those
that derive the skeletal structures of the face, heart, glia, peripheral nervous system, skin,
and teeth [Figure 1-4 (Trainor and Merrill, 2014; Watt and Trainor, 2014)]. In fact, many
ribosomopathies manifest with defects in craniofacial morphology (TCS; DBA;
acrofacial dysostosis, Cincinnati type), and studies on TCS in animal models have
implicated p53-mediated apoptosis of the neural crest cells in the development of the
craniofacial phenotype (Bowen and Attardi, 2019; Rinon et al., 2011). Furthermore, p53
inhibition, remarkably, rescues the observed craniofacial defects, linking the nucleolarmediated p53 stress response to the clinical manifestation of the disease (Calo et al.,
2018; Jones et al., 2008; Watt et al., 2018). Ribosomopathies, however, also manifest
with defects in unrelated tissues, including the liver [North American Indian childhood
cirrhosis; (Freed et al., 2012)], bone marrow [DBA; SDS; DC; (Ellis and Gleizes, 2011;
Ruggero and Shimamura, 2014; Warren, 2018)], spleen [isolated congenital asplenia;
(Bolze et al., 2013)], and brain [ANE syndrome, RPS23 ribosomopathy; Figure 1-4;
(Nousbeck et al., 2008; Paolini et al., 2017)]. While there is some evidence for the role of
p53 in the pathogenesis of some of these ribosomopathies, it is not implicated in all of
them. The underlying mechanisms for many of the ribosomopathies therefore remain to
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be thoroughly defined, and further research in animal models on the consequences of
mutations in ribosome biogenesis factors will be revealing.

How tissue specific defects arise from dysfunction in a ubiquitous process has
drawn significant recent attention. Beyond the role of p53 and the nucleolar stress
response, other leading hypotheses have emerged to describe the mechanisms underlying
tissue specificity in the ribosomopathies (Farley-Barnes* and Ogawa* et al., 2019). One
hypothesis is based on the concept of ribosome heterogeneity or “specialized ribosomes,”
and a second hypothesis is based on cellular ribosome concentration. The ribosome
concentration hypothesis suggests that reduced production of ribosomes leads to
increased competition among mRNA for the ribosomes that are available (Lodish, 1974;
Mills and Green, 2017). As a consequence, a subset of proteins may not be synthesized at
a capacity required for the normal function of a specific tissue. The most notable example
associated with this hypothesis is with the pathogenesis of DBA and the erythroid
specific transcription factor GATA1. GATA1 is required for erythroid cell development,
and decreased levels of GATA1 protein have been observed in DBA patients (Khajuria et
al., 2018; Ludwig et al., 2014). Confounding, however, is that it could then be
hypothesized that mutations in all r-proteins could lead to bone marrow failure; however,
this is not observed. The ribosome heterogeneity hypothesis, on the other hand, suggests
that unique pools of ribosomes exist in different tissues that may differentially translate
subsets of mRNAs (Genuth and Barna, 2018). This hypothesis echoes most closely the
idea regarding tissue-specific diseases in general that a causal mutation in a protein
disrupts interactions of that protein with a tissue specific network (Hekselman and Yeger-

25

Lotem, 2020). In the case of ribosome heterogeneity this would be exemplified by the
differential expression of r-proteins that interact with and/or recruit a specific subset of
mRNAs (Genuth and Barna, 2018; Shi et al., 2017). It is important to note that these
proposed mechanisms are not likely to be mutually exclusive. Both of these hypotheses,
however, are limited in the evidentiary support for the proposed mechanisms and
therefore require further substantiation (Farley-Barnes* and Ogawa* et al., 2019).
Advances in technologies and further research aimed at exploring these hypotheses in
specific disease model systems will be essential to defining the pathogenesis of the tissue
specific manifestation of ribosomopathies.
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Figure 1-4. Tissue specific clinical manifestation of ribosomopathies. Ribosomopathies
are a diverse subset of congenital disorders that arise from defects in ribosome
biogenesis. A unifying feature of several ribosomopathies are defects in the tissues that
arise from the neural crest cell lineage (green), including hearing loss, craniofacial
dysmorphology (TCS; DBA; acrofacial dysostosis, Cincinnati type), cardiac defects, and
alterations in skin pigmentation. Ribosomopathies also manifest with defects in unrelated
tissues (red), including neurological impairments (ANE syndrome; RPS23
ribosomopathy), alopecia, liver cirrhosis (North American Indian childhood cirrhosis),
asplenia (isolated congenital asplenia), and bone marrow failure (DBA; SDS; DC). Only
the ribosomopathies discussed are included in the parenthesis. Previously published in
(Farley-Barnes* and Ogawa* et al., 2019)
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Aging and related diseases
Research on longevity, premature aging disorders, and neurodegeneration support
a connection between aging and the nucleolus. Understanding the molecular basis for
aging has long interested scientists, yet the link between the nucleolus and aging is a
more recent development in the history of aging research. Some of the earliest studies
linking the nucleolus to aging began with experiments in yeast mother cells that found a
requirement for the histone deacetylase, Sir2, in maintaining genome stability at rDNA
loci. Additionally, loss-of-function mutants had a shorter lifespan and gain-of-function
mutants had a longer lifespan (Gottlieb and Esposito, 1989; Guarente, 1997; Sinclair and
Guarente, 1997). Today, genome instability in the rDNA is still one of the leading
hypotheses for why we age (Ganley and Kobayashi, 2014; Tiku and Antebi, 2018; Turi et
al., 2019). A recent study on mammalian SIRT7 has validated a role for sirtuins in
maintaining rDNA heterochromatin, connecting rDNA genome stability to lifespan
(Etchegaray and Mostoslavsky, 2018; Paredes et al., 2018). Mammalian SIRT1 has also
been reported to regulate RNAPI transcription and rDNA stability and is a leading target
in the development of anti-aging therapeutics, which include resveratrol and other
synthetic agonists (Murayama et al., 2008; Stacchiotti et al., 2018; Zhou et al., 2009).
Several lines of evidence thus support a link between rDNA genome stability and aging.
Nucleolar form and function have also been linked to aging. In a recent study,
smaller nucleolar size predicted longer lifespan in a C. elegans model of longevity,
mediated by ncl-1 [TRIM2/Brat; (Tiku et al., 2017)]. This observation also extended to
models of longevity in fly, mouse and humans, and included a concomitant observed
decrease in ribosome biogenesis (Tiku et al., 2017). Reduced nucleolar activity as a
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hallmark of longevity is consistent with other areas of research like the targeting of
mTOR (mechanistic/mammalian target of rapamycin) to treat age-related diseases.
mTOR is a kinase central to growth regulation, and inhibition is known to decrease
ribosome biogenesis and translation (Tee, 2018; Walters and Cox, 2018). Also consistent
with this view is the observation that the rDNA in aged mice, canids, and humans show
increased CpG methylation (Wang and Lemos, 2019). This may suggest not only
decreased nucleolar activity, but also perhaps a compensatory mechanism to increase
rDNA genome stability as we age. In this same study, however, it was also observed that
under paradigms associated with longevity (e.g. calorie restriction), methylation was
decreased (Wang and Lemos, 2019). One possible explanation is that decreased
methylation does not necessarily suggest increased nucleolar activity or genome
instability. It is also possible, however, that methylation may be secondary to another
cause for aging that is reversed in models of longevity. Taken together, the link between
aging and nucleolar form and function is not yet well defined.
Premature aging disorders further complicate the link between aging and the
nucleolus. Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disorder
caused by mutant lamin A/C. Intriguingly, however, a recent study on fibroblasts from
HGPS patients has revealed increased nucleolar size and function that also demonstrated
increases in rDNA transcription and translation (Buchwalter and Hetzer, 2017). In
contrast, Werner syndrome (WS), Cockayne syndrome (CS), and Bloom syndrome (BS),
are premature aging disorders caused by mutations in DNA repair proteins that exhibit
decreased nucleolar activity (Karikkineth et al., 2017; Mukherjee et al., 2018). Studies on
the proteins implicated in these syndromes have all revealed that impaired function yields
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decreased RNAPI transcription (Bradsher et al., 2002; Grierson et al., 2012; Hannan et
al., 2013; Lebedev et al., 2008; Lutomska et al., 2008; Okur et al., 2020; Shiratori et al.,
2002). Interestingly, WS models, like HGPS, exhibit disruption in the nuclear lamina,
including the nuclear pores and lamin B1 (Li et al., 2013b), and lamin B2 has been shown
to regulate nucleolar morphology and function (Sen Gupta and Sengupta, 2017) that
together may suggest a broader link among the nuclear membrane, the nucleolus, and
aging. Despite the discordance between HGPS and the other premature aging disorders,
there remains a link underlying premature aging and the nucleolus.
Neurodegenerative diseases share similar nucleolar dysfunction when compared
to the premature aging disorders. Several lines of evidence have led to the proposal that
nucleolar form and function are linked to the pathogenesis of neurodegenerative diseases
(Herrmann and Parlato, 2018; Hetman and Pietrzak, 2012; Parlato and Bierhoff, 2015;
Parlato and Kreiner, 2013; Parlato and Liss, 2014; Sia et al., 2016). In Alzheimer’s
disease (AD), observations include reduced nucleolar size (Donmez-Altuntas et al., 2005;
Mann et al., 1988), hypermethylation of the rDNA promoter (Pietrzak et al., 2011),
increased rRNA oxidation (Ding et al., 2006; Honda et al., 2005), and decreased
ribosome activity (Ding et al., 2005; Hernandez-Ortega et al., 2016; Langstrom et al.,
1989). In Parkinson’s disease (PD), nucleolar disruption has also been observed (Parlato
and Liss, 2014). In mouse models of PD, RNAPI transcription is decreased, as was
mouse lifespan (Evsyukov et al., 2017). In another study, when the RNAPI transcription
factor, RRN3/TIF-1A, is depleted in mouse dopaminergic neurons, p53-dependent
apoptosis and PD-like symptoms are exhibited (Rieker et al., 2011). This result in
particular is intriguing given that these data suggest a link between the nucleolar stress
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response and neurodegeneration that echoes that mechanism underlying craniofacial
defects among a subset of ribosomopathies. Defects in ribosome recycling have also been
shown to have impacts on nucleolar function and are also implicated in aging and
neurodegeneration (Ishimura et al., 2014; Sudmant et al., 2018). Together, these data
suggest that reduced nucleolar function underlies neurodegenerative diseases. A recent
study, however, has reported that children heterozygous for a gain-of-function mutation
in the RNAPI transcription factor, UBTF, also exhibit neurodegeneration, which
contradicts this conclusion, yet may be consistent with increased nucleolar activity
causing increased rDNA genome instability (Edvardson et al., 2017). Taken together, a
link between the nucleolus and neurodegeneration is evident (Figure 1-5); however,
informational gaps remain as they do with the association of the nucleolus with aging in
general, suggesting that there is much left to be discovered.
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Figure 1-5. A working model for the association between the nucleolus and aging.
Genome instability and CpG methylation at the tandemly arrayed rDNA loci increase as
we age. Evidence also suggests that reduced nucleolar activity is associated with aging.
The grey dashed triangle represents normal aging. The numbers 1-3 represent specific
diseases and are placed relative on the plot relative to normal aging. 1= HutchinsonGilford progeria syndrome (HGPS) and UBTF-associated childhood neurodegeneration;
2=Werner syndrome, Cockayne syndrome, Bloom syndrome, Alzheimer’s disease, and
Parkinson’s disease; 3=Models of longevity; mTOR inhibition. Created with
BioRender.com.
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The nucleolus and cancer
Changes in nucleolar morphology have long been associated with cancer. For
over a century, cancer pathologists have observed changes in nucleolar size and number
in diverse tumor types, and concluded that tumors with larger and more numerous
nucleoli predicted a worse prognosis for the patients (Derenzini et al., 2009; Penzo et al.,
2019; Pianese, 1896). The association of the nucleolus with cancer is not surprising given
that the nucleolus drives growth and cellular proliferation. Indeed, ribosome biogenesis is
a highly energy-consuming process and as such is tightly regulated, and most often at the
first step in the process, transcription (Drygin et al., 2010; Warner et al., 2001).
Furthermore, retrospective studies on the molecular mechanisms underlying common
chemotherapeutic agents revealed that several drugs in fact target stages of ribosome
biogenesis, not only at the site of RNAPI transcription, but also at stages of pre-rRNA
processing (Burger et al., 2010; Quin et al., 2014). Drugs developed specifically to target
RNAPI transcription have since proven promising both preclinically and in clinical trials
for solid tumors and hematological malignancies. CX-3543 (quarfloxin) and CX-5461
have revealed few adverse events and stable disease in some trial participants (Drygin et
al., 2011; Drygin et al., 2009; Drygin et al., 2008; Haddach et al., 2012; Hilton et al.,
2020; Khot et al., 2019; Papadopoulos et al., 2007; Sanij et al., 2020; Xu et al., 2017b).
BMH-21 is yet another novel RNAPI inhibitor that is currently in preclinical
development and which has shown promising antineoplastic properties in mouse
xenograft models of melanoma and drug-resistant prostate cancer (Colis et al., 2014; Low
et al., 2019). Taken together, nucleolar form and function are linked to pathogenesis of
cancer and is a promising target in the development of novel cancer therapeutics.
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Ribosomopathies are also comorbid with a predisposition to cancer. Observations
in patients with ribosomopathies also suggest a link between nucleolar function and
cancer pathogenesis (Ruggero and Pandolfi, 2003). This is best defined by observations
among those with the classic bone marrow failure syndromes (DBA, SDS, and DC),
however, it is also observed among patients with 5q minus syndrome and cartilage hair
hypoplasia (Aspesi and Ellis, 2019; Ruggero and Pandolfi, 2003). In SDS, patients show
an increased risk for developing myelodysplastic syndrome (MDS) and acute myeloid
leukemia (AML). In 90% of cases, SDS is caused by mutations in the ribosome assembly
factor SBDS, which is important in the final maturation steps of the 60S subunit by
releasing EIF6 (Warren, 2018). While ribosomopathies can often be categorized as
diseases of hypo-proliferation, for example of the erythroid cells in the bone marrow,
cancer as a disease of hyper-proliferation presents a paradox (Dameshek, 1967). Several
mechanisms have been proposed to explain the increased risk for cancer among patients
with ribosomopathies. One of the most compelling proposals is that patients acquire
secondary mutations to compensate for the reduced capacity to synthesize ribosomes. In a
study of SDS patients undergoing bone marrow transplants for MDS, mutations in known
oncogenes were observed, 19% of which were in p53 suggesting a selective pressure to
bypass the nucleolar stress response (Lindsley et al., 2017). Acquired mutations have also
been observed in a small longitudinal study on SDS patients, which revealed either
duplicated SBDS or deleted EIF6 to presumably overcome ribosomal deficiencies
(Pressato et al., 2015). Intriguingly, among these patients, none were reported to have
developed MDS or AML yet (Pressato et al., 2015). Overcoming ribosome deficiencies
through p53 inactivation may in fact be a common mechanism underlying the
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predisposition for cancer. In most cases where r-proteins are mutated, mutations in p53
are also observed (Ajore et al., 2017). Thus, there is a clear connection between the
nucleolus and cancer and further studies aimed at validating and elaborating the
mechanisms underlying the elevated cancer risk among ribosomopathy patients will be
informative for better understanding the molecular basis for the link.
Finally, genome instability at the rDNA loci, in addition to being associated with
aging, has also been implicated in cancer. As highly transcribed and repetitive sites, the
rDNA repeats are not only susceptible to DNA damage, but also increased rates of
recombination during repair that can result in the gain or loss of repeats (Lindstrom et al.,
2018). Interestingly, it has been observed that rearrangements at the rDNA loci are
common among tumors from lung and colorectal cancer patients (Stults et al., 2009). A
larger, more comprehensive survey of cancers supported these data by revealing that
rDNA copy number is in fact reduced in tumors relative to adjacent normal tissue from
the same patient (Xu et al., 2017a). At first, this is counterintuitive as fewer copies might
suggest a decreased proliferative capacity. However, concomitant increases in copy
number of the extra-nucleolar 5S rRNA locus were also observed, as were p53
inactivating mutations and increased proliferative capacity (Xu et al., 2017a).
Experiments in yeast complement these data, revealing that strains with low rDNA copy
number exhibit an increased proportion of active to inactive rDNA repeats and increased
rates of pre-rRNA synthesis (Ide et al., 2010). While the mechanisms underlying rDNA
gene alterations in cancer remain unclear, genome instability at rDNA loci may have a
selective advantage in cancer. The existence of endogenous sensors that detect and
maintain rDNA copy number have been proposed, but evidence in higher eukaryotes is
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limited (Nelson et al., 2019; Salim et al., 2017). While many aspects remain to be
defined, targeting the multifaceted link between the nucleolus and cancer holds promise
for the development of novel and more effective cancer therapeutics.
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Chapter 2

Genome-wide RNAi screen for increased nucleolar number reveals
regulators of cell cycle progression
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INTRODUCTION
Ribosome biogenesis is an essential biological process shared among all living
organisms (Ebersberger et al., 2014). As such, for several decades, this conserved process
in eukaryotes has been largely defined by its study in the genetically tractable singlecelled eukaryote, Saccharomyces cerevisiae (Woolford and Baserga, 2013). Humans,
however, are multi-cellular organisms with innumerable differences including a more
complex regulation of growth control (Miller, 2012). Furthermore, while a diploid S.
cerevisiae cell maintains two nucleolar organizing regions and ~150 rDNA loci
(Kobayashi et al., 1998), the diploid human genome harbors 10 nucleolar organizing
regions and ~200-600 rDNA loci (Henderson et al., 1972; Parks et al., 2018; Stults et al.,
2008). Thus, due to this increased complexity and the growing evidence linking nucleolar
dysfunction to human congenital diseases (Farley-Barnes* and Ogawa* et al., 2019;
Narla and Ebert, 2010; Warren, 2018), cancer (Bursac et al., 2020; Penzo et al., 2019;
Ruggero, 2012; Sulima et al., 2019), viral infections (Jarboui et al., 2012; Rawlinson et
al., 2018), and aging (Hetman and Pietrzak, 2012; Tiku and Antebi, 2018), it has become
imperative to study the intricacies of ribosome biogenesis in higher eukaryotes to better
understand how defects lead to the development of disease.
To this end, advances in technologies and high-throughput screening approaches
have led multiple laboratories to mount screening campaigns to explore ribosome
biogenesis in higher eukaryotes. A candidate screening approach using small interfering
RNAs (siRNA) targeting nucleolar proteins in HeLa cells, for instance, classified
regulators of pre-rRNA processing, identifying a large proportion either with different
functions from the corresponding yeast ortholog or no known yeast ortholog (Tafforeau
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et al., 2013). The former observation was independently supported by an siRNA screen
for ribosomal subunit maturation factors that identified a novel role for exportin 5
(XPO5) in the nuclear export of pre-60S subunits in vertebrates (Wild et al., 2010).
Genome-wide screens quantifying changes in nucleolar size in S. cerevisiae and
Drosophila melanogaster identified the loss of the RNA polymerase I regulatory function
of the histone information regulator (HIR) complex in higher eukaryotes (Neumuller et
al., 2013). Furthermore, in a genome-wide screen in HeLa cells for 40S ribosomal
subunit maturation factors, 302 proteins were identified, several of which were novel
factors that are not present in yeast (Badertscher et al., 2015). Results from these
pioneering studies thus not only support divergent roles for proteins in ribosome
biogenesis that are conserved from yeast to humans, but also support the hypothesis that a
subset of proteins unique to higher eukaryotes play important functional roles in the
regulation of ribosome biogenesis.
Among the early screening campaigns to identify unique regulators of ribosome
biogenesis in higher eukaryotes, we performed a screen identifying proteins that regulate
nucleolar number. This screening approach was based on the prior observation that
depletion of ribosome biogenesis factors, UTP4 and NOL11, decreased nucleolar number
from 2-3 per nucleus to one (Freed et al., 2012). Kat McCann and the Yale Center for
Molecular Discovery executed the genome-wide siRNA screen in the near-diploid
MCF10A human breast epithelial cell line for proteins involved in the regulation of
nucleolar number, and Katherine Farley-Barnes defined a high confidence set of 139 hits
that, when depleted, decreased nucleolar number in cells to one per nucleus (FarleyBarnes et al., 2018). Remarkably, a large proportion of the hits had no previously defined
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role in ribosome biogenesis and yet investigation on a subset of these proteins revealed
varied ribosome biogenesis deficits upon depletion, ranging from RNAPI transcriptional
silencing to aberrant pre-rRNA processing and decreased protein synthesis. Furthermore,
the majority of hits do not have a known ortholog in yeast, strengthening support for the
hypothesis that there exist unique regulators of ribosome biogenesis in higher eukaryotes.
Our screening for regulators of nucleolar number was therefore a viable approach for
uncovering novel human ribosome biogenesis factors.
In addition to identifying proteins that decreased nucleolar number when
depleted, our screen also uncovered proteins that increased nucleolar number. I report on
my analyses of the results from this side of the screen, where I defined 113 high
confidence hits that, when depleted, caused an increase in the percentage of cells with ≥5
nucleoli. I also performed a range of bioinformatic analyses on the screen hits, and with
the Yale Center for Molecular Discovery, performed screen validation and cell cycle
profiling. The results from these analyses reveal the identity of a unique subset of
proteins in the human proteome, the majority of which have no known ortholog in S.
cerevisiae, that are required for the maintenance of typical nucleolar numbers in the
MCF10A human breast epithelial cell line.

RESULTS
siRNA screen for increased nucleolar number revealed 113 hits
A genome-wide, high-content siRNA screen was performed by Kathleen L.
McCann, in collaboration with the Yale Center for Molecular Discovery, to identify
novel protein regulators of ribosome biogenesis in higher eukaryotes (Figure 2-1). To
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achieve this objective, the expression of 18,107 genes was targeted in the human breast
epithelial cell line, MCF10A, by pools of 4 individual siRNAs in order to identify
proteins whose depletion caused an increase in the percentage of cells with ≥5 nucleoli
(Figure 2-1, A). Nucleoli were identified based on immunofluorescent staining with a
monoclonal antibody to the abundant nucleolar protein fibrillarin [72B9 (Reimer et al.,
1987)], and cells were identified using the DNA stain, Hoechst. A pipeline in CellProfiler
(Carpenter et al., 2006; McQuin et al., 2018) was developed by the Yale Center for
Molecular Discovery to perform the unbiased enumeration of nucleoli. The average
number of nucleoli per nucleus was quantified from 3 fields of view for each gene target
and normalized to the average of the 16 negative and 16 positive control wells (3 fields of
view each) included on the same plate. The negative control was siRISC-free and set to a
0 percent effect (PE) and the positive control was siKIF11 and set to a 100 PE. The result
of this screen was therefore a calculated normalized percent effect (NPE) for each gene
target that was used to identify screen hits.
This screen for increased nucleolar number revealed 113 high-confidence hits.
Initially, hits were identified as genes with an NPE ≥ mean + 3 standard deviations (SD),
which revealed 186 hits, including the positive control KIF11 (Figure 2-1, B). I filtered
this list to identify a high confidence set of hits by first discarding 38 hits that were not
expressed in MCF10A cells. This was determined based on a transcriptome analysis I
performed in Partek Flow with RNA collected by Katherine Farley-Barnes from
MCF10A cells treated with a non-targeting (NT) control pool of siRNAs (n=3; FPKM>0;
GEO accession no. GSE154764). I then filtered the list by viability, discarding hits with a
viability of <5% relative to the calculated average viability of the 16 siRISC-free control
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wells on the same plate. This filter was included to ensure that an adequate number of
cells were used to determine the NPE. This step resulted in the elimination of 35 hits,
leaving 113 hits that I identified as high-confidence hits that, when depleted, cause an
increase in the percentage of cells with ≥5 nucleoli per nucleus (Appendix II).
Screen performance based on statistical measures was strong. The Z-prime factor
was calculated for each screening plate to monitor screen performance (n=58; Figure 2-1,
C). The Z-prime factor is a statistical measure of the separation between the negative and
positive controls. A Z-prime =1 indicates an ideal screening assay, whereas a Z-prime <0
indicates significant overlap between the controls and an unusable assay. While an
excellent screening assay is often defined as one with a Z-prime >0.5, Z-prime factors
between 0 and 0.5 are still acceptable for the positive identification of hits. The average
Z-prime for the screen was strong at 0.41, with a Z-prime for all plates >0. Additionally,
the mean signal to background ratio (S/B) was also monitored throughout the screen
(Figure 2-1, D). The average S/B for the screen was 10.29. Viability across all gene
targets was variable, ranging from 0.41-160.16, and also highly variable among the hits,
ranging from 0.80-73.70 prior to filtering, but all with a viability of <100% (Figure 2-1,
E). A representative subset of images and NPE from the scree are shown (Figure 2-2, A),
including the frequency distribution of nucleoli per nucleus, which shows a flattening and
rightward shift in the distribution from 2-3 nucleoli per nucleus to ≥5 (Figure 2-2, B).
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Figure 2-1. High-content, genome-wide siRNA screen in human MCF10A cells revealed
113 hits that increase the percentage of nuclei with ≥5 nucleoli. Previously published in
(Ogawa et al., 2021).
(A) Screen workflow. MCF10A cells were reverse transfected into 384-well plates
containing the siGENOME SMARTpool siRNA genome library (Horizon Discovery).
After 72 hours, cells were fixed, permeabilized, and stained with an antibody to the
nucleolar protein fibrillarin and Hoechst dye to stain the nucleus. Cell images were
collected on an IN Cell Analyzer 2200 widefield, multicolor, fluorescent microscope and
nucleolar number quantified using a pipeline in CellProfiler (Carpenter et al., 2006;
McQuin et al., 2018).
(B) Screen analysis workflow. 18,107 genes were screened, and hits were identified
based on a cut-off of ≥3 SD from the mean percent effect (PE) normalized to the positive
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(siKIF11, 100 PE) and negative (siRISC-free, 0 PE) controls. Viability relative to
siRISC-free negative control was quantified based on Hoechst-stained nuclei, and hits
were then discarded if not expressed in MCF10A cells and if viability was <5%. 113 high
confidence hits remained and of those we validated a subset (n=19/20; 95%) by
oligonucleotide deconvolution, where the siRNAs in the pools are re-tested individually
to ensure that the observed increase in nucleolar number is driven by more than one
siRNA.
(C) Z-prime statistic by plate (left) and as a minimum to maximum box and whiskers plot
(right) indicated a strong, screenable phenotype with an average Z-prime of 0.41 and a Zprime on all plates of >0.
(D) Signal-to-background (S/B) ratio by plate (left) and as a minimum to maximum box
and whiskers plot (right) indicated a strong S/B with an average S/B of 10.29.
(E) Violin plot of the percent viability of all target genes and the 113 hits relative to
siRISC-free. A and B were created with BioRender.com.
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Figure 2-2. Representative hits showing an increase in nuclei with ≥5 nucleoli.
Previously published in (Ogawa et al., 2021).
(A) Representative images of hits from the screen and the normalized percent effects
(NPE). Shown are a selection of nuclei (100x100 μM) stained with Hoechst 33342 (blue)
and an antibody to the nucleolar protein fibrillarin [72B9 (Reimer et al., 1987); pink]
from the negative control (siRISC-free, 0 PE), positive control (siKIF11, PE), and
representative screen hits (siH1-10, siINCENP, siMDN1, siENY2, siATAD5, and
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siRACGAP1) enlarged 3-fold using bicubic interpolation from a single field of view
(left), and a bar graph of the NPE (right).
(B) Histograms of the relative frequency of nucleoli per nucleus and the number of nuclei
quantified are shown for the controls and representative hits in A. Relative to siRISC-free
(gray bars), among the hits (and KIF11; black bars) there is a clear decrease in nuclei
with 2-3 nucleoli and an increase in nuclei with ≥5 nucleoli (gray bars=overlap between
siRISC-free and hit). Histograms for siRISC-free and siKIF11 are representative and
were generated from the images collected from a single screening plate (Plate 1; 16 wells;
48 fields of view). Histograms for each hit were made from the images collected from
their respective well and plate in the screen (3 fields of view). The x-axis was limited to
10 nucleoli per nucleus to aid in visualization; protein depletion conditions with nuclei
with >10 nucleoli include siRISC-free (n=3), siKIF11 (n=36), siH1-10 (n=1), siINCENP
(n=2), siMDN1 (n=3), siENY2 (n=4), and siRACGAP1 (n=2).
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Bioinformatic analysis reveals a unique subset of proteins
To gain insight into the subset of proteins uncovered by this screen, I performed a
range of bioinformatic analyses aimed at determining the degree of conservation,
biological functions, and cellular localization of the 113 high confidence hits. Because
the primary goal of this screen was to identify novel regulators of ribosome biogenesis in
higher eukaryotes, I first identified the proportion of hits that are conserved to the yeast,
Saccharomyces cerevisiae. To achieve this objective, I manually curated information
from the published literature and two data mining tools. Using e!Ensembl’s BioMart tool
(Kinsella et al., 2011), I identified 22/113 hits with yeast orthologs. Using the
Saccharomyces Genome Database’s YeastMine tool (Balakrishnan et al., 2012), I
identified 26/113 hits with yeast orthologs. Manual curation of these data resulted in the
identification of 39/113 hits with yeast orthologs (Table 2-1; Appendix II). This analysis
suggests that while one-third of the hits identified are conserved to yeast, two-thirds are
regulators of nucleolar number that are unique to higher eukaryotes.
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Table 2-1. One-third (39/113) of the hits identified by increased nucleolar number in
MCF10A cells are conserved to the yeast, Saccharomyces cerevisiae. For a subset of hits,
more than one gene name is listed for the yeast ortholog due to a lack of consensus in the
literature. The ≥5 nucleoli/nucleus normalized percent effect (NPE) and percent viability
from the screen are also included.
Screen hit (HGNC)

≥5 nucleoli/nucleus

Yeast ortholog

Percent viability

NPE
KIF11
CDCA8
CMPK2
ATAD5
SKP1
MAN1A1
INCENP
ENY2
CUL1

Cin8/Kip1
Nbl1
Cdc8
Elg1
Skp1
Mnl2
Sli15
Sus1
Cdc53

68.75
66.59
64.91
59.75
57.64
46.40
45.64
41.93
41.61

19.00
12.91
17.38
27.67
13.00
35.63
18.92
6.02
36.50

MDN1
ZDHHC17
PMM2
XRCC5
RRM1
SMG5
RFC1
MCM6
OSBP2

Rea1
Akr1/2
Sec53
Yku80
Rnr1/3
Ebs1/Est1
Rfc1
Mcm6
Hes1/Kes1

39.82
39.45
37.35
35.61
35.33
31.03
30.18
29.60
29.58

29.07
53.42
23.22
42.14
9.46
27.66
46.61
54.59
14.65

TARS2
ABCE1
RIMS3
H1-10
RACGAP1
STK24

Mst1
Rli1
Tcb3
Hho1
Bem2/Rga1/2/Rgd1
Kic1/Pbs2

28.66
28.57
27.82
27.78
27.62
27.53

36.20
25.65
10.82
31.61
15.60
13.92
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SLC2A12

Stl1

27.49

71.34

NGRN
LUC7L
YIPF7
WRAP53
DYNC1H1
FGD4
TOPBP1
SMAP2
OXNAD1

Rrg9
Luc7
Yip1
Swt21
Dyn1
Cdc24/Rom1/2
Dpb11
Glo3/Gts1
Aim33/Pga3

27.47
27.15
27.11
27.10
26.87
26.65
26.37
26.24
26.16

25.68
25.86
5.29
9.48
19.67
28.85
10.58
33.90
60.29

MARCH9
MPV17L2
NFYB
MASTL
NLRC5

Ssm4
Mpv17
Hap3
Pkh3/Rim15
Gip3/Her1

26.06
25.65
25.50
25.41
25.12

68.46
13.92
41.60
32.46
46.44
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To determine the biological functions associated with the 113 high confidence
hits from the screen, I performed analyses using two distinct software packages with
unique algorithms to determine statistical enrichment. First, I performed a Gene Ontology
(GO) over-representation analysis using PANTHER (Mi et al., 2017). This analysis
revealed enrichment of 80 overlapping GO-Slim categories associated with biological
process (p<0.05). The top 19 enriched categories, defined as a log2 fold enrichment
>3.33, were largely associated with DNA replication and mitosis, including Regulation of
exit from mitosis (GO:0007096), DNA double-strand break processing (GO:0000729),
Mitotic sister chromatid cohesion (GO:0007064), and Non-recombinational repair
(GO:0000726), among others (Figure 2-3, A).
Second, I performed the Molecular and Cellular Function core analysis in the
Ingenuity Pathway Analysis software (IPA, Qiagen). Results from this analysis revealed
23 molecular and cellular functions significantly associated with the 113 hits (-log10
p>1.3; Table 2-2). The top functions revealed by this analysis, defined by the highest log10 p-value, were Cell Cycle, Cellular Assembly and Organization, and DNA
Replication, Recombination, and Repair (Figure 2-3, B). However, an analysis of these
three top categories in the STRING Consortium database of protein-protein interactions,
revealed a large degree of overlap among the categories and interconnectedness among
the hits (Figure 2-3, C). Taken together, both these analyses of biological function
revealed that the screen uncovered a unique subset of proteins largely associated with cell
cycle-related processes, particularly in S and M phase, that are also required for the
regulation of nucleolar number.
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Finally, I determined the cellular localization of the 113 high confidence hits
uncovered by this screen. Specifically, I was interested in determining what proportion of
the hits localize to the nucleolus, because I hypothesize that depletion of a nucleolar
protein would cause changes to nucleolar form. To determine whether a hit localizes to
the nucleolus, I utilized 3 nucleolar proteomes, including 2 generated by mass
spectrometry (Ahmad et al., 2009; Jarboui et al., 2011; Leung et al., 2006), and 1 inferred
by immunofluorescence confocal microscopy (Thul et al., 2017). If the hit was present in
at least 1 of the 3 proteomes, I identified it as a nucleolar protein. Based on this analysis,
23/113 (20.4%) hits were identified as nucleolar (Figure 2-3, D; Appendix II). When
compared to estimates of the total number of nucleolar proteins in the human proteome
(4-14%; Figure 2-3, D), this analysis suggests that our hits are enriched in nucleolar
proteins. Thus, despite the lack of association with ribosome biogenesis categories in the
analysis of biological function, the hits are enriched for nucleolar proteins suggesting the
discovery of a unique subset of proteins required for the regulation of nucleolar number
and the putative discovery of novel proteins required for the regulation of nucleolar
function.
The enrichment in nucleolar proteins further led to me ask whether the 113 high
confidence hits are proteins required for the liquid-liquid phase separation (LLPS)
behavior reported to drive nucleolar formation. Proteins with intrinsically disordered
regions (IDRs) are thought to be key drivers of LLPS (Lafontaine et al., 2020); thus, I
looked for the hits from this screen in the DisProt database of proteins with IDRs (Hatos
et al., 2020). Intriguingly, only 4/113 hits contain IDRs (HYPK, MICA, SMG5, and
XRCC5). This analysis suggests that while the hits are enriched in nucleolar proteins, the
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majority are not proteins likely to contribute to the LLPS behavior associated with
nucleolar formation; and furthermore, LLPS may not be the key driver in the
determination of increased nucleolar number.
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Figure 2-3. Bioinformatic analysis of the 113 hits reveals a unique set of proteins
required for maintaining normal nucleolar number. Previously published in (Ogawa et al.,
2021).
(A) Gene Ontology (GO) over-representation analysis using PANTHER is shown as a bar
graph of the top enriched GO-Slim categories associated with biological process (Log2
fold enrichment >3.33; Binomial test, Bonferroni correction, p<0.05). Processes
associated with mitosis [e.g. Regulation of exit from mitosis (GO:0007096) and Mitotic
sister chromatid cohesion (GO:0007064)], and DNA replication and repair [e.g. DNA
double-strand break processing (GO:0000729) and Non-recombinational repair
(GO:0000726)] are common among the top enriched categories, but processes associated
with ribosome biogenesis are strikingly absent.
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(B) Molecular and Cellular Function analysis in Ingenuity Pathway Analysis (IPA;
Qiagen) is shown as a bar graph of the top 10 molecular and cellular functions associated
with the 113 hits using the Fisher’s Exact Test scoring method in IPA (p<0.05). Top
associated functions include Cell Cycle (n=31), Cellular Assembly and Organization
(n=24), and DNA Replication, Recombination, and Repair (n=27). Colored bars are
associated with the colored circles in C. All significantly associated categories and genes
are listed in Table 2-2.
(C) Interaction networks of the hits in the top 3 categories in B are shown as STRING
high confidence (≥0.700 interaction score) interaction networks and reveal a large degree
of overlap among the categories and interconnectedness among the hits. The heavier
weighted lines represent the highest degree of confidence (≥0.900 interaction score).
(D) Nucleolar proteins are enriched among the 113 hits. The percent of proteins in the
human proteome (left) and of the hits (right) that localize to the nucleolus are shown as a
bar graph. 20.4% of hits localize to the nucleolus, whereas the total number of nucleolar
proteins in the human proteome ranges from 4.4-13.8%. These estimates were based on 3
published datasets (Ahmad et al., 2009; Jarboui et al., 2011; Leung et al., 2006; Thul et
al., 2017), and a total number of proteins equal to 19,670 based on (Thul et al., 2017). In
our calculation based on NOPdb, we used 2,717 proteins as the number of nucleolar
proteins based on the last available dataset accessed on 01/22/2009. All=mean ± SD.
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Table 2-2. Molecular and Cellular Function core analysis in the Ingenuity Pathway
Analysis software (IPA; Qiagen) revealed a significant association of the 113 hits with 23
categories. The screen hits included in each category are listed.
Category

Cell cycle

-log10

# of

p-value

hits

5.66

31

Screen hits (HGNC)

CAMK2N1, CASP8AP2, CDCA5,
CDCA8, CIAO2B, CUL1, DYNC1H1,
ENY2, GEN1, HYPK, INCENP, KIF11,
LIG3, MASTL, MCM6, MIA, NR0B2,
RACGAP1, RBBP8, RFC1, RFFL,
RRM1, SGO1, SHROOM2, SKP1,
SUV39H1, TAF1D, TOPBP1, TPX2,
XRCC5, ZNF219

Cellular Assembly

4.95

24

CDCA5, CDCA8, CIAO2B, CUL1,

and Organization

DYNC1H1, FGD4, GEN1, IFT88,
INCENP, JHY, KIF11, LIG3, MIA,
OSBP2, PRUNE1, RACGAP1, RAPH1,
RBBP8, RIMS3, SGO1, SUV39H1,
TOPBP1, TPX2, XRCC5

DNA Replication,

4.95

27

ATAD5, CDCA5, CIAO2B, CMPK2,

Recombination, and

CUL1, DYNC1H1, ENY2, GEN1,

Repair

INCENP, KIF11, LIG3, MCM6, MICA,
PAXX, RACGAP1, RBBP8, RFC1,
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RRM1, SGO1, STK24, SUV39H1,
TOPBP1, TPX2, TYMP, WRAP53,
XRCC5, ZNF219
Cell Morphology

3.32

16

CTF1, FGD4, IFT88, KIF11, LDB1,
OSBP2, RACGAP1, RAPH1, RBBP8,
RIMS3, SMAD5, SUV39H1, TOPBP1,
TPX2, TYMP, XRCC5

Nucleic Acid

2.91

4

CMPK2, PMM2, RRM1, TYMP

Metabolism
Small
Molecule

2.91

13

CMPK2, DYNC1H1, GLYATL2,

Biochemistry

HSD11B2, KMT2C, NAT2, NR0B2,
OSBP2, PMM2, RAPH1, RRM1,
SUV39H1, TYMP

Molecular Transport

2.69

6

KMT2C, NR0B2, RACGAP1, RAPH1,

Cellular Function and

2.42

17

SLC26A7,
TYMP FGD4, IFT88,
CDCA5,
DYNC1H1,

Maintenance
Cell Death and

JHY, KIF11, MIA, PRUNE1, RAPH1,
2.42

RBBP8, RIMS3,
SGO1, SMAD5,
ABCE1,
AGR2, ASIC1,
ATAD5,
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SUV39H1, TOPBP1,
TPX2, XRCC5
CASP8AP2,
CCN4, CDCA5,
CTF1,

Survival

CUL1, DYNC1H1, FGD4, HSD11B2,
HYPK, IFT88, INCENP, KIF11, LIG3,
MDN1, MIA, MICA, NR0B2, OSBP2,
PAXX, RACGAP1, RFC1, RRM1,
SHC3, SHROOM2, SMAD5, STK24,
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SUV39H1, TM2D1, TOPBP1, TPX2,
TYMP, XRCC5
Cell-To-Cell

2.32

5

ASIC1, GTF2IRD1, HSD11B2, IFT88,

Signaling
and
Cellular Compromise

2.32

9

MICA
ASIC1, CTF1, CUL1, DYNC1H1,

Interaction
Cellular Development

2.32

15

KIF11,
MICA, RACGAP1,
SKP1,
CCN4, CDCA5,
CTF1, CUL1,
EBF3,
XRCC5
IFT88, MIA, OSBP2, PRUNE1, RAPH1,
RFC1, RIMS3, SMAD5, STK24,
SUV39H1

Cellular Growth and

2.32

16

CCN4, CDCA5, CTF1, CUL1, EBF3,

Proliferation

HSD11B2, IFT88, LDB1, MIA, OSBP2,
PRUNE1, RAPH1, RFC1, RIMS3,
SMAD5, SUV39H1

Cellular Movement

2.32

5

CCN4, FGD4, IFT88, INCENP, MIA

Cellular Response to

2.32

2

PAXX, XRCC5

Therapeutics
Drug Metabolism

2.32

3

CMPK2, HSD11B2, NAT2

Lipid Metabolism

2.32

7

DYNC1H1, GLYATL2, HSD11B2,

Amino Acid

2.02

2

KMT2C, NR0B2,
OSBP2, RAPH1
GLYATL2,
SUV39H1

Metabolism
Carbohydrate

2.02

2

PMM2, RAPH1

Metabolism
Gene
Expression

2.02

3

LIG3, NR0B2, SUV39H1

Post-Translational

2.02

4

FGD4, GLYATL2, MAP4K5, SUV39H1

Modification
Vitamin and Mineral

1.84

1

NR0B2

Metabolism
Cell
Signaling

1.70

2

FGD4, MAP4K5
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Screen validation supports approach and the identification of unique subset of proteins
Following initial evaluation of screen performance and hit analysis, I sought to
validate the screen due to the known potential for siRNAs to bind unintended targets.
While nucleolar enrichment served as primary evidence for the validity of the screening
approach, in addition I performed oligonucleotide deconvolution on a subset of hits in
collaboration with the Yale Center for Molecular Discovery. Oligonucleotide
deconvolution is a common approach to siRNA screen validation, where the siRNAs in
the pools against each target are tested individually in the primary screening assay
(Sigoillot and King, 2011). I subjectively selected a representative subset of the high
confidence hits to include in the validation assay (20/113, or ~20% of the hits; Table 23), including mitosis and DNA replication factors, nucleolar and non-nucleolar proteins,
and proteins with putative RNA binding domains. Results revealed that 19/20 hits
validated based on at least 2 of the 4 individual siRNAs in the original pools yielding an
increase in percentage of cells with ≥5 nucleoli per nucleus (Z-prime=0.61; NPE≥15;
Table 2-4). These data suggested a 95% validation rate, which supported the screen
results and the unique subset of proteins identified by this approach.
I also compared the proteins uncovered by the screen to other published screens
of nucleolar form and function. I compared the 113 high confidence hits to screens in S.
cerevisiae (Neumuller et al., 2013), D. melanogaster (Neumuller et al., 2013), and in
human cell lines (Badertscher et al., 2015; Tafforeau et al., 2013; Wild et al., 2010), to
identify the degree of overlap among the hits and different screening approaches.
Intriguingly, this analysis revealed minimal overlap between this screen for increased
nucleolar number and other approaches (<2%; Table 2-5). Notably, however, in the
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genome-wide screens for changes to nucleolar size or fragmentation in S. cerevisiae and
D. melanogaster (Neumuller et al., 2013), our positive control and hit
KIF11/Cin8/Klp61f was identified in both datasets. Furthermore, in S. cerevisiae, an
enrichment for mitotic spindle assembly proteins was uncovered (Neumuller et al., 2013),
consistent with the discovery of mitosis-associated factors in this screen. Thus, while
there was a low degree of overlap among the hits, this analysis revealed a putative
conserved link between the nucleolar regulation and mitosis.
The 113 high confidence hits were also compared to screens in human cell lines. I
compared the hits to 3 screens performed in HeLa cells that aimed to identify novel
factors required for ribosome biogenesis in humans. Two screens utilized fluorescentlytagged ribosomal proteins to identify proteins required for ribosomal subunit export
(Badertscher et al., 2015; Wild et al., 2010), and the third used northern blots to identify
proteins required for pre-rRNA processing (Tafforeau et al., 2013). Here, only 6 hits
overlapped with the high confidence hits, including ABCE1, MDN1, DYNC1H1,
CDCA8, SUV39H1, and TOPBP1 (Table 2-5). DYNC1H1 and CDCA8 both have
reported roles in mitosis (Gassmann et al., 2004; Raaijmakers and Medema, 2014;
Sampath et al., 2004); whereas ABCE1, MDN1, SUV39H1, and TOPBP1 have all been
previously reported to be required for ribosome biogenesis and/or ribosome function
(Bassler et al., 2010; Galani et al., 2004; Mooser et al., 2020; Murayama et al., 2008;
Pisarev et al., 2010; Sokka et al., 2015; Young et al., 2015). Possible explanations for the
lack of significant overlap include species (S cerevisiae vs. human) and cell line
differences (MCF10A vs. HeLa), as well as differences in scale (genome-wide vs.
candidate approach) and the screening assay itself (nucleolar number vs. fluorescent r-
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protein retention). Finally, the hits were also completely non-overlapping with the hits
from the parallel screen for decreased nucleolar number (Farley-Barnes et al., 2018).
Taken together, this unique screening approach for increased nucleolar number led to the
discovery of a distinct subset of proteins required to maintain the typical nucleolar form.
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Table 2-3. High-confidence screen hits validated by oligonucleotide deconvolution. 20
hits were selected for validation by oligonucleotide deconvolution. The 14 hits selected
for further analysis have the HGNC symbol in bold. Nucleolar localization (Y/N) and a
brief description of each hit are included.
Protein name

HGNC

Aliases

Symbol
ATP Binding

ABCE1

RNASE

Validated

Nucleolar Description

(Y/N)

(Y/N)

Y

Y

Inhibits

Cassette

L1,

endoribonuclea

Subfamily E

RNASE

se activity

Member 1

LI,

through

RNS4I

inhibition of
RNase L. Also
a ribosome
recycling
factor.

ATPase family

ATAD5

C17orf41 Y

N

DNA

AAA domain

, ELG1,

replication

containing 5

FRAG1

factor C-like
complex
subunit.

Cell division cycle
associated 8

CDCA8

Borealin,
BOR,

Y

Y

Mitotic
chromosomal
passenger
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Dynein

DYNC1H1

DasraB,

complex

Nbl1p

member.

DNECL,

Y

Y

Microtubule-

Cytoplasmic 1

DNCL,

activated

Heavy Chain 1

DNCH1

molecular
motor. Mitotic
spindle
assembly and
metaphase
plate
congression
factor.

ENY2

ENY2

Sus1

Y

N

Transcriptional

transcription and

co-activator

export complex 2

through

subunit

association
with the SAGA
complex and
others.

Cytosolic Iron-

CIAO2B

FAM96B Y

N

Mediates

Sulfur Assembly

incorporation

Component 2B

of Fe/S
proteins.
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Component of
mitotic
spindleassociated
MMXD
complex.
Family with

FAM98A

Y

N

Regulator of

sequence

arginine

similarity 98

methyltransfer

member A

ase, PRMT1,
and contains a
putative RNAbinding
domain.

H1 histone family

H1-10

H1FX

Y

Y

member X
Inner centromere

H1 linker
histone.

INCENP

Y

protein

Y

Mitotic
chromosomal
passenger
complex
member.
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Inka box actin

INKA1

regulator 1

FAM212

Y

N

PAK4 (P21

A,

activated

C3orf54

kinase)
inhibitor.

Kinectin 1

KTN1

Y

N

Binds kinesins
and elongation
factor-delta in
endoplasmic
reticulum.

LUC7-like

LUC7L

Luc7

Y

N

Putative RNAbinding protein
similar to yeast
Luc7p subunit
of the U1
snRNP
splicing
complex.

Midasin AAA

MDN1

Rea1

Y

ATPase 1

Y

Large
ribosomal
subunit
maturation
factor.
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Rac GTPase

RACGAP1

Y

N

Mitotic

Activating Protein

centralspindlin

1

complex
member.

Replication factor

RFC1

Y

Y

C subunit 1

DNA
replication
factor C
complex
subunit.

Serine/threonine

STK24

MST-3

Y

Y

kinase 24

GCK-3 family
kinase
involved in
MAPK
signaling.

TPX2 microtubule

TPX2

Y

nucleation factor

Y

Mitotic spindle
assembly
factor and
activator of
Aurora A
kinase
signaling.
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Cellular

CCN4

Wisp1

Y

N

Wnt1-

communication

inducible

network factor 4

signaling
pathway
protein.

WD repeat

WRAP53

containing

WDR79,

Y

N

Tcab1

holoenzyme

antisense to TP53
X-ray repair cross-

Telomerase

member.
XRCC5

Ku80

N`

Y

Non-

complementing

homologous

protein 5

end joining
(NHEJ) DNA
repair factor.
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Table 2-4. Oligonucleotide deconvolution of 20 screen hits supports validity of the
screen approach and the identification of a unique subset of proteins. Listed are the 4
individual siRNAs for each hit, the mean percent effect (PE) of 3 wells, standard
deviation (SD) of 3 wells, the mean normalized percent effect (NPE) relative to the
negative (siRISC-free) and positive controls (siKIF11 pool), and whether the mean NPE
was ≥15. If at least 2/4 individual siRNAs yielded a mean NPE≥15, the hit was
considered validated.
Hit (siRNA)

Mean PE

SD (PE)

Mean NPE

≥15 Mean
NPE (Y/N)

siRISC-free

4.45

0.98

0.00

siKIF11 (pool)

44.23

4.13

100.00

siKIF11-05

40.25

1.27

116.70

Y

siKIF11-06

51.64

3.09

118.62

Y

siKIF11-07

34.19

3.93

74.75

Y

siKIF11-08

50.88

1.27

116.70

Y

siATAD5-01

26.57

1.51

55.60

Y

siATAD5-02

11.01

0.39

16.49

Y

siATAD5-03

14.40

1.39

25.01

Y

siATAD5-04

13.44

5.39

22.60

Y

siKIF11

siATAD5

siCCN4
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siCCN4-01

11.55

0.45

17.85

Y

siCCN4-02

11.81

1.38

18.51

Y

siCCN4-03

13.95

0.31

23.89

Y

siCCN4-17

21.20

2.96

42.10

Y

siCDCA8-01

37.14

1.82

82.17

Y

siCDCA8-02

28.40

1.02

60.19

Y

siCDCA8-03

13.76

1.04

23.40

Y

siCDCA8-04

22.11

0.55

44.40

Y

siENY2-01

10.67

1.70

15.62

Y

siENY2-02

16.01

0.21

29.06

Y

siENY2-03

14.25

1.59

24.64

Y

siENY2-04

11.03

1.41

16.54

Y

siINCENP-01

29.64

1.48

63.31

Y

siINCENP-02

47.36

4.27

107.86

Y

siINCENP-03

38.02

4.75

84.39

Y

siINCENP-04

30.33

0.53

65.05

Y

siRACGAP1-01

24.96

2.42

51.56

Y

siRACGAP1-02

18.03

3.41

34.13

Y

siRACGAP1-03

30.90

1.33

66.49

Y

siCDCA8

siENY2

siINCENP

siRACGAP1
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siRACGAP1-04

27.69

2.63

58.42

Y

siTPX2-01

19.90

4.89

38.82

Y

siTPX2-02

45.26

2.08

102.59

Y

siTPX2-03

19.99

1.01

39.05

Y

siTPX2-04

17.00

0.77

31.55

Y

siABCE1-01

24.62

2.43

50.71

Y

siABCE1-02

13.45

0.98

22.63

Y

siABCE1-04

14.92

2.27

26.31

Y

siABCE1-17

8.37

1.08

9.86

N

siDYNC1H1-01

13.36

0.73

22.40

Y

siDYNC1H1-02

14.36

1.14

24.91

Y

siDYNC1H1-03

35.99

3.39

79.29

Y

siDYNC1H1-04

8.05

1.42

9.05

N

siCIAO2B-01

14.16

0.51

24.41

Y

siCIAO2B-03

7.48

0.72

7.62

N

siCIAO2B-04

10.61

0.13

15.48

Y

siCIAO2B-18

14.87

1.84

26.18

Y

13.77

2.40

23.43

Y

siTPX2

siABCE1

siDYNC1H1

siCIAO2B

siFAM98A
siFAM98A-01
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siFAM98A-02

16.63

2.65

30.61

Y

siFAM98A-03

4.01

0.28

-1.10

N

siFAM98A-04

19.51

2.30

37.85

Y

siH1-10-01

12.40

1.06

19.98

Y

siH1-10-02

19.69

1.57

38.30

Y

siH1-10-03

11.17

1.69

16.89

Y

siH1-10-04

8.55

1.76

10.30

N

siINKA1-01

36.83

2.22

81.39

Y

siINKA1-02

9.41

0.93

12.47

N

siINKA1-03

11.47

0.79

17.64

Y

siINKA1-04

32.87

1.73

71.44

Y

siKTN1-17

21.11

1.03

41.87

Y

siKTN1-18

21.96

1.71

44.02

Y

siKTN1-19

6.29

0.58

4.61

N

siKTN1-20

11.18

0.80

16.93

Y

siWRAP53-19

5.60

0.11

2.90

N

siWRAP53-20

15.64

1.69

28.11

Y

siWRAP53-21

11.79

1.90

18.45

Y

siWRAP53-22

19.78

1.31

38.53

Y

siH1-10

siINKA1

siKTN1

siWRAP53
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siLUC7L
siLUC7L-01

18.85

3.88

36.19

Y

siLUC7L-02

7.11

1.19

6.67

N

siLUC7L-03

7.57

0.44

7.84

N

siLUC7L-04

13.21

0.27

22.01

Y

siMDN1-03

10.91

0.66

16.23

Y

siMDN1-17

8.77

1.43

10.86

N

siMDN1-18

8.00

0.41

8.92

N

siMDN1-19

15.60

0.96

28.03

Y

siRFC1-01

9.35

0.98

12.31

N

siRFC1-02

10.73

0.82

15.79

Y

siRFC1-03

12.80

1.63

20.99

Y

siRFC1-04

4.69

0.43

0.60

N

siSTK24-05

7.25

0.96

7.04

N

siSTK24-21

5.17

0.56

1.81

N

siSTK24-22

11.48

0.98

17.66

Y

siSTK24-23

16.34

1.21

29.89

Y

siXRCC5-01

7.67

1.02

8.08

N

siXRCC5-02

7.19

0.71

6.89

N

siMDN1

siRFC1

siSTK24

siXRCC5
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siXRCC5-03

3.85

0.32

-1.50

N

siXRCC5-04

3.38

0.46

-2.68

N
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Table 2-5. Overlap of high confidence screen hits with proteins identified in other
screens for regulators of ribosome biogenesis reveals a unique subset of proteins. The 113
high confidence hits were compared to the hit lists from screens in human cell lines
(Badertscher et al., 2015; Tafforeau et al., 2013; Wild et al., 2010), S. cerevisiae
(Neumuller et al., 2013), and D. melanogaster (Neumuller et al., 2013) as indicated.
Indicated in parentheses are the number of overlapping hits compared to the total number
of hits identified by the screening approach. Gene names of the overlapping hits are
listed.
Neumüller et

Neumüller et

Wild et al.

Badertscher et

Tafforeau et

al.

al.

HeLa cells

al.

al.

S. cerevisiae

D.

(2/153)

HeLa cells

HeLa cells

(4/388)

melanogaster

(2/300)

(4/286)

(6/757)
KIF11/Cin8

IFT88/nompB

ABCE1

ABCE1

CDCA8

PMM2/Sec53

INCENP

MDN1

DYNC1H1

MDN1

SKP1/Skp1

KIF11/Klp61f

SUV39H1

YIPF7/Yip1

LIG3

TOPBP1

MAN1A1/alph
a-Man-I
RAP2C/Rap2I
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Nuclear area is significantly larger in nuclei with ≥5 nucleoli
Observations of images from the screen, like those shown in Figure 2-2, A,
suggest that the nuclei of screen hits with ≥5 nucleoli may be larger than the nuclei in the
siRISC-free control. To test whether nuclei are larger, using the images collected for the
subset of hits analyzed in the screen validation, I used CellProfiler to classify nuclei by
nucleolar number (0-4 vs. ≥5) and quantify the nuclear area of the Hoechst stain. My
analysis revealed that the nuclear area of nuclei ≥5 nucleoli are significantly larger than
nuclei with 0-4 nucleoli (n=3 or 6; q<0.01; Figure 2-4, A and B; Table 2-6). Interestingly,
however, this result is observed not only when screen hits are depleted, but also in the
negative control cells. There is some variability in the nuclear size increase among some
hits; notably, depletion of CDCA8 and INCENP resulted in a ≥2-fold increase in the
nuclear area of nuclei with ≥5 nucleoli compared to siRISC-free and a majority of the
screen hits (Figure 2-4, B). These proteins are known mitotic inhibitors and thus suggests
that this increase may be driven by a failure in cell division. As a result, and in addition to
the bioinformatic analyses revealing significant association of screen hits with the cell
cycle, these data suggest that cell cycle profiling is warranted to address whether failed
cell cycle progression, specifically in mitosis, is a unifying feature of cells treated with
these siRNAs.
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Figure 2-4. Nuclear area is significantly greater in nuclei with ≥5 nucleoli. Previously
published in (Ogawa et al., 2021).
(A) Nuclear area is greater in nuclei with ≥5 nucleoli, including in the siRISC-free
treatment. Nuclear area was quantified in pixels using analysis of the Hoechst-stained
images collected for screen validation by oligonucleotide deconvolution. Three (3)
replicates were analyzed for each screen hit depletion and 6 replicates were analyzed in
this analysis for the controls, siRISC-free and siKIF11 (pool). Blue dots=nuclei with 0-4
nucleoli. Red dots=nuclei with ≥5 nucleoli. Each dot represents the mean ± SD of an
individual siRNA (SD=black vertical line). For each blue dot there is a corresponding red
dot (Table 2-6).
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(B) Volcano plot of the statistical analysis of the data in A reveals that in all depletion
conditions, including siRISC-free, nuclei with ≥5 nucleoli are significantly larger that
nuclei with 0-4 nucleoli. Unpaired t-tests were performed, and significance was
determined based on a False Discovery Rate approach using the two-stage step-up
method of Benjamini, Krieger and Yekutieli (n=3 or 6; q<0.01/-log q-value>2; Table 26). The x-axis represents the difference in nuclear area between nuclei with 0-4 nucleoli
and ≥5 nucleoli. The purple dots=individual siRNAs with the greatest difference between
the two categories. Light orange dots=siINCENP individual siRNAs. Dark orange
dots=siCDCA8 individual siRNAs.
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Table 2-6. Nuclear area analysis of screen hit depletions comparing nuclei with 0-4
nucleoli to nuclei with ≥5 nucleoli. For each screen hit depletion, nuclei were classified
as either nuclei with 0-4 nucleoli or ≥5 nucleoli and the average nuclear area was
calculated (n=3 for hits; n=6 for controls). Significance was determined by unpaired ttests and based on a False Discovery Rate approach using the two-stage step-up method
of Benjamini, Krieger and Yekutieli (n=3 or 6; q<0.01/-log q-value>2). siRISCfree=negative control. siKIF11 (pool)=screen positive control.
Screen Hit

Nuclear area

Nuclear area

Significance

(siRNA HGNC, -

0-4 nucleoli

≥5 nucleoli

(q-value)

(mean ± SD)

(mean ± SD)

siRISC-free

206.4 ± 2.9

365.7 ± 6.5

q<0.0001

siKIF11 (pool)

435.8 ± 10.1

666.9 ± 18.1

q<0.0001

siKIF11 -05

382.2 ± 10.4

572.5 ± 14.5

q<0.0001

siKIF11 -06

374.9 ± 11.9

640.1 ± 29.5

q<0.001

siKIF11 -07

409.2 ± 16.8

676.5 ± 26.3

q<0.001

siKIF11 -08

430.4 ± 22.1

678.7 ± 28.5

q<0.001

siABCE1 -01

345.6 ± 15.5

567.6 ± 22.4

q<0.001

siABCE1 -02

244.4 ± 3.5

403.3 ± 6.5

q<0.0001

siABCE1 -04

270.8 ± 4.6

404.7 ± 11.5

q<0.0001

last 2 digits of
product number)
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siABCE1 -17

243.8 ± 6.0

374.3 ± 3.7

q<0.0001

siATAD5 -01

342.5 ± 11.0

503.6 ± 23.5

q<0.001

siATAD5 -02

245.6 ± 3.2

356.4 ± 8.2

q<0.0001

siATAD5 -03

264.5 ± 7.1

411.7 ± 8.2

q<0.0001

siATAD5 -04

262.2 ± 5.9

417.5 ± 21.0

q<0.001

siCCN4 -01

254.2 ± 6.1

437.5 ± 5.7

q<0.0001

siCCN4 -02

359.6 ± 30.2

551.9 ± 57.1

q<0.01

siCCN4 -03

294.4 ± 6.8

417.0 ± 7.5

q<0.0001

siCCN4 -17

347.8 ± 7.6

519.7 ± 11.3

q<0.0001

siCDCA8 -01

318.2 ± 21.5

892.2 ± 1.5

q<0.0001

siCDCA8 -02

342.4 ± 5.0

887.7 ± 36.1

q<0.0001

siCDCA8 -03

301.8 ± 3.9

634.8 ± 12.7

q<0.0001

siCDCA8 -04

322.3 ± 8.6

728.9 ± 4.6

q<0.0001

siCIAO2B -01

286.0 ± 5.4

412.7 ± 3.2

q<0.0001

siCIAO2B -03

277.8 ± 9.4

446.7 ± 21.1

q<0.001

siCIAO2B -04

270.5 ± 1.9

445.7 ± 4.1

q<0.0001

siCIAO2B -18

305.7 ± 4.4

433.4 ± 16.5

q<0.001

78

siDYNC1H1 -01

311.5 ± 2.3

464.9 ± 13.1

q<0.0001

siDYNC1H1 -02

296.8 ± 2.4

511.1 ± 6.1

q<0.0001

siDYNC1H1 -03

427.8 ± 2.6

644.3 ± 4.9

q<0.0001

siDYNC1H1 -04

271.8 ± 5.5

483.0 ± 3.6

q<0.0001

siENY2 -01

284.6 ± 3.5

507.5 ± 12.6

q<0.0001

siENY2 -02

254.6 ± 5.3

446.6 ± 15.3

q<0.0001

siENY2 -03

272.8 ± 1.8

464.5 ± 11.5

q<0.0001

siENY2 -04

307.5 ± 6.2

479.5 ± 1.7

q<0.0001

siFAM98A -01

395.4 ± 5.7

663.7 ± 15.4

q<0.0001

siFAM98A -02

357.8 ± 24.9

554.2 ± 27.6

q<0.001

siFAM98A -03

206.6 ± 3.9

386.6 ± 9.8

q<0.0001

siFAM98A -04

329.4 ± 4.2

505.3 ± 14.8

q<0.0001

siH1-10 -01

274.9 ± 10.2

444.9 ± 16.8

q<0.001

siH1-10 -02

313.8 ± 4.2

493.6 ± 9.2

q<0.0001

siH1-10 -03

244.2 ± 4.9

392.5 ± 8.5

q<0.0001

siH1-10 -04

323.7 ± 6.4

514.4 ± 37.9

q<0.01

siINCENP -01

340.5 ± 9.4

832.2 ± 13.0

q<0.0001

79

siINCENP -02

426.7 ± 14.7

788.9 ± 10.0

q<0.0001

siINCENP -03

449.7 ± 8.8

886.4 ± 6.5

q<0.0001

siINCENP -04

355.5 ± 6.2

672.4 ± 13.8

q<0.0001

siINKA1 -01

417.5 ± 7.3

630.3 ± 9.4

q<0.0001

siINKA1 -02

262.5 ± 3.4

488.3 ± 13.9

q<0.0001

siINKA1 -03

258.9 ± 8.2

382.9 ± 1.4

q<0.0001

siINKA1 -04

377.2 ± 5.9

579.2 ± 12.5

q<0.0001

siKTN1 -17

301.1 ± 16.8

467.2 ± 7.8

q<0.001

siKTN1 -18

364.0 ± 3.1

532.1 ± 11.4

q<0.0001

siKTN1 -19

216.3 ± 3.0

375.5 ± 5.0

q<0.0001

siKTN1 -20

262.9 ± 3.8

420.5 ± 11.7

q<0.0001

siLUC7L -01

299.1 ± 8.4

451.4 ± 14.6

q<0.001

siLUC7L -02

278.5 ± 12.5

474.4 ± 27.6

q<0.001

siLUC7L -03

245.2 ± 3.2

379.3 ± 7.9

q<0.0001

siLUC7L -04

281.2 ± 12.3

424.0 ± 21.0

q<0.001

siMDN1 -03

251.2 ± 3.0

388.2 ± 12.3

q<0.0001

siMDN1 -17

343.7 ± 4.7

542.5 ± 14.4

q<0.0001
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siMDN1 -18

280.5 ± 6.2

460.7 ± 8.9

q<0.0001

siMDN1 -19

279.3 ± 2.5

431.6 ± 10.9

q<0.0001

siRACGAP1 -01

318.7 ± 3.5

585.2 ± 6.8

q<0.0001

siRACGAP1 -02

285.1 ± 9.7

540.0 ± 5.5

q<0.0001

siRACGAP1 -03

328.5 ± 10.5

624.4 ± 13.5

q<0.0001

siRACGAP1 -04

300.5 ± 9.1

612.2 ± 28.2

q<0.0001

siRFC1 -01

268.2 ± 5.5

431.4 ± 6.8

q<0.0001

siRFC1 -02

288.4 ± 5.9

450.9 ± 3.2

q<0.0001

siRFC1 -03

288.9 ± 11.5

418.6 ± 12.7

q<0.001

siRFC1 -04

203.3 ± 1.5

412.1 ± 10.0

q<0.0001

siSTK24 -05

302.4 ± 4.7

479.9 ± 14.3

q<0.0001

siSTK24 -21

214.0 ± 0.8

385.5 ± 10.9

q<0.0001

siSTK24 -22

269.5 ± 3.2

427.1 ± 11.2

q<0.0001

siSTK24 -23

311.2 ± 3.1

439.1 ± 9.7

q<0.0001

siTPX2 -01

413.9 ± 25.9

641.0 ± 31.6

q<0.001

siTPX2 -02

367.8 ± 11.9

613.8 ± 24.1

q<0.001

siTPX2 -03

352.0 ± 4.8

559.8 ± 0.6

q<0.0001
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siTPX2 -04

299.9 ± 2.2

570.1 ± 5.9

q<0.0001

siWRAP53 -19

211.7 ± 1.4

389.8 ± 4.1

q<0.0001

siWRAP53 -20

276.9 ± 2.9

407.9 ± 7.7

q<0.0001

siWRAP53 -21

279.4 ± 5.5

457.2 ± 17.4

q<0.0001

siWRAP53 -22

288.0 ± 1.8

440.0 ± 5.4

q<0.0001

siXRCC5 -01

243.6 ± 5.8

378.0 ± 3.6

q<0.0001

siXRCC5 -02

238.6 ± 1.1

389.1 ± 10.2

q<0.0001

siXRCC5 -03

218.0 ± 2.9

370.8 ± 6.5

q<0.0001

siXRCC5 -04

204.7 ± 2.2

370.7 ± 7.4

q<0.0001
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Cell cycle analysis reveals proteins required for progression through S and G2/M phase
To evaluate whether failed cell cycle progression upon depletion of screen hits is
a unifying theme, I used high-content image analysis of the Hoechst-stained nuclei as
previously reported (Chan et al., 2013; Gomes et al., 2018; Roukos et al., 2015; Roukos
et al., 2013). Using the images collected for screen validation by oligonucleotide
deconvolution (Table 2-3), the integrated intensity of the Hoechst stain for each nucleus
was quantified and log2 values were plotted as histograms for each of the 4 individual
siRNAs from the 20 hits. Cell cycle phases were normalized to the siRISC-free 2N and
4N peaks as described in (Chan et al., 2013). I concluded cell cycle accumulation
conservatively when depletion of at least 2 of 4 individual siRNAs resulted in a
significant ≥2-fold decrease or increase in the percent of nuclei in a phase relative to
siRISC-free (q<0.01). As expected, depletion of KIF11, a mitotic kinesin, resulted in an
accumulation of cells in G2/M phase (Figure 2-5; Appendix III). However, depletion of
only 2/20 hits caused an accumulation of cells in G2/M (INCENP and TPX2), with an
additional 6/20 hits yielding a significant increase in >4N DNA content (ABCE1,
CDCA8, DYNC1H1, ENY2, INKA1, and RACGAP1; Figure 2-5; Appendix III).
Mitosis-associated factors, CDCA8, INCENP, and RACGAP1, yielded the greatest
accumulation of nuclei with >4N DNA content (>10% nuclei), while the increase among
the other hits was more modest (<10% nuclei).
Cell cycle data were confirmed by at least a 50% increase in at least 1 of 2
replicates in a separate cell cycle profiling experiment where the hits in bold in Table 2-3
were depleted using the siRNA pools (Table 2-7). Furthermore, cell cycle results are
consistent with a post hoc analysis of the screen images that I performed to evaluate how
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our CellProfiler pipeline segmented atypical nuclei and nucleoli. I observed annular and
semi-annular nuclei among some hits (e.g. siINCENP), which are indicative of late
mitotic defects, that were counted both as one and more than one nucleus potentially
skewing estimates of nucleolar number [Figure 2-6; (Verstraeten et al., 2011)]. I also
observed “stretched” nucleoli, reminiscent of anaphase bridges and mitotic defects [e.g.
siMDN1; (Daniloski et al., 2019)], that in some cases could lead to an over-estimate of
nucleolar number (Figure 2-7). Regardless, while defects in G2/M phase progression and
cytokinesis failures were present among the hits tested, they were not observed in all
cases.
Other aspects of the cell cycle were also affected to varying degrees. In addition
to hits that, when depleted, caused an accumulation of cells in G2/M phase, our analysis
also revealed that depletion of 8/20 hits caused a significant accumulation of cells in S
phase (q<0.01; CIAO2B, DYNC1H1, ENY2, FAM98A, LUC7L, RFC1, STK24, and
WRAP53; Figure 2-5; Appendix III). Interestingly, 2 of these (DYNC1H1 and ENY2)
were hits that also led to a significant increase in nuclei with >4N DNA content,
suggesting that defects in S phase progression may also contribute to failures in cell
division. Furthermore, 4 hits (CDCA8, INCENP, RACGAP1, and TPX2) resulted in a
significant decrease in nuclei in G0/G1 phase and correlate with the hits that resulted in
an accumulation of cells in either G2/M or with a >4N DNA content (q<0.01). Finally,
depletion of 6/20 hits (ATAD5, CCN4, H1-10, KTN1, MDN1, and XRCC5) showed no
change in cell cycle distribution based on our designated threshold, although significant
minor differences were observed that may be meaningful (Figure 2-5; Appendix III).
Finally, when considering whether an individual siRNA treatment that caused a
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significant cell cycle accumulation also resulted in an increase in the ≥5 nucleoli per
nucleus NPE, there are instances where a change in cell cycle distribution is observed,
but no concomitant increase in nucleolar number is observed (CIAO2B, DYNC1H1,
INKA1, LUC7L, MDN1, RFC1, STK24 and XRCC5; Figure 2-5; Appendix III). Taken
together, our cell cycle analysis using DNA content suggests that despite an increase in
the nuclear area of nuclei with ≥5 nucleoli, failures in G2/M phase progression and
cytokinesis may only in some cases explain the increased numbers of nucleoli that I
observe, and the contribution of other mechanisms may be in part responsible.
To further investigate the link between the cell cycle and ≥5 nucleoli per nucleus
NPE, I asked whether the occurrence of the ≥5 nucleoli per nucleus phenotype correlated
with an individual phase of the cell cycle. Interestingly, when I restricted our analysis of
nucleolar number by cell cycle phase and calculated the ≥5 nucleoli per nucleus NPE for
each of the 20 hits, I found that the median NPE of the 4 individual siRNAs is greater
when considering cells in the G2/M phase of the cell cycle (19/20; Figure 2-8; Table 2-8).
The one exception was XRCC5, which was also the only hit that did not pass our initial
validation. In addition, only when considering cells in the G2/M phase is there an
observable difference in PE between siRISC-free and siKIF11 (Z-prime=0.47). The Zprime statistics were negative for both cells in G0/G1 phase (Z-prime=-0.08) and S phase
(Z-prime=-0.12), suggesting no significant distinction between the negative and positive
controls. Furthermore, it has been reported that nuclear volume scales with cellular
volume, which gradually increases through the cell cycle (Cantwell and Nurse, 2019;
Jorgensen et al., 2007; Maeshima et al., 2011; Neumann and Nurse, 2007); therefore,
these data are consistent with our observation that nuclei with ≥5 nucleoli are
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significantly larger (Figure 2-4, A and B). Taken together, while these data suggest that
some hits are required for S and G2/M phase progression, in most cases it is likely the
cells specifically in G2/M phase that are driving the increase in the percentage of nuclei
with ≥5 nucleoli observed.
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Figure 2-5. Cell cycle analysis reveals that hits are required for progression through
either S or G2/M phase. Representative histograms of DNA content by quantification of
Hoechst 33342 log2 integrated intensity. The log2 integrated intensities of nuclei in the
negative, siRISC-free, control (sum of 48 replicates; n=498,155 nuclei) were plotted and
the G0/G1 peak set to 1.0 (red lines and text) and G2/M peak set to 2.0 (blue lines and
text), and all other depletion conditions were then normalized to siRISC-free. Phases
were assigned based on (Chan et al., 2013), with G2/M phase including late G2 nuclei;
G0/G1=0.75-1.25; S=1.25-1.75; G2/M=1.75-2.25 and 2.25-2.50; >4N=>2.50. Depletion
of the positive control, siKIF11 (pool) resulted in the expected accumulation of cells in
G2/M phase and a subset of cells with a >4N DNA content (sum of 48 replicates;
n=93,027 nuclei). Cell cycle profiling reveals that several hits are required for
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progression through either S or G2/M phase. Representative histograms for screen hits
are shown as a sum of the 3 replicates, yet each replicate for every depletion condition
was characterized individually to perform statistical testing (Appendix III). Significance
was determined by unpaired t-tests relative to siRISC-free and a False Discovery Rate
approach using the two-stage step-up method of Benjamini, Krieger and Yekutieli (n=3
or 48; q<0.01=*; q<0.001=**; q<0.0001=***; Appendix III). Cell cycle defects were
concluded based on a conservative threshold of whether treatment with ≥2 of 4 individual
siRNAs resulted in a ≥2-fold significant increase or decrease in the percent of nuclei in a
phase relative to siRISC-free. Each hit is listed below one of four representative
histograms for the statistically significant cell cycle defects identified. Previously
published in (Ogawa et al., 2021).
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Table 2-7. Cell cycle profiling of screen hits in bold in Table 2-3 by pooled depletion
validate hits with G2/M phase defects. Mock and siNT were included as negative
controls. siKIF11 was included as a positive control. Shown are the number of nuclei
assayed and the percent nuclei in each cell cycle phase for each of two replicates (1/23/20
and 1/27/20).
Hits

Mock

Number of
cells analyzed
Rep
Rep
1
2

% G0/G1

%S

% G2/M

% >4N

Rep
1

Rep
2

Rep
1

Rep
2

Rep
1

Rep
2

Rep
1

Rep
2

1173
5
7768

37.5

37.1

20.6

20.6

20.9

28.2

4.28

3.86

44.4

44.7

18.2

17.3

13.2

18.8

1.95

2.1

6025

46.7

47.6

12.5

11.3

9.6

14.1

1.2

2.6

siKIF11

2028
8
1529
9
1384
2
3685

1943

21.1

22.3

32.4

16.0

29.2

42.8

1.7

6.7

siINCENP

1927

765

29.9

38.2

24.7

14.9

25.7

18.2

3.5

3.5

siCDCA8

1287

648

20.6

19.4

27.0

18.8

29.2

29.8

10.6

17.4

siRACGAP
1
siINKA1

3839

1531

30.7

26.1

17.8

12.9

24.8

28.2

11.4

17.6

2340

1099

38.1

32.8

24.0

19.1

22.3

26.0

1.0

3.2

siTPX2

1168

590

24.1

29.8

31.8

19.0

23.2

26.3

1.5

3.1

siFAM98A

3331

1469

50.3

52.5

15.8

12.7

8.6

9.6

0.7

1.0

siWRAP53

5781

1943

45.3

40.1

14.8

12.8

9.2

12.1

1.0

2.0

siATAD5

6352

1749

47.1

41.0

16.9

13.0

9.7

13.7

0.9

1.9

siCCN4

3763

1215

48.8

47.2

10.9

10.9

5.7

11.3

0.3

1.5

siENY2

5378

2208

49.7

42.8

15.0

12.3

7.2

11.4

0.6

2.3

siH1-10

3490

1268

49.7

48.1

8.2

12.2

3.9

9.6

0.4

3.1

siRFC1

3728

1337

44.8

37.5

20.8

22.6

11.3

17.0

0.4

2.1

siMDN1

5064

2038

53.3

56.8

9.0

7.1

4.8

6.9

0.2

0.5

siSTK24

4179

1385

50.9

53.1

10.6

8.2

4.5

5.0

0.5

0.6

siNT
siUTP4
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Figure 2-6. Atypical annular and semi-annular nuclei were counted both as one and more
than one nucleus, potentially skewing estimates of nucleolar number per nucleus. In a
subset of screen images where atypical nuclei were observed, CellProfiler pipeline
segmentation of annular and semi-annular nuclei revealed inconsistent nuclear
identification. Annular nuclei were sometimes segmented as a single nucleus, whereas
semi-annular nuclei were sometimes segmented as more than one nucleus. Each colored
spot represents a single segmented nucleus. In the merge, blue=Hoechst (nuclei) and
pink=fibrillarin (nucleoli). Normal nuclei shown were from siRISC-free and atypical
nuclei shown were from siINCENP. Previously published in (Ogawa et al., 2021).
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Figure 2-7. Atypical “stretched” nucleoli in some cases led to an overestimate of
nucleolar number per nucleus. In a subset of screen images where atypical nucleoli were
observed, CellProfiler pipeline segmentation of “stretched” nucleoli were sometimes
incorrectly identified as multiple nucleoli. Each colored spot represents a single
segmented nucleolus. In the merge, blue=Hoechst (nuclei) and pink=fibrillarin (nucleoli).
Normal nucleoli shown were from siRISC-free and atypical nucleoli shown were from
siMDN1. Previously published in (Ogawa et al., 2021).
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Figure 2-8. The observed increase in nucleolar number (NPE) is greater when restricting
analysis to cells in G2/M phase. ≥5 nucleoli per nucleus NPE is greater when restricting
the analysis of nucleolar number to cells in G2/M phase. We restricted our analysis of the
≥5 nucleoli per nucleus NPE for each of the 20 hits based on cell cycle phase. Only when
considering nuclei in G2/M phase was there a statistical separation between siRISC-free
and siKIF11 (Z-prime=0.47). The NPE for each individual siRNA are depicted as dots.
The bars show the median NPE + interquartile range for the 4 individual siRNAs for each
hit, for all nuclei (gray) and nuclei in G2/M phase only (blue). Previously published in
(Ogawa et al., 2021).
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Table 2-8. ≥5 nucleoli per nucleus normalized percent effect (NPE) is greater when
considering cells in G2/M phase only. NPE for each siRNA in the pool of 4 comparing
NPE for all cells to cells in G2/M only.
Hits

All cells

G2/M cells

1

2

3

4

1

2

3

4

siKIF11
siINCENP
siCDCA8

89.98
63.31
82.17

118.62
107.86
60.19

74.75
84.39
23.40

116.70
65.05
44.40

104.40
103.10
116.70

130.50
119.60
90.80

111.60
106.60
41.80

133.20
85.90
74.10

siRACGAP1
siINKA1
siTPX2
siKTN1
siFAM98A
siABCE1
siDYNC1H1
siWRAP53
siATAD5

51.56
81.39
38.82
41.87
23.43
50.71
22.40
2.90
55.60

34.13
12.47
102.59
44.02
30.61
22.63
24.91
28.11
16.49

66.49
17.64
39.05
4.61
-1.10
26.31
79.29
18.45
25.01

58.42
71.44
31.55
16.93
37.85
9.86
9.05
38.53
22.60

73.40
91.90
44.60
81.80
47.70
68.80
25.70
7.50
80.00

58.90
18.70
125.30
51.40
51.00
37.60
41.80
53.00
30.30

89.90
48.80
91.20
14.90
-2.20
60.00
104.80
35.60
40.90

71.90
91.60
64.60
31.90
64.00
16.50
20.90
74.90
23.70

siCCN4
siENY2
siCIAO2B
siH1-10
siLUC7L
siRFC1
siMDN1
siSTK24
siXRCC5

17.85
15.62
24.41
19.98
36.19
12.31
16.23
7.04
8.08

18.51
29.06
7.62
38.30
6.67
15.79
10.86
1.81
6.89

23.89
24.64
15.48
16.89
7.84
20.99
8.92
17.66
-1.50

42.10
16.54
26.18
10.30
22.01
0.60
28.03
29.89
-2.68

53.00
32.70
55.40
26.20
43.50
13.60
50.30
23.10
17.10

30.50
38.70
24.40
48.60
18.50
20.00
30.80
7.50
11.20

32.30
49.70
28.10
32.10
29.50
26.80
21.50
35.80
-8.10

63.10
44.00
64.20
37.80
46.80
3.50
53.00
54.50
-5.90
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Inhibition of DNA replication and mitosis increase nucleolar number
Cell cycle analysis revealed that depletion of a subset of screen hits resulted in
failures in progression through S and G2/M phase of the cell cycle. I therefore asked
whether inhibition of DNA replication and mitosis by small molecule inhibitors is
sufficient to cause increased nucleolar numbers (Weiss et al., 2007). Small molecules
tested included tubulin inhibitors (nocodazole and paclitaxel), aurora kinase A and B
inhibitors [MK-5108 and hesperadin, respectively (de Groot et al., 2015)], topoisomerase
inhibitors (etoposide and ICRF-193), a KIF11 inhibitor (ispinesib), and the DNA
replication inhibitors, mitomycin C and 5-fluorouracil. MCF10A cells were incubated
with low doses of the inhibitors for prolonged periods of time (24, 48, and 72 hrs) to best
mimic the conditions from our siRNA screen. Following treatment, the ≥5 nucleoli per
nucleus PE was quantified relative to 0.1% dimethyl sulfoxide (DMSO) treatment, which
was set to a 100 PE. In this experiment, all mitosis and DNA replication inhibitors tested
caused a significant >2-fold increase in the percentage of cells with ≥5 nucleoli per
nucleus by the 72 hr time point (and all but 1 by the 48 hr time point; Figure 2-9).
Furthermore, the PE increased with each time point. Thus, inhibition of DNA replication
and mitosis cause an increase in the percentage of cells with ≥5 nucleoli and validates the
connection between progression through the cell cycle and maintenance of normal
nucleolar numbers.
Additionally, I also tested whether inhibition of RNAPI was sufficient to drive
increased nucleolar number. This was asked, in part, due to the known nucleolar
segregation that occurs upon treatment with AMD and other chemotherapeutic agents
(Burger et al., 2010; Reynolds et al., 1964); but was also asked to address whether
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inhibition of nucleolar function itself is enough to drive increased nucleolar numbers.
RNAPI inhibitors tested included AMD, BMH-21, and CX-5461. Interestingly, both
AMD and BMH-21 at most time points yielded a significant decrease in the percentage of
cells with ≥5 nucleoli (Figure 2-9). Only CX-5461 at the 72 hr time point caused a
significant >2-fold increase in the percentage of cells with ≥5 nucleoli, progressing from
a significant decrease at 24 hrs, distinguishing it from the other two RNAPI inhibitors.
This could be explained, in part, by the different mechanisms by which these inhibitors
are proposed to function, with the former as DNA intercalators, and the latter as a
topoisomerase inhibitor (Bruno et al., 2020). Thus, I discovered that inhibition of
ribosome biogenesis through RNAPI inhibition is not sufficient to cause an increase in
the percentage of cells with ≥5 nucleoli. Taken together, these data further support the
role of faithful cell cycle progression through S and G2/M phase as an important
component in the maintenance of normal nucleolar number.
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Figure 2-9. Inhibition of mitosis and DNA replication increase the percentage of nuclei
with ≥5 nucleoli. The ≥5 nucleoli per nucleus PE was quantified relative to DMSO (set to
a 100 PE) in MCF10A cells treated with a panel of small molecule inhibitors of the cell
cycle for 24 (light gray), 48 (dark gray), and 72 hrs (blue). A dotted line is drawn at 100
PE. M=Inhibitors of mitosis (ispinesib, nocodazole, paclitaxel, hesperadin, and MK5108). S=Inhibitors of DNA replication (mitomycin C and 5-fluorouracil).
M/S=Inhibitors of both mitosis and DNA replication (topoisomerase II inhibitors:
etoposide and ICRF-193). RNAPI=Inhibitors of RNAPI transcription (AMD, BMH-21,
and CX-5461). Statistical significance was calculated by unpaired t tests with the HolmSidak method of correction for multiple comparisons (*=p<0.05, **=p<0.01,
***=p<0.001; n=3). Previously published in (Ogawa et al., 2021).
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DISCUSSION
Through a high-content genome-wide siRNA screen in the near-diploid MCF10A
human breast epithelial cell line, I have identified a high confidence set of 113 proteins
that, when depleted, cause an increase in the percentage of cells with ≥5 nucleoli. Of the
113 proteins, two-thirds are proteins without a known ortholog in S. cerevisiae,
suggesting the identification of a subset of proteins with putative nucleolar regulatory
functions that are unique to higher eukaryotes. My subsequent analyses revealed that the
hits are enriched for nucleolar proteins (20%), yet not for proteins typically associated
with the nucleolar function of ribosome biogenesis. While multiple factors associated
with ribosome biogenesis were identified [e.g. ABCE1 (Pisarev et al., 2010; Young et al.,
2015), MDN1 (Bassler et al., 2010; Galani et al., 2004), SUV39H1 (Murayama et al.,
2008), and TAF1D (Gorski et al., 2007)], enrichment analyses revealed that the hits are
instead significantly associated with cell cycle processes including mitosis and
replication. Cell cycle profiling on a subset of hits confirmed that several, but not all, are
required for progression through S and G2/M phase of the cell cycle. Thus, this screen for
increased nucleolar number uncovered a subset of proteins required for the regulation of
nucleolar number and suggests an interdependence between faithful cell cycle
progression and the nucleolus.
The 113 hits uncovered by this screen are a unique subset of proteins when
compared to other screens for regulators of nucleolar form and function. When compared
to other screens for regulators of ribosome biogenesis in higher eukaryotes, the overlap
among the hits was <2%. Of the hits that are shared (ABCE1, MDN1, DYNC1H1,
SUV39H1, TOPBP1, and CDCA8), there is no clear underlying theme that connects
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them. Differences among the model systems employed or experimental readouts
evaluated however may largely explain the lack of overlap. For instance, the screens for
human ribosome biogenesis factors were all performed in the aneuploid HeLa cervical
cancer cell line (Badertscher et al., 2015; Tafforeau et al., 2013; Wild et al., 2010),
whereas my study was performed in a near-diploid non-cancer-derived cell line,
MCF10A. Each screen also utilized different experimental methodologies and readouts to
establish ribosome biogenesis factors, where it is conceivable that the proteins required
for the regulation of nucleolar number may be different from the proteins that regulate
ribosomal subunit export. Despite minimal overlap, however, comparison of the 113 hits
to the screens for changes in nucleolar size in S. cerevisiae and D. melanogaster lends
support to potentially conserved links between the nucleolus and both mitosis and
mannose metabolism (Neumuller et al., 2013). For instance, spindle pole body proteins
required for mitotic spindle assembly were enriched in the S. cerevisiae dataset, and
spindle assembly factor, KIF11/Cin8/Klp61f, specifically was present in both datasets as
well as in my screen (a hit and the positive control). Also shared among the datasets and
my screen are the mannose-associated proteins PMM2/Sec53 identified in S. cerevisiae
and MAN1A1/alpha-Man-I identified in D. melanogaster, which suggests a novel
putative role for glycoprotein biosynthesis in the regulation of nucleolar form and
function. Finally, and perhaps most intriguing, is that I also observed no overlap among
the hits and over-represented GO categories (Fold enrichment ≥5, p<0.05) when
compared to our hits for decreased nucleolar number (Farley-Barnes et al., 2018). These
results suggest that the mechanisms underlying the regulation of nucleolar number are
likely distinct depending on whether the number has increased or decreased. The 113 hits
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identified by my screen for increased nucleolar number are therefore unique compared to
proteins uncovered by other screens for ribosome biogenesis factors and may serve to
broaden our understanding of the regulation of nucleolar form and function in higher
eukaryotes.
Among the discoveries uncovered by my screen are the diverse subset of proteins
that support a connection between the nucleolus and mitosis. Bioinformatic analyses
revealed that the hits are enriched for cell cycle-associated proteins, including proteins
required for mitosis. Cell cycle profiling supported the role for a subset of the hits in
progression through G2/M phase. Included among the mitosis-associated hits are proteins
required for mitotic spindle assembly, including KIF11, RACGAP1, and TPX2, as well
as the aurora B kinase (AURKB)-associated proteins, CDCA8 and INCENP (Uehara et
al., 2013). In addition, sister chromatid cohesion proteins (CDCA5 and SGOL1) and
mitosis-associated cell cycle regulators [CUL1, SKP1, and MASTL; (Nakayama and
Nakayama, 2006)] were also identified. There has long been an appreciation for the role
of the nucleolus in cell cycle regulation, including in the nucleolar sequestration of
proteins required for cell cycle progression (Boisvert et al., 2007; Visintin and Amon,
2000). It is also well known that the nucleolus undergoes dynamic remodeling as a
consequence of the cell cycle, exemplified by cyclin-dependent kinase 1 (CDK1)mediated silencing of RNAPI and the disassembly and reformation of nucleoli in mitosis
(Hernandez-Verdun, 2011). Furthermore, a novel complex of ribosome biogenesis factors
required for RNAPI transcription was recently implicated in the regulation of mitotic
entry, chromatid cohesion, and spindle assembly through AURKB (Fujimura et al.,
2020). Taken together, these data strengthen the support for significant crosstalk between
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the nucleolus and the cell cycle. Thus, my screen revealed a unique subset of proteins that
both regulate nucleolar number and mitosis and raises the question of whether they also
regulate nucleolar function through RNAPI transcription.
The results from my screen also support a connection between the nucleolus and
DNA replication. Bioinformatic analyses revealed that the hits are also enriched for
proteins required for DNA replication, recombination, and repair. Cell cycle profiling
again supported the role for a subset of hits in the progression through S phase. Included
among these hits are two proteins, ATAD5 and RFC1, that form heteromeric replication
factor complexes that are required for the loading and unloading of the DNA clamp and
processivity factor, PCNA. In eukaryotic genomes, the rDNA loci are the most highly
transcribed loci and conflict between the transcription and replication machinery can lead
to genome instability at replication forks (Lindstrom et al., 2018). Furthermore,
replication stress, particularly at fragile site loci like the rDNA, has been associated with
defects in mitosis including increased DNA bridges in anaphase, chromosome breakage,
and cancer (Chan et al., 2009; Franchitto, 2013; Stults et al., 2009; Warmerdam and
Wolthuis, 2019). As a result, mechanisms have evolved to ensure replication fidelity,
including evidence for transient silencing of RNAPI in response to DNA damage (Ciccia
et al., 2014; Kruhlak et al., 2007; Larsen et al., 2014; Larsen and Stucki, 2016). Thus, the
hits from this screen may represent additional mechanisms by which the fidelity of the
rDNA loci are maintained through S phase, which may be through regulation of RNAPI
transcription. Taken together, these data also support an interdependency between the
nucleolus and DNA replication that has important consequences for cell cycle
progression.
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Testing small molecule compounds for their impact on nucleolar number further
supports the association between S and G2/M phase progression and increased nucleolar
number. I found that prolonged inhibition of mitosis and DNA replication with several
different inhibitors led to significant increases in the percentage of cells with ≥5 nucleoli
per nucleus. Furthermore, duration of treatment was an important factor in driving the
PE, as we observed little to no effect at 24 hrs and the greatest effect at 72 hrs. The drugs
tested included the KIF11 inhibitor, ispinesib, which independently validated the role for
KIF11 in the regulation of nucleolar number. Also tested was the AURKB-selective
inhibitor, hesperadin, and inhibitors of topoisomerases known to aid in the resolution of
DNA in both anaphase (Daniloski et al., 2019; Gemble et al., 2020) and during
replication (Vesela et al., 2017). Interestingly, however, prolonged inhibition of nucleolar
function with the RNAPI inhibitors, BMH-21 and AMD, did not cause an increase in the
percentage of nuclei with ≥5 nucleoli. These results suggest that disruption of nucleolar
function alone is not sufficient to cause increased nucleolar numbers; although,
actinomycin D and BMH-21 both cause nucleolar segregation by 3 hr (Peltonen et al.,
2014; Reynolds et al., 1964), which might appear as an increase in number, and thus we
may be missing the effect by looking at longer time points. Taken together, these data
validate the role of faithful cell cycle progression in maintaining typical numbers of
nucleoli per cell.
Screening for increased nucleolar number in MCF10A cells was thus a novel
screening approach that led to the identification of 113 high confidence proteins.
Included among the hits were a large proportion that do not have a known ortholog in S.
cerevisiae, supporting the hypothesis that higher eukaryotes may harbor additional
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regulatory mechanisms over nucleolar form and function. Additionally, subsequent
analyses of the 113 hits strengthens prior established links between the nucleolus and cell
cycle regulation and suggests an underappreciated role for mitosis and replication factors,
in particular, in nucleolar biology. While the mechanisms underlying increased nucleolar
number remain unknown, we do know that increases in nucleolar number are correlated
with increased RNAPI transcription and poor prognosis in cancer (Derenzini et al., 2009;
Montanaro et al., 2008). Furthermore, our screen for decreased nucleolar number was
successful in identifying proteins with previously undefined roles in the regulation of
ribosome biogenesis; thus, I hypothesize that my hits too may be proteins that regulate
nucleolar function. This unique screening approach was therefore successful in
identifying a novel subset of proteins in the human proteome that are required for the
maintenance of typical nucleolar numbers in human cells, and may represent proteins
with fundamental roles in the regulation of nucleolar function.

MATERIALS AND METHODS
Cell lines
The human breast epithelial cell line, MCF10A (ATCC, CRL-10317), was 2D
subcultured in DMEM/F-12 medium (Gibco, 1130-032) supplemented with 5% horse
serum (Gibco, 16050), 10 μg/mL insulin (Sigma, I1882), 0.5 μg/mL hydrocortisone
(Sigma, H0135), 100 ng/mL cholera toxin (Sigma, C8052), and 20 ng/mL epidermal
growth factor (Peprotech, AF-100-15).

RNAi
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For screen validation and cell cycle analysis, the individual siGENOME Set of 4
siRNAs (Horizon Discovery) for each hit were used. Unless otherwise noted,
subconfluent cells (log phase) were transfected with siRNAs (20-30 nM, final
concentration) using Lipofectamine RNAiMAX Transfection Reagent (ThermoFisher
Scientific, 13778150) and incubated for 72 hrs prior to the experimental assays.

siRNA screen
The high-content genome-wide siRNA screen was performed as reported in
(Farley-Barnes et al., 2018) by Kat McCann and the Yale Center for Molecular
Discovery using the human siGENOME SMARTpool siRNA library that contained
18,107 pools of 4 siRNAs against each target. Cells were imaged on an IN Cell Analyzer
2200 (Cytiva), which is a widefield, multicolor, fluorescence microscope. 3 fields of view
(20X; 665.63 μm x 665.63 μm) were acquired per well and high throughput image
analysis was performed using CellProfiler (Carpenter et al., 2006; McQuin et al., 2018) to
segment nucleoli based on fibrillarin staining (72B9; (Reimer et al., 1987)) and nuclei
based on Hoechst 33342 staining. In this analysis, raw nucleolar number data was
normalized to the 16 negative (siRISC-free; 0 PE) and 16 positive (siKIF11; 100 PE)
control wells run on the same plate and averaged across the fields of view to yield a mean
NPE. Screen performance was monitored by Z-prime factors and signal-to-background
(S/B). Hits with ≥5 nucleoli per nucleus were identified based on a stringent cut-off of 3
standard deviations (SD) from the mean NPE yielding 186 hits, and then I filtered the hits
by expression and viability to yield a subset of 113 high confidence hits.
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RNA sequencing analysis
Hits were filtered by expression in MCF10A cells based on a poly(A)
transcriptome analysis by RNA sequencing performed at the Yale Center for Genome
Analysis (West Haven, CT; GEO accession no. GSE154764) on siNT-treated RNA
collected by Katherine Farley-Barnes and analyzed using a pipeline I developed in Partek
Flow (Partek Inc., St. Louis, MO). Sequencing reads were aligned to the human genome
(hg19 assembly) using Bowtie 2 (v2.2.5) and quantified to the transcriptome (RefSeq 16
08 01 v2) using Cufflinks (v2.2.1) (n=3; FPKM>0). Thirty-eight (38) hits are not
expressed in MCF10A cells based on this analysis and were therefore discarded.
Since my initial analysis of gene expression in MCF10A cells, however, 3
additional MCF10A RNA sequencing datasets have been deposited in Gene Expression
Omnibus (GEO; NCBI). Carson J. Bryant analyzed these datasets in Partek Flow, and reanalyzed the dataset generated by our laboratory, to identify the genes expressed in
MCF10A cells based on the zFPKM normalization metric developed by the Salomon
laboratory (Hart et al., 2013). If the hits were expressed in any one of the 4 RNA
sequencing datasets, they were considered expressed (log2 zTPM > -3). When aligned to
the Ensembl annotation database (v99) Carson found that 8 of the 113 high-confidence
hits that I identified are not likely expressed in MCF10A cells. These hits include
FAM58A, GOLGA8EP, MARCH9, MICA, NR0B2, PRAM1, SCN2B, and YIPF7, and
may represent off-target effects from the siRNA pools used to deplete them.
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Screen validation by oligonucleotide deconvolution
Oligonucleotide deconvolution was performed on the 20 hits listed in Table 2-3,
as well as on the positive control siKIF11, where the 4 siRNAs in each pool are re-tested
individually to ensure that the observed increase in nucleolar number is driven by more
than one siRNA. Three wells per individual siRNA were included in the assay to
determine the mean percent effect. These data were normalized to the mean of 48 wells
of the negative control, siRISC-free, and positive control, siKIF11 (pool), yielding a
mean NPE for each individual siRNA. Hits were validated if the NPE was ≥15.0 in at
least 2/4 individual siRNAs in the pool. This cutoff was less than the screen cutoff of
NPE=25.0 based on an analysis of known LSU maturation factor, MDN1. Deconvolution
of MDN1 yielded 3/4 individual siRNAs with an NPE<25.0, with one siRNA yielding an
NPE=8.92; yet, all 4 siRNAs yielded pre-rRNA processing defects when analyzed by
northern blot for defects in the processing of LSU pre-rRNA precursors (Figure 2-10).
Thus, an NPE≥15.0 was arbitrarily selected as a cutoff to be inclusive, yet conservative.
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Figure 2-10. Northern blot analysis of pre-rRNA intermediates of MDN1 depletion by
the pool and each individual siRNA revealed the expected large subunit (LSU)
processing defect in all depletion conditions.
(A) Schematic depicting the 47S pre-rRNA and position of the probe, P4, used to detect
the LSU pre-rRNA intermediates. Black arrows=cleavage sites.
(B) Northern blot (n=1) of total RNA, which revealed that depletion by the pool and
each individual siRNA targeting MDN1 all yielded the accumulation of the 32/36S and
12S pre-rRNA intermediates, despite 3/4 individual siRNAs yielding an NPE less than
the screen cutoff of 25.0. Mock and siNT=negative controls. 7SL RNA=loading control.
Black arrows=accumulated LSU pre-rRNA intermediates.
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Northern blots
Total RNA was extracted from siRNA-depleted cells using TRIzol Reagent. To
assay for changes in levels of pre-rRNA intermediates, 4 μg of total RNA was run on a
1% agarose/1.25% formaldehyde gel in a 1.5M tricine/1.5M triethanolamine buffer. RNA
was transferred overnight to a Hybond XL nylon membrane (GE Healthcare, RPN 303S)
by capillary transfer in 10X saline-sodium citrate (SSC) transfer buffer after a brief 15
min soak in a 0.5M sodium hydroxide solution. Membranes were then exposed to UV
(254 nm) to immobilize the RNA, and incubated with denatured yeast tRNA for 1 hr at
42° C and hybridized overnight at 37° C with 5’ end radiolabeled oligonucleotide probes
in a solution of 7.5X Denhardt’s solution, 5X sodium chloride-sodium phosphate-EDTA
(SSPE) buffer, and 0.1% SDS as in (Farley-Barnes et al., 2018).

Cell cycle analysis
We analyzed the images of the 20 hits collected for oligonucleotide deconvolution
to evaluate cell cycle based on the integrated intensity of the Hoechst DNA stain. A
histogram of the log2 integrated intensities for the negative control (siRISC-free; 48
wells) was plotted and the G1 peak set to 1.0 and G2 peak set to 2.0. Each hit depletion
condition (3 wells per siRNA) was then normalized to siRISC-free, including siKIF11 as
individual siRNAs (3 wells per siRNA) as well as a pool (48 wells). Cell cycle phases
were defined as in (Chan et al., 2013). G0/G1 phase nuclei were defined as normalized
log2 integrated intensities of 0.75-1.25, S phase nuclei were defined as 1.25-1.75, and
G2/M phase nuclei were defined as 1.75-2.50, and nuclei with >4N were defined as
>2.50.
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Small molecule inhibition
MCF10A cells were treated with inhibitors of the cell cycle for 24, 48, and 72 hrs
in triplicate. Drugs were all dissolved in dimethyl sulfoxide (DMSO) and doses were
selected based on reported EC50 values in cell culture conditions for each drug, with final
DMSO concentration=0.1%. The ≥5 nucleoli per nucleus PE was quantified by the same
CellProfiler pipeline use in the initial screen and analyzed relative to the 0.1% DMSO
treatment, which was set to a 100 PE. Tested inhibitors of mitosis included ispinesib
(0.082 μM; Cayman Chemical, 18014), nocodazole (0.741 μM; Cayman Chemical,
13857), paclitaxel (0.0274 μM; Sigma, T7402), hesperadin (0.082 μM; Cayman
Chemical, 24199), and MK-5108 (0.247 μM; Cayman Chemical, 19167). Inhibitors of
DNA replication included mitomycin C (0.741 μM; Cayman Chemical, 11435) and 5fluorouracil (0.741 μM; Sigma, F6627). Topoisomerase inhibitors included etoposide
(0.741 μM; Sigma, E1383) and ICRF-193 (6.67 μM; Sigma, I4659), and inhibitors of
RNAPI transcription included AMD (0.00914 μM; Sigma, A1410), BMH-21 (0.741 μM;
Sigma, SML1183), and CX-5461 (0.741 μM; Cayman Chemical, 18392). Doses were
selected based on doses used at prolonged time points as reported in the literature.

Statistical analyses
All statistical analyses were performed in GraphPad Prism 8.2.1 (GraphPad
Software, Inc.) using the tests described in the Figure Legends.
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Chapter 3

Increased nucleolar number reveals regulators of RNA polymerase I transcription
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INTRODUCTION
In eukaryotic organisms, nucleoli are large, membraneless, nuclear condensates
associated with the biogenesis of ribosomes. In mammalian cells, nucleoli form upon
initiation of transcription by RNAPI around the tandemly arrayed rDNA loci known as
NORs (Bersaglieri and Santoro, 2019; Grob et al., 2014; Hernandez-Verdun, 2011;
Potapova and Gerton, 2019). The total number of nucleoli present in mammalian cells is
highly variable. In the human genome there are 10 NORs located on the short arms of the
5 acrocentric chromosomes [13-15, 21, and 22; (Floutsakou et al., 2013; Henderson et al.,
1972)]. Yet, high throughput resolution of nucleolar number by fluorescence microscopy
in diverse cell lines reveals few cells with 10 nucleoli per nucleus, with many averaging
as few as 3 nucleoli per nucleus (Farley et al., 2015). Furthermore, increased nucleolar
number and size in the tumors of cancer patients are often associated with increased
nucleolar activity and a poor prognosis (Derenzini et al., 2009; Montanaro et al., 2008).
Dynamic remodeling of nucleolar structure, however, is not restricted to changes in
nucleolar number. During mitosis the nucleolus undergoes dynamic remodeling that is
exemplified by the disassembly and reformation of nucleoli in an open mitosis
(Hernandez-Verdun, 2011). Furthermore, diverse cellular stress signals can cause
nucleolar disruption and large changes to the nucleolar proteome (Boisvert et al., 2010;
Moore et al., 2011; Rubbi and Milner, 2003). This observation has been studied most
extensively in the nucleolar response to DNA damage (Kruhlak et al., 2007; Larsen et al.,
2014; Larsen and Stucki, 2016), and most notably upon treatment with AMD, where
RNAPI transcription is silenced and nucleolar caps are formed at the nucleolar periphery
(Floutsakou et al., 2013; Reynolds et al., 1964). Thus, the nucleolus is a highly
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responsive organelle that integrates signals from a vast network of cellular processes and
that nucleolar form, including both number and morphology, is not fixed.
Intriguingly, the genome-wide siRNA screen for proteins that regulate nucleolar
number described in Chapter 2 revealed a unique subset of proteins that are not enriched
for ribosome biogenesis factors. From this screen I identified 113 hits that cause an
increase in the percentage of nuclei with ≥5 nucleoli. These hits are enriched for proteins
that localize to the nucleolus, as well as proteins associated with the cell cycle, including
specifically mitosis and DNA replication. Furthermore, cell cycle profiling confirmed the
association of a subset of proteins with S and G2/M phase progression, and several
proteins were identified as yielding an accumulation of nuclei with a >4N DNA content
when depleted. These data support failed cell division among a subset of the hits
evaluated and lend a possible explanation for the increased number of nucleoli observed.
However, there were several hits that did not reveal accumulation of nuclei with a >4N
DNA content when depleted and thus a unifying rationale for the observed increase in
nucleolar number remains unknown. Given that we previously identified novel ribosome
biogenesis factors when screening for a decrease in nucleolar number, I asked whether
proteins that, when depleted, increase nucleolar numbers also reveal novel regulators of
nucleolar function?
Screening for changes in nucleolar number previously uncovered proteins with
undefined roles in the regulation of ribosome biogenesis. In our prior screen for
decreased nucleolar number we reported more than 100 proteins that caused a decrease in
nucleolar number from 2-3 to just 1 (Farley-Barnes et al., 2018). Of these hits, further
investigation on a subset revealed varied deficits in ribosome biogenesis upon depletion,
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including RNAPI transcriptional repression and aberrant pre-rRNA processing. Here,
based on these discoveries, I likewise tested the role of 14 validated screen hits revealed
by increased nucleolar number for roles in the regulation of RNAPI transcription and prerRNA processing. Amber Buhagiar confirmed depletion of the selected hits by qPCR,
and I performed the remaining experiments to ascertain roles in nucleolar function. The
results from these experiments revealed that the majority of hits evaluated are required
strictly for the regulation of RNAPI transcription and supports the hypothesis that
screening for increased nucleolar number could also uncover novel regulators of
nucleolar function.

RESULTS
Rationale for the selection of hits
Hits were subjectively selected to be representative of the dataset based on
bioinformatic analyses described in Chapter 2 (Table 2-3, in bold). The selected hits
include cell cycle-associated proteins, including those associated with mitosis and DNA
replication. Proteins with and without yeast orthologs were also selected. Finally, I
selected proteins that localize to the nucleolus, as well as those not reported to localized
to the nucleolus.

72 hr depletion by siGENOME pools yields effective knockdown of screen hits
To test whether the screen hits are involved in the nucleolar function of ribosome
biogenesis, I first sought to validate knockdown of the mRNA levels of the 14 screen hits
selected for further analysis. This was performed by quantitative reverse transcription
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polymerase chain reaction (qRT-PCR) by Amber Buhagiar, using RNA collected and
reverse transcribed by me. Hits were depleted in MCF10A cells for 72 hrs, as they were
in the screen, by siGENOME pools of 4 siRNAs. In all conditions, depletion for 72 hrs
with the siRNA pools led to a significant decrease in the mRNA of the target relative to
the non-targeting (NT) negative control (Figure 3-1). Depletion of UTP4 and KIF11 were
also confirmed (Figure 3-1). UTP4 is a nucleolar protein required for ribosome
biogenesis and the positive control in the screen that identified proteins that when
depleted caused a decrease in nucleolar number (Farley-Barnes et al., 2018). KIF11 is a
mitotic kinesin and the positive control in this screen for increased nucleolar number
described in Chapter 2. These data suggest that this method of depletion is sufficient to
knockdown the mRNAs for the 14 screen hits selected for further analysis.
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Figure 3-1. 72 hr depletion using siGENOME pools yields effective mRNA knockdown
of hits. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis
confirms depletion of a subset of validated nucleolar (n=7; gray) and non-nucleolar (n=7;
white) screen hits in MCF10A cells. After depletion using pools of siRNAs targeting the
indicated genes, respectively, or non-targeting siRNA control (siNT), the mRNA levels
were quantified relative to beta-actin mRNA expression. Relative expression values were
calculated using the comparative CT method. Statistical significance for three biological
replicates, each with three technical replicates, was performed using a two-tailed,
unpaired t-test. All comparisons are relative to siNT (p<0.05=*, p<0.01=**,
p<0.001=***; n=3). Data are shown as a bar graph (mean ± SD), and with each replicate
shown as a dot. These data were collected, analyzed, and graphed by Amber Buhagiar,
using RNA collected and reverse transcribed by me. Previously published in (Ogawa et
al., 2021).
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11/14 screen hits are required for RNA polymerase I transcription
To test the hypothesis that increased nucleolar number reflects changes in RNAPI
transcription, I used an established dual-luciferase reporter assay system (Ghoshal et al.,
2004). In this system, two plasmids are co-transfected into cells 24 hrs prior to lysis and
luminescence detection. One plasmid encodes the firefly luciferase gene, in which
expression is driven by the human rDNA promoter. The second plasmid is included as a
transfection control and encodes the Renilla luciferase gene, in which expression is
driven by a constitutively active cytomegalovirus promoter. MCF10A cells were depleted
for 72 hrs of the 14 selected hits, as well as the NT negative control, the screen positive
control, KIF11, and known ribosome biogenesis factors, UTP4 and NOL11. Cells were
then lysed, and firefly luminescence was normalized to Renilla luminescence and plotted
relative to siNT.
Strikingly, depletion of 11/14 hits significantly affect RNAPI transcription. An
increase in the ratio of firefly to Renilla luminescence suggests increased transcription by
RNAPI, whereas a decrease in the ratio of firefly to Renilla luminescence suggests
decreased transcription by RNAPI. As expected, depletion of known RNAPI transcription
co-factors, UTP4 and NOL11, decreased RNAPI transcription relative to siNT [(Freed et
al., 2012); n=10; p<0.05; Figure 3-2], whereas mock treated cells revealed no effect. Of
the 14 selected hits, depletion of only 2 caused a significant increase in RNAPI
transcription (RFC1 and ATAD5; n=5 or 6; p<0.05); whereas depletion of 9 caused
significant decreases in RNAPI transcription (H1-10, INCENP, MDN1, TPX2, ENY2,
FAM98A, RACGAP1, CCN4, and WRAP53; n=5 or 6; p<0.05; Figure 3-2). Of these
hits, INCENP, H1-10, MDN1, TPX2, and RFC1 are reported in the nucleolus suggesting
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that this regulation may be direct at the rDNA loci (Appendix II). ENY2, FAM98A,
RACGAP1, CCN4, WRAP53, and ATAD5, on the other hand, have not been reported in
the nucleolus and thus their regulation of RNAPI may be indirect. In contrast, depletion
of CDCA8, STK24, and INKA1 showed no significant impact on RNAPI transcription;
however, depletion of the screen positive control KIF11 revealed an unexpected decrease
in RNAPI transcription. These data suggest that increased nucleolar number is indeed
reflective of impacts on nucleolar function. Furthermore, these data reveal that screening
for an increase in the percentage of cells with ≥5 nucleoli per nucleus was successful in
the identification of proteins required for the regulation of RNAPI transcription.
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Figure 3-2. Depletion of the selected hits reveal 11/14 significantly decrease or increase
RNAPI transcription. RNAPI transcription was assayed using a dual-luciferase reporter
system utilizing a plasmid encoding the firefly luciferase gene, in which expression is
driven by the human rDNA promoter [-410 to +314; (Ghoshal et al., 2004)]. Data were
normalized to Renilla luciferase gene expression driven by a constitutively active
cytomegalovirus promoter. Statistical significance for 5 or 6 replicates relative to siNT
was calculated by two-tailed, unpaired t tests (*=p<0.05, **=p<0.01, ***=p<0.001; n=5
or 6). Mock=negative control; siNOL11 and siUTP4=positive controls. Data are shown
as minimum to maximum box and whiskers plots, and with each replicate represented as
a dot. Gray=nucleolar proteins; white=non-nucleolar proteins (Table 2-3; Appendix II).
Previously published in (Ogawa et al., 2021).

117

1/14 screen hits are required for pre-rRNA processing
Several ribosome biogenesis factors that are required for transcription of the
rDNA also have defined roles in processing the pre-rRNA (Calo et al., 2015; FarleyBarnes et al., 2018; Freed et al., 2012; Gallagher et al., 2004; Prieto and McStay, 2007).
These factors include nucleolar proteins like those in the SSU subcomplex t-UTP/UTPA
(Freed et al., 2012; Gallagher et al., 2004; Prieto and McStay, 2007), as well as nonnucleolar proteins including several previously identified in the screen for decreased
nucleolar number (Farley-Barnes et al., 2018). To test whether the 14 selected screen hits
are required for pre-rRNA processing I used northern blots to quantify steady-state levels
of pre-rRNA intermediates and analyzed precursor-product relationships. Northern blots
were performed using RNA from MCF10A cells depleted of each of the 14 hits, as well
as UTP4 as a positive control, and hybridized to 4 previously reported oligonucleotide
probes that detect different intermediates in the pre-rRNA processing pathways [(FarleyBarnes et al., 2018); Figure 3-3; Figure 3-4]. Intermediates were then quantified by
phosphorimager and Ratio Analysis of Multiple Precursors profiles were plotted relative
to siNT [RAMP; (Wang et al., 2014); Figure 3-5; Figure 3-6].
Interestingly, depletion of only 1/14 hits resulted in aberrant pre-rRNA
processing. Overall, while depletion of the 14 selected hits led to some ratios from
individual probes to be statistically significant, only depletion of the nucleolar protein
MDN1 caused a more than 2-fold change in ratios of intermediates relative to siNT (n=3;
p<0.05; Figure-3-4; Figure 3-5; Figure 3-6). Specifically, MDN1 depletion resulted in a
significant increase in the ratios of the 12S pre-rRNA to its precursors and is an
intermediate of the large ribosomal subunit (LSU) 5.8S rRNA (Figure 3-4, D; Figure 3-
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5), which is consistent with the protein’s reported role in LSU maturation (Bassler et al.,
2010; Galani et al., 2004). As expected, RNA from mock-treated cells showed no
significant difference relative to siNT (Figure 3-4; Figure 3-5), whereas UTP4 depletion
caused a significant increase in the 30S+1 pre-rRNA precursor and a decrease in the 21S
product (n=3; p<0.05; Figure 3-4, A-C; Figure 3-5). These results suggest that increased
nucleolar number is largely not reflective of impacts on pre-rRNA processing for either
nucleolar or non-nucleolar hits.
Further analysis of the northern blots also revealed a decreasing trend in the
overall steady-state levels of pre-rRNA intermediates after depletion of the 14 selected
hits. Individual pre-rRNA intermediates were quantified relative to the 7SL RNA
component of the signal recognition particle, which was probed on all northern blots as a
loading control (Figure 3-7). As expected, UTP4-depleted cells showed a significant
increase in the primary transcript plus (43S-47S; PTP) and 30S+1, and decrease in the
30S and 21S pre-rRNAs, whereas mock-treated cells showed little impact on the levels of
steady-state intermediates. Overall, among the 14 hits, steady-state levels trended towards
a modest decrease (<2-fold) among all pre-rRNA intermediates measured, with all but 2
showing a significant decrease of at least 1 intermediate by a single probe. While these
differences are small, they are consistent with the majority of selected hits causing
significant decreases in RNAPI transcription (Figure 3-2). Intriguingly, the 2 that did not
show a significant decrease of an intermediate (ATAD5 and RFC1) were also the only 2
hits to show a significant increase in RNAPI transcription. Taken together, analysis of
pre-rRNA intermediates by northern blots revealed that screening for an increase in the
percentage of cells with ≥5 nucleoli per nucleus uncovered proteins that are less likely to
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be required for pre-rRNA processing and more likely to be required for the regulation of
overall levels of pre-rRNA intermediates.
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Figure 3-3. Pre-rRNA processing diagram labeled with the oligonucleotide probes used
to detect pre-rRNA intermediates. Depletion of a subset of nucleolar (n=7) and nonnucleolar (n=7) hits in MCF10A cells were analyzed by northern blot to ask whether
depletion affects steady-state levels of pre-rRNA intermediates, and whether pre-rRNA
processing defects can be inferred from observed changes in precursor-product
relationships. The two predominant pathways for releasing the mature ribosomal RNAs
(18S, 5.8S, and 28S) from the primary 47S transcript are depicted. Cleavage sites are
indicated with black triangles and are listed next to the black arrows. The 4
oligonucleotide probes used to quantify levels of the different pre-rRNA intermediates
are indicated below the 47S both by colored lines and probe number (P5’ETS, P5’ITS1,
P3, and P4). Previously published in (Ogawa et al., 2021).
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Figure 3-4. Qualitative analysis of pre-rRNA intermediates reveals no obvious pre-rRNA
processing defects among the 14 selected hits. Representative northern blots are shown
for each of the 4 probes, (A) P5’ETS, (B) P5’ITS1, (C) P3, and (D) P4. The 7SL RNA
component of the signal recognition particle was used as a loading control. In each blot,
mock and siNT=negative controls, and siUTP4=positive control. PTP=primary transcript
plus or the 43S-47S pre-rRNA. Previously published in (Ogawa et al., 2021).
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Figure 3-5. Quantitative analysis of the northern blots of total RNA from nucleolar hits
reveals that MDN1-depletion significantly affects processing of the 12S pre-rRNA.
Quantitative analysis of the northern blots of nucleolar hits was performed by Ratio
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Analysis of Multiple Precursors (RAMP) relative to siNT (mean ± SD). Mock-treated
cells and UTP4-depleted cells were included as negative and positive controls,
respectively. Depletion of the screen positive control, KIF11, was also analyzed.
Statistical significance was calculated for 3 replicates by unpaired t tests for each ratio
with the Holm-Sidak method of correction for multiple comparisons (*=p<0.05,
**=p<0.01, ***=p<0.001; n=3). PTP=primary transcript plus, 43S-47S. Previously
published in (Ogawa et al., 2021).
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Figure 3-6. Quantitative analysis of the northern blots of total RNA from non-nucleolar
hits reveals pre-rRNA processing is not impacted. Quantitative analysis of the northern
blots of non-nucleolar hits was performed by Ratio Analysis of Multiple Precursors
(RAMP) relative to siNT (mean ± SD). Statistical significance was calculated for 3
replicates by unpaired t tests for each ratio with the Holm-Sidak method of correction for
multiple comparisons (*=p<0.05, **=p<0.01, ***=p<0.001; n=3). PTP=primary
transcript plus, 43S-47S. Previously published in (Ogawa et al., 2021).
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Figure 3-7. Quantitative analysis of pre-rRNA intermediates relative to the 7SL RNA
loading control reveals a general trending decrease in overall levels of pre-rRNA
intermediates.

126

Quantitative analysis of the northern blots was performed relative to the 7SL RNA
component of the signal recognition particle relative to siNT (mean ± SD). Statistical
significance for 3 replicates was calculated by unpaired t tests for each ratio with the
Holm-Sidak method of correction for multiple comparisons (*=p<0.05, **=p<0.01,
***=p<0.001; n=3). PTP=primary transcript plus, 43S-47S. Previously published in
(Ogawa et al., 2021).
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13/14 screen hits are required for global protein synthesis
Finally, if depletion of a protein impacts ribosome biogenesis through either
RNAPI transcription or pre-rRNA processing, I hypothesize that ribosome levels and
translational function will also be impacted. To test whether depletion of the 14 selected
screen hits impacts global protein synthesis, I used an established puromycin labeling
assay of nascent peptides followed by western blot with a puromycin antibody (Kelleher
et al., 2013). MCF10A cells were depleted of the 14 screen hits prior to puromycin
treatment (1 μM) and protein harvest. MCF10A cells were also mock-treated and treated
with siNT as negative controls, and half the concentration of puromycin (0.5 μM) and the
ribosome biogenesis factor siUTP4 as positive controls.
Puromycin labeling followed by western blot revealed that depletion of 13/14 hits
caused a significant decrease in global protein synthesis (p<0.05; Figure 3-8). As
expected, mock-treated cells showed no significant difference relative to siNT, and cells
treated with half the concentration of puromycin (0.5 μM) showed a decrease in global
protein synthesis by half. Furthermore, as predicted, depletion of the ribosome biogenesis
factor UTP4 also led to a decrease in protein synthesis. Results from this assay therefore
suggest that depletion of nearly all hits tested, 13/14, cause a significant reduction in
global levels of protein synthesis. Furthermore, consistent with previous reporting
(Bartoli et al., 2011), depletion of the screen positive control, KIF11, also yielded a
significant decrease in protein synthesis. Intriguingly, while depletion of ATAD5 and
RFC1 caused an increase in the transcription of the pre-rRNA (p<0.001; Figure 3-2),
protein synthesis was reduced (p<0.05; Figure 3-8). These data suggest that in the case of
ATAD5 or RFC1 depletion, increased transcription does not necessarily lead to an
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increase in ribosome levels and consequently ribosomal function. Additionally, INKA1,
STK24, and CDCA8 were not identified as either pre-rRNA transcription or processing
factors (Figure 3-2; Figure 3-5; Figure 3-6), yet depletion also resulted in a significant
decrease in protein synthesis (p<0.001; Figure 3-8). These data suggest that these
INKA1, STK24, and CDCA8 may have an as yet unidentified role in some other aspect
of ribosome biogenesis, such as ribosome assembly or subunit export. Conversely,
depletion of FAM98A revealed a significant decrease in RNAPI transcription by nearly
50% (p<0.001; Figure 3-2), but did not yield a significant impact on global protein
synthesis (Figure 3-8), suggesting possible limitations in using this assay to infer
functional consequences of defects in RNAPI transcription, or a downstream
compensatory response that limited the impacts of FAM98A on ribosome biogenesis and
ribosomal function. Thus, from these results, I conclude that screening for an increase in
the percentage of nuclei with ≥5 nucleoli uncovered proteins, in most cases, required for
the ribosomal function of translation.
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Figure 3-8. Global protein synthesis was significantly decreased upon depletion of 13/14
of the selected screen hits. Previously published in (Ogawa et al., 2021).
(A) Shown are representative western blots from the total protein harvested from hitdepleted MCF10A cells treated with 1 μM puromycin for 1h. Protein was quantified by
Bradford assay and run on a 10% SDS-PAGE gel followed by western blots using an
antibody to puromycin to test for puromycin incorporation into the nascent peptides.
Beta-actin (ACTB)=loading control. Mock (1 μM) and siNT=negative controls. Mock
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(0.5 μM)=cells treated with half the concentration of puromycin. Depletion of ribosome
biogenesis factor UTP4=positive control.
(B) Quantification of results in A from 3 replicates. ImageJ was used to quantify the
differences in puromycin signal intensity, normalized to the beta-actin signal intensity.
Statistical significance for the 3 replicates relative to siNT was calculated by two-tailed,
unpaired t tests (*=p<0.05, **=p<0.01, ***=p<0.001; n=3). Data are shown as a bar
graph (mean ± SD), and with each replicate represented as a dot. Gray=nucleolar
proteins; white=non-nucleolar proteins.
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Depletion of 2/14 screen hits results in p53 stabilization
Considering that I identified defects in cell cycle progression for several of the
screen hits analyzed as reported in Chapter 2, it may be possible that these defects could
lead to RNAPI transcription and translation defects through TP53 (p53) repression of
RNAPI (Beckerman and Prives, 2010). On the contrary, it is also possible that defects in
RNAPI transcription and translation could lead to cell cycle arrest through both p53mediated and p53-independent mechanisms through what is commonly referred to as the
nucleolar stress response (James et al., 2014; Rubbi and Milner, 2003). As a result, I also
evaluated levels of p53 by western blot. As expected, depletion of the known ribosome
biogenesis factor, NOL11, resulted in a significant 2-fold increase in p53 levels [n=3;
p<0.05; (Griffin et al., 2015)]. Depletion of a subset of screen hits, on the other hand,
revealed that only 2/14 caused a significant increase in p53 (RFC1 and RACGAP1; n=3;
p<0.05; Figure 3-9). These data suggest that while it is possible that p53 could be
mediating the effects on RNAPI transcription that I observe when RFC1 and RACGAP1
are depleted, it is not likely mediating the effects I observe in all cases. In conclusion,
screening for increased nucleolar number was successful in identifying novel regulators
of ribosome biogenesis (Table 3-1).
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Figure 3-9. Depletion of only 2 hits results in the stabilization of the tumor suppressor
protein, p53. Previously published in (Ogawa et al., 2021).
(A) Representative western blots from the total protein harvested from MCF10A cells
depleted of the screen hits in Table 2-3 (in bold). Protein was quantified by Bradford
assay and run on a 10% SDS-PAGE gel followed by western blots using an HRPconjugated antibody to the tumor suppressor protein, p53 (TP53). Beta-actin (ACTB) was
used as a loading control. Mock and siNT-treated cells=negative controls.
siNOL11=positive control. siUTP4 was included as a known ribosome biogenesis factor,
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and siKIF11 was included because it was the screen positive control and elicited a
RNAPI and protein synthesis defect upon treatment.
(B) Quantification of results in A from 3 replicates. ImageJ was used to quantify the
differences in p53 signal intensity, normalized to the beta-actin signal intensity.
Statistical significance for the 3 replicates relative to siNT was calculated by two-tailed,
unpaired t tests (*=p<0.05; n=3). Data are shown as a bar graph (mean ± SD), and with
each replicate represented as a dot. Gray=nucleolar proteins; white=non-nucleolar
proteins.
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Table 3-1. Summary of discoveries associated with nucleolar function upon depletion of
a subset of screen hits, and the screen positive control, KIF11. Inc=Increased,
Dec=Decreased, Y=Yes, N=No, and Dash (“-“)=No significant change are concluded
based on statistical analysis that identified a significant difference from siNT (p<0.05).
Screen hit (HGNC)

RNAPI

Pre-rRNA

Global protein

p53

transcription

processing

synthesis

stabilization

(Inc/Dec)

defect

(Inc/Dec)

ATAD5
CDCA8
ENY2
FAM98A
H1-10
INCENP
INKA1
KIF11
MDN1

Inc
Dec
Dec
Dec
Dec
Dec
Dec

Y

Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec

-

RACGAP1
RFC1
STK24
TPX2
CCN4
WRAP53

Dec
Inc
Dec
Dec
Dec

-

Dec
Dec
Dec
Dec
Dec
Dec

Y
Y
-
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DISCUSSION
A genome-wide siRNA screen for increased nucleolar number has uncovered
proteins required for nucleolar function. Biochemical analyses of a subset of the 113
identified proteins revealed several required for ribosome biogenesis, including 11/14
required for RNAPI transcription and 1/14 required for pre-rRNA processing. The
identified pre-rRNA processing factor (MDN1), however, also resulted in decreased
RNAPI transcription, suggesting the overwhelming association of screen hits with the
transcriptional regulation of the pre-ribosomal RNA. Additionally, as expected for
defects in the biogenesis of ribosomes, depletion of 13/14 screen hits further resulted in
decreased protein synthesis. These data are in contrast to the dataset generated when
screening for a decrease in nucleolar number (Farley-Barnes et al., 2018). In the screen
for proteins that cause a decrease in nucleolar number when depleted, of the hits
evaluated for roles in ribosome biogenesis, the majority were associated with defects in
pre-rRNA processing (16/20). Proteins required for RNAPI transcription were also
uncovered (7/20); however, all but one demonstrated a concomitant pre-rRNA processing
defect (Farley-Barnes et al., 2018). Taken together, these data suggest that changes in
nucleolar number in MCF10A cells are indicative of a negative impact on nucleolar
function. Screening for increased nucleolar number revealed a unique subset of proteins
required primarily for the nucleolar function of RNAPI transcription.
Of the identified regulators of RNAPI transcription few were repressors of
nucleolar activity. Cancer pathologists know that increased nucleolar number and area are
associated with increased nucleolar activity and poor prognosis in cancer patients
(Derenzini et al., 2009). As such, one possibility is that hits that cause an increase in
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nucleolar number when depleted will also reveal increased RNAPI transcription. In this
analysis, however, only 2/14 screen hits evaluated resulted in an increase in RNAPI
transcription upon depletion (RFC1 and ATAD5), suggesting roles as repressors. In
support of this finding, RFC1 has previously been reported to repress rDNA transcription
in S. cerevisiae (Smith et al., 1999), and in plants (Liu et al., 2010). Furthermore, both
proteins are large subunits of heteropentameric protein complexes that share subunits,
RFC2-5, and associate with proliferating cell nuclear antigen (PCNA) during DNA
replication. The majority of hits tested were thus promoters of rDNA transcription. Of the
14 hits tested, 9 caused a decrease in RNAPI transcription upon depletion, as well as the
screen positive control, KIF11. In all, each screen hit that caused defects in RNAPI
transcription upon depletion, with the exception of FAM98A, which also resulted in
decreased protein synthesis. Thus, while increased nucleolar number and size are
commonly associated with cancer and increased growth and proliferation, our screen for
increased nucleolar number identified primarily promoters of RNAPI transcription.
The p53-mediated nucleolar stress response is not likely to be the only root cause
of the observed reduction in RNAPI transcription. The tumor suppressor protein, p53
(TP53), is a well-documented cellular stress sensor that suppresses oncogenic activity
through its regulation of transcription, which leads to cell cycle arrest and apoptosis
(Mantovani et al., 2019). Mutations in p53 are some of the most commonly observed in
human cancer (Kandoth et al., 2013). While the most widely reported gene targets of p53
include genes transcribed by RNA polymerase II (Allen et al., 2014; Kim et al., 2011),
p53 has also been reported to directly inhibit RNAPI (Zhai and Comai, 2000).
Furthermore, the stabilization of p53 is mediated by the nucleolus and scales with the
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degree of cellular stress, with greater stress eliciting higher levels of p53 and vice versa
(Rubbi and Milner, 2003). Thus, the inhibition of RNAPI transcription I observe upon
depletion of a subset of screen hits can be a cause or consequence of p53 stabilization.
Intriguingly, however, while MCF10A cells maintain wild-type p53 (Merlo et al., 1995)
inhibition of RNAPI is concomitant only with increased levels of p53 after depletion of
2/14 proteins (siRFC1 and siRACGAP1). These data suggest that not only is the RNAPI
transcriptional inhibition I observe not likely caused by p53-mediated inhibition of
RNAPI, but also that the level of RNAPI transcription is not sufficient to trigger p53
stabilization. Furthermore, RFC1 depletion led to increased RNAPI transcription rather
than decreased transcription counter to what would be expected with p53 stabilization,
and thus further analysis is required to better understand the specific relationship between
RFC1 and p53. Together, these data suggest that for 12/14 hits, the reduction in RNAPI
transcription is independent of increased levels of p53, and further supports that this
screen for increased nucleolar number identified novel regulators of ribosome biogenesis.
Finally, depletion of several of the novel regulators of RNAPI transcription
yielded defects in cell cycle progression and cell division. Of the screen hits evaluated,
depletion of KIF11 and 8/20 hits resulted in the accumulation of cells with a >4N DNA
content (Chapter 2). Failures in cell division could provide an explanation for the
observed increase in the percentage of nuclei with ≥5 nucleoli. However, given that
several of these proteins also resulted in defects in RNAPI transcription (KIF11, ENY2,
INCENP, RACGAP1, and TPX2), the cause for increased nucleolar number may not be
so easily explained. Additionally, depletion of KIF11, INCENP, and TPX2 resulted in the
accumulation of cells in G2/M phase and depletion of ENY2, FAM98A, RFC1, and
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WRAP53 resulted in an accumulation of cells in S phase (Chapter 2). Thus, alternatively,
failures in the regulation of RNAPI transcription during S or G2/M phase could lead to
the increase in nucleolar number observed. While it is possible that each of the screen hits
may function in ribosome biogenesis outside of S or G2/M phase, as reported previously
for KIF11 in translation (Bartoli et al., 2011), the enrichment of replication and mitosis
factors among the hits supports the possibility that the regulation of RNAPI specifically
during S and G2/M phase is essential to maintaining nucleolar integrity. In conclusion,
the functional analysis of a subset of screen hits has supported the hypothesis that
screening for increased nucleolar number could also identify novel regulators of
nucleolar function and has further broadened our understanding of the regulation of
ribosome biogenesis in higher eukaryotes.

MATERIALS AND METHODS

Cell lines
As described in Chapter 2, the human breast epithelial cell line, MCF10A (ATCC,
CRL-10317), was 2D subcultured in DMEM/F-12 medium (Gibco, 1130-032)
supplemented with 5% horse serum (Gibco, 16050), 10 μg/mL insulin (Sigma, I1882),
0.5 μg/mL hydrocortisone (Sigma, H0135), 100 ng/mL cholera toxin (Sigma, C8052),
and 20 ng/mL epidermal growth factor (Peprotech, AF-100-15).

RNAi
For biochemical assays on the subset of validated hits, the siGENOME
SMARTpool siRNAs (Horizon Discovery) were used, except for with siNT, which was
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the ON-TARGETplus Non-targeting pool (D-001810-10-20). Unless otherwise noted,
subconfluent cells (log phase) were transfected with siRNAs (20-30 nM, final
concentration) using Lipofectamine RNAiMAX Transfection Reagent (ThermoFisher
Scientific, 13778150) and incubated for 72 hrs prior to the experimental assays.

Quantitative reverse transcription polymerase chain reaction (qRT-PCR)
Total RNA was extracted from siRNA-depleted cells using TRIzol reagent
(ThermoFisher Scientific, 15596018) as per the manufacturer’s instructions. After
validating that A260/280 values were >1.80 and A260/230 values were >1.7,
complementary DNA synthesis was performed using the iScript gDNA Clear cDNA
Synthesis Kit (Bio-Rad, 172–5035) using 1 μg of total RNA and a mix of random
hexamer and oligo dT primers. Previously published primers were used to test mRNA
levels of ATAD5 (Bell et. al, 2011) and RFC1 (Stielow et. al, 2014). BioRad PrimePCR
Assay gene-specific primers were used to test mRNA levels of the remaining hits (BioRad, 10025636; UTP4, qHsaCID0021354; KIF11, qHsaCID0015908; CDCA8,
qHsaCED0044566; H1-10, qHsaCED0019411; INCENP, qHsaCID0010103; MDN1,
qHsaCID0006754; STK24, qHsaCID0012429; TPX2, qHsaCID0016024; ENY2,
qHsaCED0003040; FAM98A, qHsaCID0010948; INKA, qHsaCED0020031;
RACGAP1, qHsaCID0011308; CCN4, qHsaCED0036389; WRAP53,
qHsaCID0006849). Beta-actin primers were designed in our laboratory (intron-spanning;
Forward - 5’ ATT GGC AAT GAG CGG TTC 3’ and Reverse - 5’ CGT GGA TGC CAC
AGG ACT 3’). All qPCR reactions were completed using the iTaq Universal SYBR
Green Supermix (Bio-Rad, 172-5121). To verify the amplification of a single PCR
product, melt curves were generated for each sample. Three biological replicates, each
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with three technical replicates, were measured for each of the 14 tested hits as well as
siUTP4, siKIF11, and the negative non-targeting control (siNT). Amplification of the
beta-actin mRNA was used as an internal control, and analysis was completed using the
comparative CT method (ΔΔCT).

Dual-luciferase reporter assay
Following siRNA-depletion of hits for 48 hrs, cells were transfected with 1000 ng
of pHrD-IRES-Luc (Ghoshal et al., 2004) and 0.1 ng of a plasmid that constitutively
expresses Renilla luciferase (Freed et al., 2012) using Lipofectamine 3000 Reagent
(ThermoFisher Scientific, L3000015). After 72 hrs of siRNA-depletion and 24 hrs of
incubation with the reporter plasmids, luminescence was detected using the DualLuciferase Reporter Assay System (Promega, E1910) and a GloMax 20/20 luminometer
(Promega). In addition to incubation with the 1X passive lysis buffer for 15 min,
MCF10A cells were scraped prior to collection for luminescence readings.

Northern blots
Total RNA was extracted from siRNA-depleted cells using TRIzol Reagent. To
assay for changes in levels of pre-rRNA intermediates, 4 μg of total RNA was run on a
1% agarose/1.25% formaldehyde gel in a 1.5M tricine/1.5M triethanolamine buffer. RNA
was transferred overnight to a Hybond XL nylon membrane (GE Healthcare, RPN 303S)
by capillary transfer in 10X saline-sodium citrate (SSC) transfer buffer after a brief 15
min soak in a 0.5M sodium hydroxide solution. Membranes were then exposed to UV
(254 nm) to immobilize the RNA, and incubated with denatured yeast tRNA for 1 hr at
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42° C and hybridized overnight at 37° C with 5’ end radiolabeled oligonucleotide probes
in a solution of 7.5X Denhardt’s solution, 5X sodium chloride-sodium phosphate-EDTA
(SSPE) buffer, and 0.1% SDS as in (Farley-Barnes et al., 2018). The oligonucleotide
probes used were the same as in (Farley-Barnes et al., 2018) and include:
5’ETS 5’ – CCTCTCCAGCGACAGGTCGCCAGAGGACAGCGTGTCAGC - 3’
5’ITS1 5’ – CCTCGCCCTCCGGGCTCCGTTAATGATC - 3’ (Sloan et al., 2013)
P3 5’ – AAGGGGTCTTTAAACCTCCGCGCCGGAACGCGCTAGGTAC - 3’
P4 5’ – CGGGAACTCGGCCCGAGCCGGCTCTCTCTTTCCCTCTCCG - 3’
7SL 5’ – TGCTCCGTTTCCGACCTGGGCCGGTTCACCCCTCCTT - 3’

Puromycin labeling assay
Following siRNA-depletion of hits for 72 hrs, cells were treated as described in
(Farley-Barnes et al., 2018), with the exception that puromycin antibody (Kerafast,
EQ0001) was used at a 1:500 dilution.

Western blots
Following siRNA-depletion of hits for 72 hrs, total protein was harvested by the
same method used in the puromycin labeling assay described in (Farley-Barnes et al.,
2018). Protein concentration was quantified by Bradford assay and 30 μg of total protein
was run by SDS-PAGE on a 10% gel with a 5% stacking gel. Protein was transferred to a
PVDF membrane using a Trans-Blot Turbo Transfer System (Bio-Rad) and blocked for 1
hr with 5% milk in PBST before incubating overnight with HRP-conjugated p53 antibody
(Santa Cruz Biotechnology, sc-126) diluted in PBST (1:5000). Following imaging on a
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ChemiDoc Imaging System (Bio-Rad), blots were stripped and re-probed for beta-actin
as performed in the puromycin labeling assay and quantified using ImageJ.

Statistical analyses
All statistical analyses were performed in GraphPad Prism 8.2.1 (GraphPad
Software, Inc.) using the tests described in the Figure Legends.
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Chapter 4

High-throughput screen for nucleolar-targeted cancer therapies reveals small
molecule regulators of nucleolar number
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INTRODUCTION
Ribosome biogenesis is essential for cell growth and proliferation and is linked to
cancer pathogenesis. Cancer pathologists observe larger and more numerous nucleoli in
aggressive tumors (Derenzini et al., 2009), and retrospective studies found that several
chemotherapeutic agents target ribosome biogenesis either directly or indirectly (Burger
et al., 2010; Quin et al., 2014). While the enthusiasm was initially put towards identifying
inhibitors of translation for cancer therapy (Hagner et al., 2010; Malina et al., 2012;
Novac et al., 2004; Ruggero, 2013; Silvera et al., 2010), interest surrounding the
development of drugs targeting ribosome biogenesis specifically has gained recent
momentum (Brighenti et al., 2015; Drygin et al., 2010; Pelletier et al., 2018; Quin et al.,
2014). Thus, targeting the nucleolus and ribosome biogenesis holds promising therapeutic
potential.
Preclinical and clinical data support that drugs developed specifically to target
RNAPI transcription hold promise in the treatment of cancer. While drugs targeting a
ubiquitous cellular function may hold limited therapeutic efficacy and yield poor toxicity
profiles, studies on pioneering RNAPI-selective inhibitors suggest instead that growth
adaptations in cancer may actually make tumors more sensitive to the inhibition of
ribosome biogenesis (Brighenti et al., 2015; Ruggero, 2012). The RNAPI inhibitor, CX3543 (quarfloxin), may in part target rDNA-enriched G-quadruplexes (Drygin et al.,
2009; Drygin et al., 2008). Phase I and II clinical trials of CX-3543 in solid tumors and
blood cancer revealed no serious adverse events and resulted in stable disease through the
course of the study for several participants (Papadopoulos et al., 2007). CX-5461,
likewise, has shown promising preclinical and clinical data for the treatment of
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hematological malignancies and DNA repair-deficient cancers (Hilton et al., 2020; Khot
et al., 2019; Sanij et al., 2020; Xu et al., 2017b). CX-5461 inhibits RNAPI by disrupting
the interaction between RNAPI and the transcription initiation factor, SL1 (Drygin et al.,
2011). More recent studies on the mechanism, however, suggest that CX-5461 may also
inhibit topoisomerase II (Bruno et al., 2020), and therefore the therapeutic benefit from
its effect on RNAPI versus topoisomerase remains to be elucidated. Finally, the RNAPI
inhibitor, BMH-21, a planar heterocyclic DNA intercalator, leads to the selective
degradation of the large catalytic subunit of RNAPI, RPA194 (Peltonen et al., 2014). In
preclinical studies, BMH-21 treatment has shown promising antiproliferative activity
across a range of cancer cell lines with limited impact on normal fibroblast cells (Fu et
al., 2017; Peltonen et al., 2014). Furthermore, BMH-21 also has promising antineoplastic
activity in mouse xenograft models of melanoma and drug-resistant prostate cancer (Low
et al., 2019; Peltonen et al., 2014). Taken together, promising preclinical and clinical
research on these pioneering compounds have energized some laboratories to further
explore inhibition of ribosome biogenesis for cancer drug discovery.
High-throughput screens to identify novel inhibitors of ribosome biogenesis have
yielded some success in identifying promising new drug candidates. In one screen,
~150,000 compounds were screened for reduced nascent ribosome levels in the human
melanoma A375 cell line (Scull et al., 2019). This primary screen was then followed by a
secondary screen for compounds that specifically decrease pre-rRNA levels, which
revealed 2 structurally similar compounds, RB1 and RB2, that both decreased cell
viability. Furthermore, RB2 had limited impact on viability of normal, HUVEC, cells and
RB2 treatment resulted in decreased colony growth in a metastatic, anchorage-
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independent growth model (Scull et al., 2019). Another screen of ~700 compounds used a
virtual structure-based screening approach using the yeast crystal structure of the human
RNAPI ortholog (Tan and Awuah, 2019). Six compounds were identified in this virtual
screen, including CX-5461 and, intriguingly, the HMG-CoA reductase inhibitor,
cerivastatin sodium. Follow up using a yeast cell line engineered with the human rDNA
and promoter sequence revealed that cerivastatin sodium inhibited yeast growth and also
decreased proliferation when tested in human cancer cell lines (Tan and Awuah, 2019).
Finally, in yet another recent high-throughput screen for inhibitors of ribosome
biogenesis, ~1,000 compounds were surveyed in a yeast system detecting defects in
ribosomal subunit export. Of the compounds tested, several were identified to impact
either 40S or 60S export and subsequent analysis of hits revealed that many inhibit prerRNA processing; however, they have yet to be validated in a mammalian system (Awad
et al., 2019). Thus, there has been success in screening for small molecule inhibitors of
ribosome biogenesis in eukaryotes and the data suggest that the approach may be a
promising opportunity for the identification of novel drugs for therapeutic development.
Previously, the Baserga lab, including myself, was successful in identifying
proteins required for ribosome biogenesis by performing a high-throughput RNAi screen
in the non-cancer-derived human, MCF10A, breast epithelial cell line for changes in
nucleolar number [(Farley-Barnes et al., 2018); Chapter 2]. I applied this robust assay to
discover putative new cancer therapeutics by screening for small molecule compounds
that effect nucleolar number. I therefore performed two high-throughput screens for small
molecules that regulate nucleolar number. Here, I report on the results from these two
screens, which included a pilot screen of nearly 4,000 FDA-approved drugs, followed by
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a screen of a curated collection of approximately 25,000 synthetic compounds selected
based on exhibiting promising pharmaceutical properties. Through these screens I
discovered several small molecule regulators of nucleolar number, including both
compounds that decrease nucleolar number and those that increase nucleolar number.
Validation screening of the hits as well as bioinformatic analyses to classify hits reveal
not only several promising drug candidates, but also common molecular targets that lend
insight into the regulation of nucleolar number and activity. I performed these two
screens, screen validation, and the structure clustering in collaboration with the Yale
Center for Molecular Discovery.

RESULTS
Identification of small molecule positive controls for high-throughput screening
To identify novel cancer therapeutics by screening for small molecule regulators
of nucleolar number I needed to identify small molecule compounds that yield a strong
and reproducible decrease in nucleolar number [one nucleolus per nucleus percent effect
(PE)] and increase in nucleolar number (≥5 nucleoli per nucleus PE) to use as positive
controls. To identify these positive controls, I tested 25 compounds with different
mechanisms of action at eight different concentrations (20 μM-9.14 nM, 3-fold dilutions),
three different time points (24, 48, and 72 hrs), and two cell seeding densities (1,000 and
2,000 cells/well; Table 4-1). I curated the list of compounds with Katherine FarleyBarnes and Cecelia Harold, and I performed the high-throughput screen and data analysis
in collaboration with the Yale Center for Molecular Discovery. Nucleoli were identified
based on immunofluorescent staining with a monoclonal antibody to the abundant
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nucleolar protein fibrillarin [72B9 (Reimer et al., 1987)], and cells were identified using
the DNA stain, Hoechst. Nucleolar number was quantified using CellProfiler as described
in (Farley-Barnes et al., 2018), and the one nucleolus PE and ≥5 nucleoli PE were both
quantified relative to the negative control (0.1% DMSO; DMSO=100 PE). The seeding
density of 2,000 cells per well and a 48 hr incubation led to several promising candidates
with adequate viability (Appendix IV). As a result, we selected several with which to
perform follow-up testing in order to identify the best candidates with which to move
forward with as positive controls for the screen.
To identify positive controls from among the candidates in this small screen, we
selected compounds that yielded a high PE for each phenotype (one nucleolus and ≥5
nucleoli) to re-screen for reproducibility. The Z-prime statistic is the best measure of a
strong and reproducible control as it reports the separation between the distributions of
the positive and negative controls. As described in Chapter 2, a Z-prime =1 indicates an
ideal screening assay, whereas a Z-prime <0 indicates overlap between the controls and a
noisy assay. While in high-throughput screening a Z-prime ≥0.5 is desired, Z-prime
values <0.5 may still identify positive hits. I selected two compounds for each phenotype
to re-screen at several different concentrations at a seeding density of 2,000 cells per well
and an incubation time of 48 hr and calculated the Z-prime statistic for each condition.
These compounds included RNAPI inhibitors, BMH-21 and CX-5461, for the one
nucleolus per nucleus phenotype, and mitomycin C and topotecan for the ≥5 nucleoli per
nucleus phenotype. Interestingly, based on the results from this experiment, BMH-21 (1
and 1.5 μM) and mitomycin C (14 μM) both yielded promising Z-prime values (Z-prime
≥0.5) for decreased nucleolar number (Table 4-2). This was intriguing given that
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mitomycin C had originally been selected as a putative positive control for increased
nucleolar number and suggests a possible relationship between the two unique
phenotypes. With regards to the ≥5 nucleoli per nucleus phenotype neither of the selected
compounds yielded Z-prime values ≥0.5; however, mitomycin C at 250 nM did yield a
positive Z-prime value (Z’=0.11; Table 4-3). Based on these data, BMH-21 (1 μM) and
mitomycin C (250 nM) were selected as the two positive controls for our screen.
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Table 4-1. Candidate compounds screened in positive control search for a highthroughput screen to identify small molecule regulators of nucleolar number. The twentyfive (25) compounds selected harbored a wide range of mechanisms of action and
reported effects on the nucleolus or nucleolar proteins.
Compound

Catalog no.

Mechanism of

Rationale

action
5-

F6627 (Sigma-

Thymidylate

Reported to effect late pre-rRNA

Fluorouracil

Aldrich)

synthase

processing (Burger and Eick,

inhibitor

2013)

Actinomycin

A1410 (Sigma- DNA intercalator

RNA polymerase inhibitor;

D

Aldrich)

causes nucleolar disruption
(Reynolds et al., 1964)

Amperozide

sc-203512

5-HT receptor

Treated cells may show one

(Santa Cruz

agonist

nucleolus phenotype

Biotechnology)
BMH-21

C646

(Gustafsdottir et al., 2013)

SML1183

DNA

RNAPI inhibitor (Peltonen et al.,

(Sigma-

intercalator;

2014)

Aldrich)

RNAPI inhibitor

328968-36-1

UBTF

UBTF is an RNAPI transcription

(Cayman

acetylation

co-factor (McStay and Grummt,

Chemical)

inhibitor

2008; Sanij and Hannan, 2009)
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CDK9

238811

CDK9 inhibitor

Preclinical blood cancer drug and

Inhibitor II

(Sigma-

putative rRNA processing

Aldrich)

inhibitor (Burger et al., 2013;
Yin et al., 2014)

Cisplatin

CX-5461

C2210000

Platinum-

Breast cancer therapeutic; Binds

(Sigma-

containing

the ribosome (Melnikov et al.,

Aldrich)

chemotherapeutic 2016)

1138549-36-6

RNAPI inhibitor;

RNAPI inhibitor (Drygin et al.,

(Cayman

Topoisomerase

2011; Haddach et al., 2012)

Chemical)

inhibitor (Bruno
et al., 2020)

Doxorubicin

Topoisomerase

Breast cancer therapeutic;

inhibitor

Inhibits RNAPI transcription
(Burger et al., 2010)

Etoposide

E1383 (Sigma-

Topoisomerase

Treated cells show large, flat

Aldrich)

inhibitor

nucleoli (Gustafsdottir et al.,
2013)

Fenbendazole F5396 (SigmaAldrich)

Tubulin

Reported effect on nucleolar

modulator

morphology (Gustafsdottir et al.,
2013)

Flavopiridol

131740-09-5

CDK1 inhibitor

CDK1 activity is required for

(Cayman

RNAPI silencing during mitosis

Chemical)

(Hernandez-Verdun, 2011)
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Hesperadin

422513-13-1

Aurora B kinase-

Aurora B kinase interacting

(Cayman

selective

proteins were hits in siRNA

Chemical)

inhibitor

screen for increased nucleolar
number (Chapter 2)

Ispinesib

IWP-2

336113-53-2

KIF11 inhibitor

KIF11 inhibition by siRNA

(Cayman

yields an increase in nucleolar

Chemical)

number (Chapter 2)

I0536 (Sigma-

WNT inhibitor

Aldrich)

Wnt proteins regulate ribosome
biogenesis (Pfister and Kuhl,
2018)

LY411575

209984-57-6

Gamma-secretase Notch pathway implicated in

(Cayman

inhibitor

Chemical)
Metarrestin

breast cancer progression
(Kontomanolis et al., 2018)

AOB1384

Peri-nucleolar

Inhibits RNAPI transcription

(Aobious)

compartment

(Frankowski et al., 2018)

inhibitor
Metformin

Mitomycin C

PHR1084

mTOR inhibitor

mTOR regulates ribosome

(Sigma-

biogenesis (Mayer and Grummt,

Aldrich)

2006)

50-07-7

DNA crosslinker

(Cayman

Inhibits rRNA synthesis
(Snodgrass et al., 2010)

Chemical)
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Paclitaxel

T7402 (Sigma-

Microtubule

Breast cancer therapeutic;

Aldrich)

depolymerization

Mitosis inhibitor; siRNA screen

inhibitor

for increased nucleolar number
revealed enrichment of mitosis
factors (Chapter 2)

SBE 13

SML0012

PLK1 inhibitor

Mitosis inhibitor; siRNA screen

(Sigma-

for increased nucleolar number

Aldrich)

revealed enrichment of mitosis
factors (Chapter 2)

Temsirolimus PZ0020

Topotecan

mTOR inhibitor

mTOR regulates ribosome

(Sigma-

biogenesis (Mayer and Grummt,

Aldrich)

2006)

119413-54-6

Topoisomerase

Topoisomerase inhibitors have

(Cayman

inhibitor

reported effects on ribosome

Chemical)
Trichostatin

T8552 (Sigma-

A

Aldrich)

biogenesis (Burger et al., 2010)
HDAC inhibitor

UBTF RNA polymerase I
transcription co-factor is a
substrate (Pelletier et al., 2000)

XAV939

X3004 (Sigma- WNT inhibitor

Wnt proteins regulated ribosome

Aldrich)

biogenesis (Pfister and Kuhl,
2018)
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Table 4-2. Screen statistics for re-screened one nucleolus per nucleus candidates.
Compound, concentration tested (μM), coefficient of variation (CV), signal-tobackground (S/B), and Z-prime value are reported. A Z-prime >0.5 is desired for highthroughput screening, although Z-prime values between 0 and 0.5 are still acceptable for
the positive identification of hits. Compounds at concentrations that led to a viability of
<10% are not reported. Compound and concentration selected as the positive control is in
bold.
Compound

Concentration

Coefficient of

Signal-to-

(μM)

Variation (%)

Background

Z-prime

(S/B)
BMH-21

2.2

14.3

3.3

0.24

BMH-21

1.5

5.7

3.7

0.64

BMH-21

1.0

7.0

3.5

0.57

BMH-21

0.75

6.3

3.5

0.59

BMH-21

0.375

7.1

2.3

0.37

CX-5461

20

8.5

2.5

0.36

Mitomycin C

14

5.4

4.1

0.67

Mitomycin C

7

8.0

3.2

0.49

Mitomycin C

3.5

8.1

2.4

0.33
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Table 4-3. Screen statistics for re-screened ≥5 nucleoli per nucleus candidates.
Compound, concentration tested (μM), coefficient of variation, signal-to-background
(S/B), and Z-prime values are reported. A Z-prime >0.5 is desired for high-throughput
screening, although Z-prime values <0.5 may still identify positive hits. Compounds at
concentrations that led to a viability of <10% are not reported. Compound and
concentration selected as the positive control is in bold.
Compound

Concentration

Coefficient of

Signal-to-

(μM)

Variation (%)

Background

Z-prime

(S/B)
Mitomycin C

0.5

16.7

2.4

-0.3

Mitomycin C

0.25

10.7

2.6

0.11

Mitomycin C

0.125

11.3

2.3

-0.05

Topotecan

0.018

9.4

2.2

-0.02
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Pilot screen of FDA-approved drugs revealed 140 compounds
To identify new cancer therapeutics by screening for small molecule regulators of
nucleolar number, I first performed a pilot screen of FDA-approved compounds to test
whether any proven small molecule drugs impact nucleolar number. I screened 3,923
compounds maintained in 3 different drug libraries curated by the Yale Center for
Molecular Discovery. MCF10A cells were seeded at a density of 2,000 cells per well and
24 hrs later cells were treated for 48 hrs with compounds at a final concentration of 10
μM. Nucleolar number was quantified by CellProfiler as reported in (Farley-Barnes et al.,
2018), and the one nucleolus PE and ≥5 nucleoli PE were both quantified and normalized
to the average of the 12 negative (0.1% DMSO; PE=0) and 12 positive (1 μM BMH-21
or 0.25 μM mitomycin C; PE=100) control replicates included on each screening plate.
The calculated normalized percent effect (NPE) values were then used to identify hits in
the screen.
The screen for compounds that cause a decrease in nucleolar number was robust
and revealed 110 active compounds. Statistical monitoring of the 13 screening plates
revealed a mean S/B of 3.09 (range, 2.91 to 3.26) and mean Z-prime value of 0.56 (range,
0.40 to 0.68), suggesting good signal and separation of the two controls (Figure 4-1, A).
Based on a conservative threshold of ≥3 standard deviations (SD) from the median NPE,
compounds that yielded a one nucleolus NPE ≥53.2 were considered a hit. This yielded a
hit rate of 2.8%, or 110 compounds, with a mean percent viability of 10.9% relative to
DMSO (range, 0.5 to 33.6; Figure 4-1, B-D; Appendix V). Of the 110 hits, several were
identified multiple times due to overlap in the compound libraries (Table 4-4). As a
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result, 83 unique compounds were identified to cause a decrease in nucleolar number and
suggests the identification of several putative new regulators of nucleolar function.
In contrast, the screen for compounds that cause an increase in nucleolar number
was not as robust. Statistical monitoring of the 13 screening plates revealed a mean S/B
of 1.88 (range, 1.56 to 2.28) and mean Z-prime value of -0.56 (range, -1.05 to -0.20).
Negative Z-prime values suggest overlap among the percent effect distributions of the
controls; however, the means of the controls were separated with only slight overlap of
the distributions (Figure 4-2, A), and therefore I proceeded with caution. I identified hits
based on the same conservative threshold of ≥3 SD from the median NPE (NPE ≥108.3),
which yielded a NPE greater than the positive control. Based on this threshold, 30 hits
were identified to cause an increase in the percentage of nuclei with ≥5 nucleoli (hit
rate=0.8%) with a mean percent viability relative to DMSO among the hits of 35.7%
(range, 0.8 to 99.2; Figure 4-2, B-D; Appendix VI). While some of these hits may be
false positives, they are good candidates for re-screening to identify a better positive
control.
The pilot screen to identify small molecule regulators of nucleolar number was
therefore effective in identifying 140 compounds that either decrease or increase
nucleolar number. While the screen for decreased nucleolar number was more robust
with favorable and reproducible Z-prime values among the screening plates, the screen
for increased nucleolar number may still hold promise and revealed 30 hits with an
NPE>100. Interestingly, mebendazole was a hit in both screens (Appendix V; Appendix
VI). Comparisons to prior screens for inhibitors of ribosome biogenesis revealed several
overlapping hits (Table 4-5). These data support to my results, but also suggest that the
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Baserga lab’s unique screening approach may reveal a broader range of regulators of
nucleolar function than the previously reported screens. While promising, these data
necessitate further analysis and validation, including repeat testing, dose-response curves
to identify EC50 concentrations, and testing in cancer versus normal cell lines to identify
the extent to which hits share any common targets and whether they harbor any anticancer potential.
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Figure 4-1. High-throughput screen of FDA-approved drugs revealed 110 compounds
(2.8%) that caused a decreased in nucleolar number.
(A) Frequency distribution of the one nucleolus phenotype mean percent effect (PE) of
the negative and positive control treatments included on each screening plate (n=13).
DMSO=negative control (red line) and mean PE set to 0. BMH-21=positive control (dark
blue line) and mean PE set to 100. All FDA-approved drugs tested=compounds (light
blue line). Mean Z-prime value for the screen was 0.56 (range, 0.40 to 0.68).
(B) Distribution of the one nucleolus per nucleus normalized percent effect (NPE) for
each of the 3,923 compounds tested in the pilot screen of FDA-approved compounds.
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Threshold used to define hits was ≥3 standard deviations from the median NPE (red
dashed line) or NPE ≥53.2.
(C) Percent viability relative to the one nucleolus per nucleus NPE for the 110 hits. Each
dot represents a hit. Mean percent viability of the 110 hits was 10.9% relative to DMSO,
set to 100% (range, 0.5 to 33.6).
(D) Representative images of the controls and top hits that caused a decrease in nucleolar
number to one nucleolus per nucleus. DMSO=negative control and BMH-21=positive
control. Hits represented include sanguinarine sulfate, pixantrone dimaleate, vindesine,
pyrvinium pamoate, digitoxin, and benzethonium choloride.
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Table 4-4. Compounds identified more than once in the screen for decreased nucleolar
number. Drug name, the number (No.) of times the drug appeared in the hit list, and the
range of the normalized percent effect (NPE) for the drug in the screen are indicated.
Drug name

No. of times

Mean NPE

in hit list

(Lowest NPE, Highest NPE)

Vinblastine (Velban)

5

106.0 (78.2, 125.7)

Mycophenolic acid (Mycophenolate

4

77.8 (63.8, 99.7)

Vinorelbine (Navelbine)

3

106.0 (91.7, 114.8)

Plicamycin (Mithracin)

3

86.2 (73.6, 100.9)

Vincristine (Oncovin)

3

112.7 (105.8, 122.5)

Podofilox (Condylox)

2

83.6 (81.0, 86.2)

Piroctone olamine (Octopirox;

2

94.1 (94.0, 94.1)

Ouabain

2

98.1 (96.3, 99.8)

Colchicine

2

81.7 (75.3, 88.1)

Mitoxantrone hydrochloride

2

160.3 (131.9, 188.7)

Ciclopirox olamine (Ciclopirox)

2

84.6 (83.7, 85.5)

Albendazole

2

73.4 (70.4, 76.4)

Mebendazole (Vermox)

2

60.1 (55.0, 65.2)

Aclarubicin

2

107.7 (96.8, 118.6)

Proscillaridin (Caradrin)

2

107.7 (99.1, 116.3)

mofetil; CellCept)

piroctone)

(Mitoxantrone)
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Digitoxin (Crystodigin)

2

107.5 (102.3, 112.7)

Mitomycin (Mitomycin C;

2

90.4 (77.3, 103.5)

Vindesine sulfate (Eldesine)

2

117.3 (96.5, 138.1)

Topotecan hydrochloride (Topotecan)

2

123.5 (120.5, 126.4)

Mutamycin)
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Figure 4-2. High-throughput screen of FDA-approved drugs revealed 30 compounds
(0.8%) that caused an increase in nucleolar number.
(A) Frequency distribution of the one nucleolus phenotype percent effect (PE) of the
negative and positive control treatments included on each screening plate.
DMSO=negative control (red line) and mean PE set to 0. Mitomycin C=positive control
(purple line) and mean PE set to 100. All FDA-approved drugs tested=compounds (light
blue line). Mean Z-prime value for the screen was -0.56 (range, -1.05 to -0.20).
(B) Distribution of the normalized percent effect (NPE) for each of the 3,923 compounds
tested in the pilot screen of FDA-approved compounds. Threshold used to define hits was
≥3 standard deviations from the median NPE (red dashed line) or NPE ≥108.3.
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(C) Percent viability relative to the ≥5 nucleoli per nucleus NPE for the 30 hits. Each dot
represents a hit. Mean percent viability of the 30 hits was 35.7% relative to DMSO, set to
100% (range, 0.8 to 99.2).
(D) Representative images of the controls and top hits yielding an increase in the
percentage of nuclei with ≥5 nucleoli. DMSO=negative control and mitomycin
C=positive control. Hits represented include melphalan, merimepodib, docetaxel,
oxiconazole, butoconazole, and alvocidib.
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Table 4-5. Comparison to other screens for small molecule inhibitors of ribosome
biogenesis. Drug names are indicated. In parentheses are the number of overlapping hits
compared to the total number of hits identified by the screening approach.
Low-throughput screen of

Virtual structure-based

Screen for ribosomal

chemotherapeutic drugs for

screen for RNAPI

subunit export and pre-

inhibition of ribosome

inhibitors

rRNA processing

biogenesis

(Tan and Awuah, 2019)

inhibitors

(Burger et al., 2010)

(1/6)

(Awad et al., 2019)

(7/20)
Cycloheximide

(7/128)
Cerivastatin sodium

Daunorubicin

Doxorubicin

Doxorubicin

Etoposide

Flubendazole

Melphalan

Idarubicin

Mitoxantrone

Lasalocid A

Mitomycin C

Mycophenolic acid

Vinblastine

Vindesine sulfate
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Bioinformatic analysis of screen hits reveals known cancer therapeutics
Screening for changes in nucleolar number was successful in identifying
compounds that regulate nucleolar number; but, was I successful in identifying drugs
approved for use in cancer treatment? To address this question, I manually curated
medical use and molecular target information for each of the 140 hits using KEGG
DRUG Database, DrugBank Online and a review of relevant literature (Appendix V;
Appendix VI). The analysis of drug hits by medical use revealed that when screening for
regulators of nucleolar number, antineoplastic drugs were the most common type of
drugs among the hits (Figure 4-3; Appendix V; Appendix VI). Also represented among
top hits were several unexpected categories of drugs, including antiparasitic compounds,
cardiovascular agents, antifungals, antiseptics, and antibiotics. Among the antiparasitc
drugs, antihelmintics were the most common; among the cardiovascular agents, cardiac
glycosides were the primary drugs identified. Interestingly, however, differences between
decreased and increased nucleolar number among the drug medical uses identified were
minimal, which suggests in part a possible shared mechanism by which these two
phenotypes are generated. Taken together, screening for changes in nucleolar number
was successful in identifying several antineoplastic drugs and may therefore be a viable
approach for the discovery of novel antineoplastic compounds.
Classification of the molecular target for each hit also revealed significant
overlap among the drugs identified by decreased versus increased nucleolar number.
Common molecular targets among the drug hits include tubulin, DNA, topoisomerases
and inosine-5’-monophosphate dehydrogenase (IMPDH; Figure 4-4; Appendix V;
Appendix VI). Interestingly, a common mechanism underlying the targeting of DNA,
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topoisomerases, and IMPHD is the inhibition of DNA and RNA synthesis and implies,
not unexpectedly, the importance of these essential cellular functions in maintaining
normal nucleolar numbers. Other notable drug targets among the hits include the
ribosome, which supports a putative feedback mechanism between translation and
ribosome biogenesis (Figure 4-4, A and B), and the Na+/K+ ATPase, which is the
molecular target for cardiac glycosides, but has also been reported to be up-regulated in
cancer [Figure 4-4, A-C (Khajah et al., 2018)]. Differences, among the two datasets
however are also present, including most notably the identification of several drugs
identified by increased nucleolar number that target ergosterol, a fungal cell wall lipid
(Figure 4-4, B and D; Appendix V; Appendix VI). Intriguingly, however, ergosterol is
also a provitamin in humans that is converted into vitamin D2 upon UV exposure and
suggests a putative link between vitamin D2 and the nucleolus that has yet to be
elucidated. Thus, analysis of the molecular targets among the drugs identified by
screening for changes in nucleolar number again support common mechanisms
underlying the generation of the two phenotypes, and further emphasize promising drug
targets for the development of new cancer therapeutics.
In conclusion, I screened for compounds that regulate nucleolar number and
identified several known antineoplastic drugs. Furthermore, I identified several common
unexpected categories of drugs that will be interesting to explore in greater detail with
regards to harboring antineoplastic potential. Additionally, I identified drugs with several
common molecular targets that will be intriguing to explore with regards to putative
functional roles in nucleolar biology. In all, these data suggest that screening FDAapproved compounds for changes in nucleolar number was a successful endeavor, and
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one that supports expanding our search for novel cancer therapeutics using our approach
with a larger library of small molecule compounds.
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Figure 4-3. Antineoplastic drugs were the most frequently identified compounds among
the FDA-approved drugs that regulate nucleolar number.
(A) Compounds that caused a decrease in nucleolar number classified by medical use. Of
the 110 hits identified, 13 categories of drugs were defined. Antineoplastic drugs were
the most common (n=52 hits). Cardiovascular agents include cardiac glycosides (n=10),
statins (n=1), vasopressin receptor antagonists (n=1), and Ca+ channel blockers (n=1).
Antiparasitics include anthelmintics (n=12) and antiprotozoals (n=3). 11 drugs were
classified in more than one category.
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(B) Compounds that caused an increase in nucleolar number classified by medical use. Of
the 30 hits identified, 11 categories of drugs were defined. Antineoplastic drugs were the
most common (n=11). Antiparasitics include broad-spectrum antiparasitic (n=2) and
antihelmintics (n=1). Four drugs were classified in more than one category.
(C) Pie chart of top 4 categories of drugs that cause a decrease in nucleolar number by
medical use. The most common categories of drugs identified were (1) antineoplastic
drugs, (2) antiparasitics, (3) cardiovascular agents, and (4) antiseptics. Created, in part,
with Biorender.com.
(D) Pie chart of top 4 categories of drugs that cause an increase in nucleolar number by
medical use. The most common categories of drugs identified were (1) antineoplastic
drugs, (2) antifungals, (3) antiparasitics, and (4) antiseptics. Created, in part, with
Biorender.com.
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Figure 4-4. Several common molecular targets were identified among the FDA-approved
drugs that regulate nucleolar number.
(A) Compounds that caused a decrease in nucleolar number classified by molecular
target. Of the 110 hits identified, 24 different categories were defined. The most common
molecular target among the hits was tubulin (n=32).
(B) Compounds that caused an increase in nucleolar number classified by molecular
target. Of the 30 hits identified, 15 different categories were defined. The most common
molecular target among the hits was ergosterol, a sterol found in fungal cell membranes
and also precursor to vitamin D2 (n=6).
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(C) Pie chart of top 4 molecular targets that cause a decrease in nucleolar number. The
most common molecular targets are (1) tubulin, (2) plasma membrane, (3) topoisomerase,
and (4) Na+/K+ ATPase. Created, in part, with Biorender.com.
(D) Pie chart of top 4 molecular targets that cause an increase in nucleolar number. The
most common categories of drugs identified were (1) ergosterol, (2) DNA, (3) tubulin,
and (4) inosine-5’-monophosphate dehydrogenase (IMPDH). Created, in part, with
Biorender.com.
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Screen of synthetic library of drug-like small molecules identified 234 hits
With the objective of identifying new cancer therapeutics, I therefore expanded
our search by screening a library of novel, synthetic, drug-like compounds to identify
regulators of nucleolar number. First, however, given the poor Z-prime values obtained in
the pilot screen for increased nucleolar number due to a low PE among some treatments, I
selected 3 of the top hits to re-screen as new positive controls. The 3 hits included,
oxiconazole, butoconazole, and melphalan, which all yielded a NPE ≥100 and were
therefore promising candidates. Re-screening, however at several different concentrations
for each compound, revealed that only melphalan yielded positive Z-prime values and a
high signal to background (S/B; Table 4-6). Mitomycin C, however, was included in the
experiment for comparison and yielded similar results. As a result, I decided to proceed
with the original positive control, mitomycin C (250 nM), with which to expand our
search for novel small molecule regulators of nucleolar number.
The high-throughput screen for novel small molecule regulators of nucleolar
number revealed 202 compounds that decrease nucleolar number. I screened 25,246
compounds on 79 plates that contained a synthetic library of compounds enriched in sp3
tetravalent carbons (3-D) and other physicochemical properties common among known
bioactive, therapeutic compounds (Life Chemicals, Inc.). The library was also designed
to be void in known pan-assay interference compounds (PAINS). Screening for
compounds that cause a decrease in nucleolar number revealed 202 compounds. The
mean S/B across all 79 screening plates was 3.17 (range, 1.96 to 5.60) and the mean Zprime value was 0.53 (range, 0.21 to 0.74), suggesting good separation between the
negative (DMSO) and positive control (BMH-21; Figure 4-5, A). As with the FDA-
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approved pilot screen, hits were then identified based on a conservative threshold of ≥3
SD from the median NPE of all 25,246 compounds. As a result, compounds that yielded a
one nucleolus per nucleus NPE ≥16.8 were considered a hit, yielding 202 hits with a
mean percent viability of 68.1 (range, 6.2 to 354.7; Figure 4-5, B-D; Appendix VII). As
with the pilot screen for decreased nucleolar number, this screen was robust and
identified 234 novel small molecular regulators of nucleolar number with the potential to
harbor antineoplastic activity.
The screen for novel small molecules that cause an increase in nucleolar number
revealed 32 compounds. Again, however, Z-prime calculation of the screen controls
revealed a less than robust screen. While the mean S/B across the 79 screening plates was
strong, 2.38 (range, 1.15 to 3.46), the mean Z-prime value was -0.39 (range, -6.70 to
0.41) suggesting poor separation of the controls due to variability in PE of mitomycin C,
at least on some assay plates (Figure 4-6, A). The majority of screening plates, however,
yielded relatively consistent Z-prime values >0, except for a few of the early plates and a
later batch of plates. I therefore decided again to proceed with caution in evaluating the
results for increased nucleolar number. Hits were identified as those that yielded a NPE
≥3 SD from the median NPE of all 25,246 compounds. As a result, compounds that
yielded a ≥5 nucleoli per nucleus NPE ≥139.9 were considered a hit, yielding 32 hits with
a mean percent viability of 81.3 (range, 24.3 to 155.0; Figure 4-6, B-D; Appendix VII).
While some of these hits may again be false positives due to the poor screening statistics,
several may still be valuable novel regulators of nucleolar number and worth including in
validation studies.
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In conclusion, the screen of a synthetic library of drug-like compounds was
effective in identifying 234 compounds that regulate nucleolar number. As observed in
the pilot screen of FDA-approved drugs, the screen for decreased nucleolar number was
more robust with favorable and reproducible Z-prime values, while the screen for
increased nucleolar number was more variable. The one nucleolus per nucleus NPE was
also more successful in the number of compounds it identified, uncovering 202
compounds. However, while the ≥5 nucleoli per nucleus NPE identified only 32, each
compound yielded an NPE greater than the positive control (NPE≥100). Given the high
percentage of antineoplastic compounds identified in the pilot screen by screening for
regulators of nucleolar number, these results are promising candidates for the discovery
of novel antineoplastic compounds and necessitate validation and further evaluation.
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Table 4-6. Summary statistics of candidate positive controls for increased nucleolar
number. Top hits from the pilot screen of FDA-approved drugs were re-screened at three
different concentrations. Signal-to-background (S/B), Z-prime values, and percent
viability were calculated to evaluate suitability as a new control and compared to
statistics from the current control, mitomycin C (in bold).
Candidate

Concentration

S/B

Z-prime

(μM)

Percent
viability
(relative to
DMSO)

Mitomycin C

0.25

3.9

0.26

35.8

Melphalan

20

4.3

0.17

16.8

Melphalan

10

4.7

0.14

20.9

Melphalan

5

2.7

-0.26

35.4

Oxiconazole

20

1.6

-1.63

62.1

Oxiconazole

10

1.7

-0.82

84.6

Oxiconazole

5

1.4

-1.74

100.6

Butoconazole

10

1.8

-1.05

65.2

Butoconazole

5

1.4

-2.08

98.7

Butoconazole

2.5

1.5

-1.78

106.2
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Figure 4-5. High-throughput screen of a synthetic library of drug-like compounds
identified 202 hits that decrease nucleolar number.
(A) Z-prime values across all 79 screening plates. The mean Z-prime value was 0.53
(range, 0.21 to 0.74). A Z-prime >0 suggests separation between the positive and
negative controls and ≥0.5 is a robust screening assay (black dashed line).
(B) Distribution of the normalized percent effect (NPE) for each of the 25,246
compounds. Threshold used to define hits was ≥3 standard deviations from the median
NPE (red dashed line) or NPE ≥16.8. Screen hits are compounds (black dots) above the
red dashed line.
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(C) Percent viability relative to the one nucleolus per nucleus NPE. Each dot represents a
hit. Mean percent viability of the hits was 68.1% relative to DMSO (range, 6.2 to 354.7).
(D) Representative images of the controls and top hits yielding an increase in the
percentage of cells with one nucleolus per nucleus. DMSO=negative control and BMH21=positive control. Top hits are represented.
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Figure 4-6. High-throughput screen of a synthetic library of drug-like compounds
identified 32 hits that increase nucleolar number.
(A) Z-prime values across all 79 screening plates. The mean Z-prime value was -0.39
(range, -6.70 to 0.41). A Z-prime >0 suggests separation between the positive and
negative controls and ≥0.5 is a robust screening assay (black dashed line).
(B) Distribution of the normalized percent effect (NPE) for each of the 25,246
compounds. Threshold used to define hits was ≥3 standard deviations from the median
NPE (red dashed line) or NPE ≥139.9. Screen hits are compounds (black dots) above the
red dashed line.
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(C) Percent viability relative to the ≥5 nucleoli per nucleus NPE. Each dot represents a
hit. Mean percent viability of the hits was 81.3% relative to DMSO (range, 24.3 to
155.0).
(D) Representative images of the controls and top hits yielding an increase in the
percentage of cells with ≥5 nucleoli per nucleus. DMSO=negative control and mitomycin
C=positive control. Top hits are represented.
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Re-screening revealed 185 high confidence hits
The Baserga lab’s unique screening approach identified several hundred
compounds required to maintain typical numbers of nucleoli in cells. Furthermore,
analysis of the FDA-approved drug hits revealed several antineoplastic compounds.
Together, these data suggest that the hits identified in the screen of the synthetic, druglike library are promising novel antineoplastic drug candidates. To identify a promising
subset of compounds to investigate for antineoplastic potential, I validated each hit and
its ability to yield the initially observed effect on nucleolar number. To validate the hits, I
re-screened each hit from both the FDA-approved drug libraries and the synthetic druglike compound library. Re-screening was performed in duplicate and hits were identified
based on an average of the negative, DMSO, control wells on the 3 screening plates. The
threshold was thus designated as ≥3 SD from the median percent effect (PE) of the
negative control (Table 4-7). This change was necessary given that the population of
compounds tested are now enriched for compounds known to regulate nucleolar number
and therefore setting a threshold based on the median of the screened population of
compounds would exclude those with milder, yet still potentially significant effect. Hits
were considered validated if they yielded the same phenotype in at least 1 of the 2
replicates.
Of the FDA-approved drug hits, I re-screened 130 compounds. One-hundred and
four (104) were compounds that decreased nucleolar number, 26 were compounds that
increased nucleolar number, and 10 were compounds discarded prior to re-screening
based on a manual review of the images to confirm the quality of the images and
presence of the expected phenotype. Of the 120 hits re-screened, 105 were identified as
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compounds that yielded the one nucleolus per nucleus phenotype. Interestingly, however,
12 of these compounds were originally designated as hits that caused an increase in
nucleolar number. Thus, excluding those, 93 of 104 hits that decreased nucleolar number
validated (89%), 84 of which were identified in both replicates (Table 4-8; Appendix
VIII). With regard to the hits that caused an increase in nucleolar number, 27 were
identified as yielding an increase in nuclei with ≥5 nucleoli. Of these, however, 13 were
originally designated as hits that decrease nucleolar number, and therefore 14 of the 26
compounds re-screened validated (54%), of which 11 were identified in both replicates
(Table 4-8; Appendix VIII). In all, of the 130 FDA-approved compounds re-screened,
107 showed reproducible activity with a consistent phenotype suggesting a strong
approach for identifying novel compounds with antineoplastic potential.
Of the synthetic, drug-like hits, I re-screened 233 compounds. 183 were
compounds that decreased nucleolar number, 50 were compounds that increased
nucleolar number, and 1 was discarded based on a manual review of the images. Of the
183 hits re-screened that yielded a decrease in nucleolar number, 157 were identified as
compounds that yielded the one nucleolus per nucleus phenotype, 11 of which were
originally designated as hits that yielded an increase nucleolar number. Excluding those
hits that switched designation, 147 hits validated (80%), 92 of which were identified in
both replicates (Table 4-8; Appendix VIII). With regards to the hits that increased
nucleolar number, the reproducibility of these compounds was poor. Strikingly, of the 50
hits re-screened, only 8 yielded an increase in the percentage of nuclei with ≥5 nucleoli,
and all 8 were originally designated as hits that caused a decrease in nucleolar number.
As a result, no hits from the initial screen that were designated to increase nucleolar
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number validated (Table 4-8). In reviewing data from the original screen, all but 1 of the
hits that caused an increase in nucleolar number came from the same 2 assay plates. The
Z-prime values for these two plates were, -1.53 and -6.7, which suggests that the positive
control (100 PE) was not significantly different from the negative control (0 PE). Because
compounds are normalized to the controls screened on the same plate, this could cause
some compounds on plates with poor Z-prime values to have exaggerated NPE values
relative to compounds on plates with good Z-prime values and lead to false positives.
This may likely explain the lack of reproducibility among hits that increased nucleolar
number and suggests that this dataset should be re-analyzed following the removal of
plates with poor Z-prime values in order to identify true positive hits. In all, re-screening
the synthetic, drug-like library of compounds resulted in the identification of 147 novel
compounds that have a reproducible effect nucleolar number.
Finally, in addition to validation by identifying hits that yield reproducible effects
on nucleolar number, I also considered viability in order to identify a high confidence
subset of hits to investigate for putative antineoplastic potential. In this analysis, hits were
discarded if viability was <10% between the two replicates. The rationale for discarding
hits with low viability is to ensure an adequate population of cells with which to calculate
the PE on nucleolar number. Furthermore, our objective is to identify drugs that effect
cancer cell viability more than normal cell viability and since MCF10A cells are not
derived from cancer, a viability filter seems appropriate. Using this threshold, among the
107 validated hits identified in the re-screening of the FDA-approved drugs, 59 were
discarded due to low viability (Table 4-8; Appendix VIII). This left 48 high confidence
hits, and of those, 39 decreased nucleolar number and 9 increased nucleolar number.
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Among the 147 validated hits identified in the re-screening of the synthetic, drug-like
compounds, 10 were discarded due to low viability (Table 4-8; Appendix VIII). This left
137 high confidence hits, and of those, all 137 decreased nucleolar number. In all, by rescreening hits and applying reproducibility and viability filters I identified 185 high
confidence compounds that regulate nucleolar number and that may harbor antineoplastic
potential.
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Table 4-7. Designated thresholds to identify hits in the validation re-screening assays.
Two replicates were performed, each with their own set of thresholds. Thresholds were
set at the median of the DMSO percent effect (PE) for each phenotype +3 standard
deviations (SD). Hits with a percent effect ≥ the designated threshold were considered a
validated hit. DMSO=negative control.
Replicate DMSO one nucleolus per nucleus PE

DMSO ≥5 nucleoli per nucleus PE

(median + 3SD)

(median + 3SD)

1

14.0

26.6

2

9.1

52.8
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Table 4-8. Number of high confidence hits identified by re-screening all hits in duplicate
and applying reproducibility and viability filters. Compounds were considered high
confidence hits if they yielded the same phenotype in at least 1 of the 2 replicates
(“validated”). Hits were also included if the mean viability of the 2 replicates was >10%.
Screen

Phenotype No. of

No. of

No. of

No. of

Total no.

(1/≥5)

hits re-

hits

hits

hits with

of high

screened

validated

validated

mean

confidence

in both

viability

hits

replicates <10%
FDA-

1

104

93

84

54

39

≥5

26

14

11

5

9

1

183

147

92

10

137

≥5

50

0

0

0

0

approved
drugs
FDAapproved
drugs
Synthetic
drug-like
compounds
Synthetic
drug-like
compounds

187

Cluster analysis reveals diverse structures among the high confidence hits
High-throughput screening for regulators of nucleolar number identified 185 high
confidence compounds, 137 of which are novel, synthetic, drug-like compounds with no
known medical use or molecular target. Due to the large number of compounds
identified, to help select compounds for further evaluation, I decided to perform a
chemical structure cluster analysis to determine whether there were any structural
similarities shared among the hits. Using the DataWarrior software [OSIRIS (Sander et
al., 2015)], I performed the Cluster Compounds analysis to identify structural clusters
among the 137 high confidence hits from the synthetic, drug-like compounds library.
Compounds were analyzed based on the Simplified Molecular Input Line Entry System
(SMILES) code structure, and the number of clusters present in the dataset were
identified.
To determine whether screening for changes in nucleolar number identified
compounds with high structural similarity, I performed the cluster analysis based on a
threshold of ≥80% similarity. This initial analysis of the 137 high confidence hits from
the synthetic drug-like library returned 98 clusters, suggesting few compounds with
highly similar structural features (Table 4-9). While initially striking given the shared
effect on nucleolar number for each compound, it is common in order to enhance
discovery for curated compound libraries to be designed to limit compounds with a high
degree of structural similarity [≥85 similarity; (Martin et al., 2002)]. As a result, I
repeated the cluster analysis with two additional thresholds, ≥65% and ≥50% similarity.
Clustering based on a ≥65% similarity revealed 47 clusters, 20 of which included just one
compound; and, at a threshold of ≥50% similarity, 11 clusters were revealed, 3 of which
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included just a single compound. Furthermore, at the latter threshold, one cluster included
75 compounds or nearly 55% of the dataset. Taken together, there is little similarity
among the high confidence compounds identified in the synthetic drug-like compound
screen, thus further analysis of these clusters is necessary to help identify candidate
compounds for exploring antineoplastic potential.
In an attempt to gain additional information on the 137 high confidence
compounds identified by screening the synthetic drug-like library, I also evaluated the
high confidence compounds identified in the screen of FDA-approved drugs.
Interestingly, structure cluster analysis alone on the 48 high confidence FDA-approved
drugs revealed similar results. At a similarity threshold of ≥80%, 40 clusters were
identified, suggesting very little structural similarity among the FDA-approved drugs hits
that regulate nucleolar number (Table 4-9). Decreasing the threshold to ≥50% similarity,
only reduced the number of clusters to 23, with 15 including just a single drug. Finally, I
decided to evaluate the synthetic, drug-like hits together with the FDA-approved drug
hits. Because more about the mechanisms underlying the FDA-approved drugs are
known, any clusters containing both an FDA-approved drug and a synthetic, drug-like
compound could be informative. In this analysis of the 185 total high confidence
compounds, 138 clusters were identified at a ≥80% similarity threshold, 82 were
identified at a ≥65% similarity threshold, and 31 were identified at ≥50% similarity
threshold (Table 4-9; Appendix VIII). Among the 31 clusters including drugs with ≥50%
similarity, 5 clusters contained both FDA-approved drug hits and the synthetic drug-like
hits. Interesting clusters from this analysis are cluster 3 and cluster 11. Cluster 3 is the
largest with 73 synthetic, drug-like compounds and 7 FDA-approved drugs, including
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antineoplastic mitotic inhibitors and antifungal metal ion chelators. Cluster 11 contained
4 compounds, 3 synthetic compounds and the FDA-approved translation inhibitor,
cycloheximide. In all, analyzing the FDA-approved drugs together with the synthetic,
drug-like compounds revealed limited structural similarities between the two sets of
compounds, and further reinforced that the synthetic, drug-like library contains diverse
and novel compounds that may lead to the discovery of novel cancer therapeutics.

190

Table 4-9. Number of compound clusters identified among the high confidence hits using
different structure similarity thresholds. Cluster analysis was performed in DataWarrior
software based the Simplified Molecular Input Line Entry System (SMILES) codederived structure.
Screen

No. of high No. of

No. of

No. of

confidence

clusters

clusters

(≥65%

(≥50%

clusters

compounds (≥80%

FDA-

analyzed

similarity) similarity) similarity)

48

40

35

23

137

98

47

11

185

138

82

31

approved
drugs
Synthetic
drug-like
compounds
Combined
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DISCUSSION
To identify putative new cancer therapeutics, I performed two high-throughput
screens for small molecules that regulate nucleolar number in MCF10A cells. In a pilot
screen of nearly 4,000 FDA-approved drugs, I identified 140 compounds that impact
nucleolar number, the majority of which decreased the percentage of nuclei with 2-3
nucleoli and increased the percentage of nuclei with just a single nucleolus.
Bioinformatic analysis of these drugs revealed that several are antineoplastic agents used
in the treatment of cancer, suggesting that regulators of nucleolar number are promising
targets for cancer therapeutics. I therefore expanded the search for regulators of nucleolar
number by screening a curated collection of approximately 25,000 synthetic drug-like
compounds and uncovered 234 novel small molecules that alter nucleolar number. Rescreening of both drug libraries to test for reproducibility and viability ≥10% led to the
identification of 185 high confidence compounds, several of which may harbor
antineoplastic activity. This screening campaign was thus successful as it revealed several
small molecular compounds that regulate nucleolar number and that have putative drug
development potential.
Antineoplastic compounds were the most frequently identified compounds in the
screen of FDA-approved drugs, even when filtering from the analysis the compounds that
were included more than once in screened libraries. Some of the more common molecular
targets for these drugs included tubulin and DNA. The mechanism underlying targeting
tubulin in cancer therapeutics lies in the stabilization of microtubules and impairing
mitosis in actively dividing cells or neoplasms (Mukhtar et al., 2014; Zhou and
Giannakakou, 2005). These data suggest a strong interdependence between microtubule
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dynamics and nucleolar biology, that may be related to the dissolution and reformation of
nucleoli that occurs during mitosis (Hernandez-Verdun, 2011). The targeting of DNA on
the other hand included compounds that are either intercalators or crosslinking agents,
both leading to impaired replication and RNA synthesis. The preclinical cancer
therapeutic, BMH-21, that specifically targets RNAPI transcription is also a DNA
intercalator and was the positive control for increased nucleolar number in these screens.
While structure analyses clustered few novel compounds with drugs known to function
through interactions with tubulin or DNA, this does not rule out the possible
identification of novel classes of tubulin and DNA-targeting drugs. Thus, screening for
changes in nucleolar number identified several antineoplastic drugs, including modulators
of tubulin dynamics and DNA replication, and further validates the approach of screening
novel compounds for effects on the nucleolus in order to identify novel cancer
therapeutics.
While the structure analysis clustered many of the FDA-approved drug hits
together, the synthetic, drug-like hits often formed distinct clusters. While it is possible
that the synthetic drug-like hits may represent novel classes of compounds that target the
same molecular targets revealed by the FDA-approved drug hits, it is also likely that
these compounds target different proteins and ones that specifically regulate nucleolar
function. Prior screening for changes in nucleolar number using a genome-wide siRNA
approach identified several hundred proteins required for maintaining typical nucleolar
numbers [(Farley-Barnes et al., 2018); Chapter 2-3]. Follow up biochemical studies
revealed that depletion of both hits that decrease and increase nucleolar number, caused
defects not only in protein synthesis, but also in RNAPI transcription or pre-rRNA
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processing (and in some cases, both). It is, however, exciting to speculate that the
targeting of tubulin and/or other molecular targets revealed by the bioinformatic analysis,
like ergosterol and the Na+/K+ ATPase may also regulate ribosome biogenesis. In fact,
there is a literature on the potential of repositioning cardiac glycosides as cancer
therapeutics (Newman et al., 2008; Prassas and Diamandis, 2008). Furthermore, the
recent discovery that the cardiovascular drug and HMG-CoA inhibitor, cerivastatin
sodium (which was also a hit in our screen), inhibits RNAPI (Tan and Awuah, 2019), acts
as independent validation. Additional validation includes the prevalence of the vinca
alkaloid cancer drugs among the screen hits [vincristine, vinblastine, vinorelbine,
(Johnson et al., 1963; Martino et al., 2018), and literature proposing antihelmintics, like
mebendazole, as putative cancer therapies although further research on clinical efficacy
and safety are required (Laudisi et al., 2020; Mezzatesta et al., 2020). In all, these data
suggest that while some of the novel compounds identified in this screen may be
targeting tubulin, DNA or topoisomerases, it is also possible that these compounds target
proteins that regulate ribosome biogenesis, which have not yet been fully explored as
therapeutic targets.
Finally, the screen for small molecule regulators of nucleolar number has revealed
confounding results regarding the putative mechanisms underlying increased versus
decreased nucleolar number. The Baserga lab has often considered the two phenomena as
produced by distinct processes. This understanding is supported by the non-overlapping
subset of proteins uncovered in our prior screens using a genome-wide siRNA approach
for decreased and increased nucleolar number, respectively [(Farley-Barnes et al., 2018);
Chapter 2]. In this study, however, in re-screening to validate reproducibility of the hits
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in regulating nucleolar number, 23 compounds were identified as switching from either a
compound that decreases nucleolar number to one that increases nucleolar number, or
vice versa. This switching phenomenon was even evident in our initial screening to
identify positive controls for the screens. For example, BMH-21, at 1 μM caused an
increase in the one nucleolus per nucleus PE, whereas at lower concentrations resulted in
an increase in the ≥5 nucleoli per nucleus PE (Appendix IV). Mitomycin C, as well,
caused an increase in the ≥5 nucleoli per nucleus PE at low concentrations, but at higher
concentrations caused an increase in the one nucleolus per nucleus PE (Appendix IV;
Table 4-2; Table 4-3). In fact, although mitomycin C was the positive control for the
screen for increased nucleolar number, it was also a hit (screened at 10 μM) among the
FDA-approved drugs that caused a decrease in nucleolar number (Appendix V). Finally,
the clustering analysis of the high confidence compounds based on structural similarities
revealed that both subsets of hits can be found in the same clusters (e.g. cluster 2). Taken
together, these data suggest that while there are some identifiable differences between the
two phenotypes and >80% yielded the same phenotype in subsequent replicate
experiments, changes in nucleolar number may be more dynamic and may represent
different stages of nucleolar disruption by impacts on nucleolar function.
In conclusion, this high-throughput screening campaign to uncover small
molecule regulators of nucleolar number was effective in identifying several hundred
compounds that either increase or decrease nucleolar number. Several of these
compounds are FDA-approved as cancer therapeutics and suggests that the novel druglike compounds also identified may too harbor antineoplastic potential. Furthermore, it is
known that the assay reports changes in nucleolar number that predict changes in
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nucleolar function [(Farley-Barnes et al., 2018); Chapter 2-3], and several cancer
therapeutics are reported to have secondary effects on nucleolar activity (Burger et al.,
2010; Quin et al., 2014); thus, it is probable that we have identified new compounds that
regulate ribosome biogenesis that will be important to test in future studies. Furthermore,
this screen has also identified several unexpected drug targets that not only may be
promising novel targets for drug discovery programs, but further may lend insight into
mechanisms underlying the regulation of nucleolar number and activity. Thus, this screen
not only broadens our understanding of what governs changes in nucleolar number, but
also revealed several compounds that hold potential as next generation cancer
therapeutics.

MATERIALS AND METHODS

Cell culture
As described in Chapter 2, the human breast epithelial cell line, MCF10A (ATCC,
CRL-10317), was 2D subcultured in DMEM/F-12 medium (Gibco, 1130-032)
supplemented with 5% horse serum (Gibco, 16050), 10 μg/mL insulin (Sigma, I1882),
0.5 μg/mL hydrocortisone (Sigma, H0135), 100 ng/mL cholera toxin (Sigma, C8052),
and 20 ng/mL epidermal growth factor (Peprotech, AF-100-15).

High-content screening
The high-content small molecule screening was performed as reported in (FarleyBarnes et al., 2018) with the Yale Center for Molecular Discovery. Cells were imaged on
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an IN Cell Analyzer 2200 (Cytiva), which is a widefield, multicolor, fluorescence
microscope. 9 fields of view (20X; 665.63 μm x 665.63 μm) were acquired per well and
high throughput image analysis was performed using CellProfiler (Carpenter et al., 2006;
McQuin et al., 2018) to segment nucleoli based on fibrillarin staining (72B9; (Reimer et
al., 1987)) and nuclei based on Hoechst 33342 staining.

Positive control identification
To identify positive controls to use in a high-throughput screen for small molecule
regulators of nucleolar number, we tested 25 unique compounds with different
mechanisms of action (Table 4-1). All compounds were dissolved in DMSO and tested at
eight different concentrations, 20.0 μM, 6.67 μM, 2.22 μM, 741 nM, 247 nM, 82.3 nM,
27.4 nM, 9.14 nM (3-fold dilutions), three times points (24, 48, and 72 hrs), and two cellseeding densities (1,000 and 2,000 cells/well) in 384-well plates. MCF10A cells were
seeded in 30 uL growth medium 24 hrs prior to adding the different compounds or
DMSO control (0.1%, final concentration). 30 nL of compounds were dispensed at
1000X by an Echo 550 Acoustic Liquid Handler (Labcyte, Inc.). Following compound
addition, plates were incubated at 37° C and 5% CO2. At 24, 48, or 72 hrs, the plates
were then fixed, permeabilized, stained and imaged as described in (Farley-Barnes et al.,
2018). For each compound, concentration, time point and seeding density, 3 replicates
were performed and 9 fields of view imaged (20X). Select candidates were re-screened at
several different concentrations, 16 replicates each (9 fields of view), and Z’ statistics
were calculated relative to 64 replicates of DMSO (9 fields of view; Table 4-2; Table 43). These candidates included BMH-21 (8.8 μM, 4.4 μM, 2.2 μM, 1.5 μM, 1 μM, 750
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nM, and 375 nM) and CX-5461 (30 μM, 20 μM, and 10 μM) for the one nucleolus
phenotype, and mitomycin C (14 μM, 7 μM, 3.5 μM, 500 nM, 250 nM, and 125 nM) and
topotecan (18 nM, 9 nM, 4.5 nM and 2.3 nM) for the ≥5 nucleoli phenotype.

High-throughput FDA drug screen
FDA-approved compounds were screened in a high-throughput assay for small
molecule regulators of nucleolar number. Three libraries comprising a total of 3,923
drugs were screened. The libraries included the MicroSource Pharmakon 1600, Enzo 640
FDA-approved drug, and the Yale Center for Molecular Discovery curated “Tested in
Humans” collection. Compounds were screened in MCF10A cells seeded at a cell density
of 2,000 cells per well in 13 x 384-well plates. Cells were incubated with 10 μM of each
compound dissolved in 0.1% DMSO for 48 hrs, and then fixed and stained to detect
nuclei and nucleoli as described in (Farley-Barnes et al., 2018). Nucleolar number per
nucleus was quantified using the same CellProfiler pipeline developed in (Farley-Barnes
et al., 2018), and a normalized percent effect (NPE) from an average of 9 fields of view
(20X) was calculated relative to the average of the 12 negative (PE=0) and 12 positive
(PE=100) control replicates included on each screening plate. The negative control was
0.1% DMSO, and the positive controls were BMH-21 (1 μM) for the one nucleolus per
nucleus phenotype and mitomycin C (0.25 μM) for the ≥5 nucleoli per nucleus
phenotype.
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High-throughput synthetic, drug-like screen
Synthetic, drug-like compounds were screened in the same high-throughput assay
as performed for the FDA-approved drug pilot screen. The compounds screened were
from an Fsp3-enriched screening library curated by Life Chemicals, Inc. Included in the
library were 25,246 small molecules enriched in sp3 tetravalent carbons (3-D) and other
physicochemical properties common among known bioactive, therapeutic compounds,
including molecular weight <450 Da and ClogP values <4 (Lipinski, 2000, 2004;
Lovering et al., 2009). The library was also curated to limit common pan-assay
interference compounds (PAINS).
Three (3) top hits from the FDA-approved pilot screen for increased nucleolar
number were re-screened to test for a new positive control following the inconsistent Zprime values attained in the pilot screen. The three hits included oxiconazole (SML1474,
Sigma-Aldrich), butoconazole (SML1663, Sigma-Aldrich), and melphalan (M2011,
Sigma-Aldrich), and were tested at three different concentrations (Table 4-6). Screening
statistics were compared to mitomycin C and only melphalan yielded comparable results.
As a result, mitomycin C was kept as the positive control for increased nucleolar number.

Bioinformatic analysis
The bioinformatic analysis of the FDA-approved pilot screen hits was performed
by manual curation of the medical use and molecular target from the KEGG DRUG
Database (https://www.genome.jp/kegg/drug/), DrugBank Online
(https://go.drugbank.com/), and a review of relevant literature. Compounds with more
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than one medical use or molecular target were classified as both, and led to the total
number classified exceeding the total number of screen hits.

Cluster Compounds analysis
The Cluster Compounds analysis was performed in the open-source software,
DataWarrior [OSIRIS; http://www.openmolecules.org/datawarrior/; (Sander et al.,
2015)]. The analysis was performed based on the Simplified Molecular Input Line Entry
System (SMILES) code structure produced by DataWarrior and compared to database of
512 predefined structure fragments. Compound clusters were evaluated multiple times
using different Tanimoto similarity thresholds, 0.8, 0.65, and 0.5 (Bajusz et al., 2015) on
each set of screen results separately and combined (Table 4-9).
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Chapter 5

Perspectives and future directions
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INTRODUCTION
High-throughput screening for changes in nucleolar number has revealed several
novel discoveries in the regulation of nucleolar form and function in higher eukaryotes.
Here, I asked whether novel factors governing ribosome biogenesis could be identified by
investigating regulators of nucleolar number in the human breast epithelial cell line,
MCF10A. What I discovered was that, indeed, identifying factors required to maintain
typical nucleolar number is a viable approach for identifying factors required for
maintaining typical nucleolar function. In Chapter 1, I provided background on the
nucleolus, its primary function in ribosome biogenesis, and its association with a panoply
of diseases. In Chapter 2, I identified 113 proteins that when depleted cause an increase
in nucleolar number that were enriched in cell cycle related proteins, including ones
required specifically for faithful progression through S and G2/M phase. In Chapter 3, I
discovered that a subset of the proteins identified were also overwhelmingly required for
the regulation of RNAPI transcription and protein synthesis. In Chapter 4, based on these
discoveries and prior results from our lab (Farley-Barnes et al., 2018), I applied our
screening platform to cancer drug discovery and identified several small molecule
regulators of nucleolar number. Together, the data presented in this thesis broaden our
understanding of the regulation of nucleolar number and provide a foundation for
defining novel mechanisms and proteins required to maintain nucleolar form and
function.
Several novel discoveries have thus been made, however several questions still
remain. While it is clear that nucleolar number artificially increased by siRNA depletion
overwhelmingly predicts defects in RNAPI transcription and protein synthesis, the
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mechanisms that underly the increase in nucleolar number remain incompletely
understood. Other questions stemming from this research include: (1) How do DNA
replication, recombination and repair factors contribute to maintaining typical nucleolar
form and function?; (2) How do mitosis factors contribute to maintaining typical
nucleolar form and function?; and, (3) Are small molecule regulators of nucleolar number
effective cancer therapies? In this chapter, I will elaborate on these questions, suggest
testable models, and present possible future directions.

Increased nucleolar number reflects changes in RNAPI transcription
siRNA screening for increased nucleolar number has revealed several proteins
required for cell cycle progression and RNAPI transcription. These results, however,
were based on a functional analysis of only a subset of the 113 high confidence hits.
While my initial bioinformatic analysis of the screen hits did not necessarily suggest
factors required for ribosome biogenesis or RNAPI transcriptional regulation (Chapter 2),
I questioned whether there were other known transcription factors among the screen hits
that might suggest novel transcriptional regulators of RNAPI. Thus, using the PANTHER
classification system (v16.0; (Thomas et al., 2003)), I identified the screen hits by protein
class and performed an overrepresentation analysis to determine whether any of the
protein classes were enriched. Although 40 hits could not be defined using this
classification system (“undefined”), in this analysis only 1 protein class was significantly
enriched among the hits. DNA metabolism protein (PC00009) was enriched 6-fold
among the hits (Binomial test with Bonferroni correction for multiple testing; p<0.05),
and is a sub-class within nucleic acid metabolism protein (PC00171), which was among
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the top represented protein classes (Figure 5-1, A; Table 5-1). The discovery of proteins
associated with nucleic acid metabolism is not unexpected given that ribosomes are
comprised mostly of RNA that are transcribed from DNA. What is striking, however, is
that proteins associated with DNA metabolism were not only enriched, but also more
abundant relative to proteins associated with RNA metabolism (Figure 5-1, B; Table 5-1).
The screen hits associated with DNA metabolism are primarily associated with DNA
replication, recombination, and repair, which is consistent with prior bioinformatic
analysis (Chapter 2). Furthermore, among these hits, RFC1 and ATAD5 were also tested
for functional roles in ribosome biogenesis and identified as repressors of RNAPI
transcription (Chapter 3). Thus, while these results were unexpected, together these data
support the intriguing connection between DNA-associated processes and nucleolar
function.
Proteins associated with RNA metabolism were also identified among the screen
hits. Of the hits associated with nucleic acid metabolism, only 4 were associated with
RNA metabolism, and they were all unique (Table 5-1). TAF1D is a known RNAPI
transcription cofactor, whereas SMG5 is associated with non-sense mediated decay and
telomerase function. FAM98A is a regulator of the arginine methyltransferase, PRMT1,
and I also identified it as a regulator of RNAPI transcription in my functional analysis
(Chapter 3). Finally, GTF2IRD1 may function as a positive transcriptional regulator with
the tumor suppressor, retinoblastoma protein, but intriguingly has also been identified in
the 7q11.23 deletion associated with Williams-Beuren syndrome (Franke et al., 1999).
Williams-Beuren syndrome is a congenital disorder that manifests with craniofacial
dysmorphology and cognitive delays that are consistent with features of those with
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ribosomopathies (Farley-Barnes* and Ogawa* et al., 2019; Franke et al., 1999).
Williams-Beuren syndrome has also previously been suggested to be a putative
ribosomopathy based on homology of WBSCR20 and WBSCR22 in the 7q11.23 deletion
to yeast proteins, Nol1 and Bud23, respectively (Doll and Grzeschik, 2001; Sondalle and
Baserga, 2014). Nol1 is a nucleolar protein and Bud23 is a methyltransferase required for
SSU maturation (Black et al., 2020). GTF2IRD1-null mice, however, also show features
consistent with William-Beuren syndrome (Tassabehji et al., 2005), and it is intriguing to
speculate that as a hit identified in this screen GTF2IRD1 may also contribute to the
pathophysiology of the syndrome through a role in ribosome biogenesis. Thus, while
proteins associated specifically with RNA metabolism were few, they highlight a range
of functions that may be linked to the function of the nucleolus.
Remarkably, also among the top represented protein classes were transcriptional
regulators. In the PANTHER protein class analysis, 12 proteins were classified as genespecific transcription regulators [(PC00264); Figure 5-1, A). Of these, the majority were
DNA-binding transcription factors, rather than transcription cofactors (Figure 5-1, C).
Manual review of the screen hits also revealed 2 additional “undefined” proteins that are
known or probable regulators of transcription (Table 5-2). Included among these proteins
are 2 nucleolar proteins based on my analysis in Chapter 2, GZF1 and ZNF678. ZFN678
is a ubiquitously expressed zinc finger protein that has not been reported in the literature
(Thul et al., 2017). GZF1, on the other hand, is a zinc finger protein that is also expressed
in all tissues and has recently been associated with a form of Larsen syndrome (Patel et
al., 2017; Thul et al., 2017). Larsen syndrome is a congenital disorder caused by several
genes including FLNB and is associated with joint dislocations and an abnormal facial
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appearance, including cleft palate and hearing loss (Patel et al., 2017; Stanley et al., 1988;
Zeng et al., 2021). Again, craniofacial dysmorphology is a common clinical feature of the
ribosomopathies, as is hearing loss in some patients (Farley-Barnes* and Ogawa* et al.,
2019). Together, these data are again intriguing in that, as a hit identified in this screen,
GZF1 may regulate RNAPI transcription and contribute to the pathophysiology of the
disease.
Several other intriguing transcription regulators were identified among the screen
hits. Included among these are putative tumor suppressors, including EBF3 and RBBP1.
EBF3, or early B-cell factor, is required not only for B-cell differentiation, but has also
been reported to be important for bone development and neurogenesis (Chao et al., 2017;
Seike et al., 2018; Sleven et al., 2017). RBBP1, on the other hand, is reported as a
putative tumor suppressor through its interaction with the retinoblastoma protein (pRB).
pRB is required for cell cycle progression and has been reported to also regulate RNAPI
transcription (Giacinti and Giordano, 2006; Voit et al., 1997), suggesting a possible role
for RBBP1 in the regulation of RNAPI through pRB. NFYB, on the other hand, was
another identified transcription factor among the screen hits; it functions in a trimeric
complex that directly regulates c-Myc (Izumi et al., 2001). The myc-family of
transcription factors are also reported regulators of ribosome biogenesis and thus NFYB
may be a regulator of ribosome biogenesis through its interaction with myc (van Riggelen
et al., 2010). Additionally, NFYB depletion has also been reported to inhibit cell cycle
progression through G2/M phase and stabilize p53 independent of DNA damage (Benatti
et al., 2008). These data suggest activation of the nucleolar stress response, which is
concomitant with inhibition of RNAP1, and suggest another possible indirect mechanism
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through which NFYB may regulate nucleolar function. Finally, ENY2 was also identified
among the transcription factors and is a known RNAPII transcription co-activator
through its association with the SAGA complex and others (García-Oliver et al., 2012;
Kopytova et al., 2010; Vijayalingam et al., 2016). Interestingly, ENY2 was also a protein
that I tested for a role in ribosome biogenesis and identified that depletion caused a
significant decrease in not only RNAPI transcription but also protein synthesis. Taken
together, these results suggest that although I tested only a subset of screen hits for roles
in ribosome biogenesis, given the identification of several transcription factors and
cofactors, it is possible there are several more novel regulators of RNAPI transcription
among the screen hits waiting to be defined.
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Figure 5-1. Screen hit classification by protein class reveals several proteins involved in
nucleic acid metabolism and transcriptional regulation.
(A) Bar graph of the PANTHER protein classifications for the screen hits. 40 hits were
undefined in the PANTHER classification system.
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(B) Eleven hits (~10%) were classified as proteins associated with nucleic acid
metabolism. PANTHER sub-classification revealed proteins associated with both DNA
(PC00009) and RNA metabolism (PC00031).
(C) Twelve hits (~11%) were classified as proteins associated with gene-specific
transcriptional regulation. PANTHER sub-classification revealed both DNA-binding
transcription factors (PC00218) and transcription cofactors (PC00217).
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Table 5-1. Screen hits identified as nucleic acid metabolism proteins (PC00171) using
the PANTHER classification system by protein class. Sub-classification [DNA
metabolism (PC00009) or RNA metabolism (PC00031)] and protein descriptions are
included. Descriptions are summarized from GeneCards (Stelzer et al., 2016), and the
literature.
Screen hit

Gene name

(HGNC)

Nucleic acid

Description

metabolism
protein subclass

RFC1

Replication factor

DNA

Large subunit of the DNA

C subunit 1

metabolism

replication factor C complex; PCNA
clamp loader

MCM6

XRCC5

Minichromosome

DNA

Minichromosome maintenance

maintenance

metabolism

complex subunit; complex is a key

complex

component of the pre-replication

component 6

complex

X-ray repair cross

DNA

Ku protein (80 kDa) that binds DNA

complementing 5

metabolism

in non-homologous end joining
DNA repair

LIG3

DNA ligase 3

DNA

DNA ligase in base-excision DNA

metabolism

repair
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ATAD5

ATPase family

DNA

Large subunit of an alternate DNA

AAA domain

metabolism

replication factor C complex; PCNA

containing 5
TOPBP1

clamp unloader

DNA

DNA

Interacts with topoisomerase and

topoisomerase II

metabolism

supports DNA double strand break

binding protein 1

repair; aids in rescue of stalled
replication forks

GEN1

GEN1 Holliday

DNA

Required for Holliday junction

junction 5’ flap

metabolism

resolution in DNA repair by

endonuclease
SMG5

homologous recombination

SMG5 nonsense

RNA

Required for nonsense-mediated

mediated mRNA

metabolism

mRNA decay; also necessary for

decay factor

telomerase reverse transcriptase
activity

GTF2IRD1

GTF2I repeat

RNA

May function as a positive

domain

metabolism

transcriptional regulator with

containing 1

retinoblastoma protein; plays a role
in craniofacial and cognitive
development, associated with
Williams-Beuren syndrome

TAF1D

TATA-box

RNA

RNAPI transcription-associated

binding protein

metabolism

factor containing the TATA-binding
protein; member of the SL1 complex
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associated factor,
RNAPI subunit D
FAM98A

Family with

RNA

Regulator of arginine

sequence

metabolism

methyltransferase, PRMT1, and

similarity 98

contains a putative RNA-binding

member A

domain
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Table 5-2. Screen hits identified as gene-specific transcription regulators (PC00264)
using the PANTHER classification system by protein class. Sub-classification [DNAbinding transcription factor (PC00218) or transcription co-factor (PC00217)] and protein
descriptions are included. Two “Undefined” proteins that were not included in the
PANTHER classification, but were included based on a manual review of the screen hits.
Descriptions are summarized from GeneCards (Stelzer et al., 2016), and the literature.
Screen hit

Gene name

(HGNC)

Gene-specific

Description

transcriptional
regulator sub-class

EBF3

Early B-cell

DNA-binding

Required for B-cell differentiation,

factor

transcription factor bone development and
neurogenesis, and may function as
a tumor suppressor

NFYB

Nuclear

DNA-binding

transcription

transcription factor trimeric complex; complex

factor Y beta

Recognizes CCAAT motifs in a

regulates MYC and also interacts
with p53

SMAD5

SMAD family

DNA-binding

Inhibits proliferation of

member 5

transcription factor hematopoietic progenitor cells
through TGF-beta signaling;
activated by BMP1 kinase

ZNF219

Zinc finger

DNA-binding

protein 219

transcription factor Repressor of HMGN1 expression
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Krüppel-like zinc finger protein;

ZNF678

Zinc finger

DNA-binding

Data deficient; mainly localized to

protein 678

transcription factor cytosol and mitochondria, but also
nucleoli (Thul et al., 2017)

LCORL

Ligand

DNA-binding

dependent

transcription factor associated with measures of height

nuclear

May function in spermatogenesis;

(Carty et al., 2012)

receptor
corepressorlike
ENY2

Enhancer of

DNA-binding

yellow 2

transcription factor through association with the

homolog
IRF2BP1

Transcriptional co-activator

SAGA complex and others

Interferon

DNA-binding

regulatory

transcription factor IRF-2 dependent manner; may

factor 2

Transcriptional corepressor in a

also have E3 ligase activity

binding protein
1
GZF1

GDNF-

DNA-binding

inducible zinc

transcription factor binds the GZF1 responsive

finger protein 1

Transcriptional repressor that

element; associated with joint
laxity, short stature and myopia
(Patel et al., 2017)
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NR0B2

Nuclear

DNA-binding

Orphan nuclear receptor; inhibits

receptor

transcription factor estrogen receptor function

subfamily 0
group B
member 2
RBBP8

Retinoblastoma Transcription

Leukemia and tumor suppressor

binding protein

that interacts with the

cofactor

8
LDB1

retinoblastoma protein

LIM domain

Transcription

Binds LIM domain in LIM

binding 1

cofactor

domain-containing transcription
factors; acts with LMO2 in red
blood cell development

KRBA1

TAF1D

KRAB-A

Undefined

Data deficient; Krüppel-associated

domain

box proteins are transcriptional

containing 1

repressors

TATA box

Undefined

RNAPI transcription-associated

binding

factor containing the TATA-

protein-

binding protein; member of the

associated

SL1 complex

factor RNAPI
D (41 kDa)

215

An interaction network of the high confidence screen hits also revealed several
intriguing proteins that were not selected as part of my functional analysis. An interaction
network was generated in STRINGdb, using a medium confidence threshold and MCL
clustering (inflation parameter=2; Figure 5-2). This analysis revealed 12 distinct clusters
of proteins representing 44 of the 113 hits. As expected, the largest clusters were mitosis
and DNA replication, recombination, and repair factors, as determined from my
bioinformatic analysis in Chapter 2. However, in addition to these proteins, other small
protein clusters stood out. MAN1A1 and PMM2 are interacting proteins associated with
mannose metabolism and were also uncovered in screens identifying regulators of
nucleolar size (Neumuller et al., 2013). PMM2/Sec53 was identified in S. cerevisiae and
MAN1A1/alpha-Man-I was identified in D. melanogaster, together supporting a putative
novel role for glycoprotein biosynthesis in the regulation of nucleolar form and function.
Additionally, the interacting proteins SKP1 and CUL1 are also intriguing. These two
proteins are both members of the Skp1-Cul1-Fbox protein (SCF) E3 ubiquitin ligase
complex required for cell cycle progression from late G1 through anaphase (Nakayama
and Nakayama, 2006). Although no SCF-associated Fbox proteins were identified among
the screen hits, the association with progression through S and G2/M phase are consistent
with the cell cycle defects observed when screen hits were depleted. Finally, a cluster of
3 interacting proteins, SMG5, WRAP53, and ZNF219, is also interesting in that SMG5
and WRAP53 are both associated with telomerase activity. In fact, WRAP53 is an
essential component of the telomerase enzyme. Furthermore, depletion of WRAP53 led
to a significant decrease in both RNAPI transcription and protein synthesis. A link
between telomeres and the nucleolus is tantalizing given the relatively close physical
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proximity between the telomeres and the rDNA arrays on the short arms of the
acrocentric chromosomes. While ZNF219 has not been reported to be associated with
telomerase function its interaction with this cluster of proteins suggests perhaps an
associated role that links telomerase function to nucleolar function. In all, analyzing the
screen hits as an interaction network highlights clusters of proteins that may otherwise
have been overlooked and suggests intriguingly cellular functions that may integral to the
regulation of ribosome biogenesis.
In conclusion, several intriguing proteins were identified as important for the
maintenance of typical nucleolar numbers. While the majority of these hits were not
tested in the screen validation assay, of the 20 hits that were tested, 19 or 95% validated.
That being said, prior to follow up on any of these hits, the appropriate validation should
be performed to rule out potential off-target effects that can be common with siRNAmediated knockdown. Once validated, however, screen hits beyond the initial subset
tested in Chapter 3 hold significant promise in revealing proteins and novel mechanisms
required for the nucleolar function of ribosome biogenesis.

217

Figure 5-2. Interaction network of high confidence screen hits that, when depleted, cause
an increase in nucleolar number. Interaction network was generated in STRINGdb, using
a medium confidence threshold and MCL clustering (inflation parameter=2) revealing 12
clusters. Screen hits that did not interact with other screen hits are not shown. Mitosis
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(red circle) and DNA replication, recombination, & repair (yellow circle) clusters are
highlighted.
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What mechanism underlies the increase in nucleolar number?
Screening for increased nucleolar number has revealed several proteins required
for cell cycle progression and RNAPI transcription, yet the mechanisms underlying the
change in number remains unclear. I now know that several screen hits, but not all, are
required for S and G2/M phase progression (Figure 5-3; Table 5-3). I also know that the
increased number of nucleoli observed is largely driven by cells in G2/M phase of the
cell cycle and cells with ≥5 nucleoli exhibit significantly larger nuclei. Furthermore, of a
subset of hits tested, the majority regulate RNAPI transcription, and consequently global
protein synthesis (Table 5-3). Yet, how failures in cell cycle progression and RNAPI
transcription regulate nucleolar number remains unclear. Two leading models emerge
based on the discoveries described herein, and will be described in the following two
sections.
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Figure 5-3. Model illustrating our current understanding of increased nucleolar number
based on discoveries reported in this thesis. Observed increases in nucleolar number are
linked to RNAPI transcription and the cell cycle. Depletion of several proteins required
for S and G2/M phase progression resulted in an increase in the percentage of nuclei with
≥5 nucleoli (solid-line rectangle). The increase is largely driven by cells in G2/M phase
of the cell cycle (dashed-line rectangle). Consistent with the latter, nuclear volume is
significantly increased in nuclei with ≥5 nucleoli. Blue dashed circles=nuclei; Pink solid
circles=nucleoli.
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Table 5-3. Expanded summary of discoveries on the subset of screen hits that cause an
increase in nucleolar number. Depleted hits were tested for defects in RNAPI
transcription, pre-rRNA processing, global protein synthesis, p53 stabilization, and cell
cycle defects inferred by accumulation of nuclei in a particular phase. Inc=Increased;
Dec=Decreased; Y=Yes; N=No; Dash (“-“)=No significant change or no defect detected.
Screen hit

RNAPI

Pre-rRNA

Global

p53

Cell cycle

(HGNC)

transcription

processing

protein

stabiliz-

defect

(Inc/Dec)

defect

synthesis

ation

(Y/N)

(Inc/Dec)

(Y/N)

siATAD5
siCDCA8
siENY2
siFAM98A
siH1-10
siINCENP

Inc
Dec
Dec
Dec
Dec

-

Dec
Dec
Dec
Dec
Dec

-

>4N
S; >4N
S
G2/M; >4N

siINKA1
siKIF11
siMDN1
siRACGAP1
siRFC1
siSTK24
siTPX2
siCCN4
siWRAP53

Dec
Dec
Dec
Inc
Dec
Dec
Dec

Y
-

Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec
Dec

Y
Y
-

>4N
G2/M
>4N
S
S
G2/M; >4N
S
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What mechanism underlies the increased nucleolar number observed when DNA
replication, recombination, and repair factors are depleted?
Proteins required for DNA replication, recombination, and repair, were among
some of the most common proteins identified in the screen for increased nucleolar
number. Furthermore, depletion of a subset of hits resulted in failures in S phase
progression (Chapter 2). The mechanism that underlies the connection between these
processes and nucleolar number remain unknown; however, based on results obtained
upon depletion of DNA replication and repair proteins in functional assays (Chapter 3), a
possible model has emerged. Depletion of RFC1 and ATAD5 both resulted in a
significant increase in RNAPI transcription; however, depletion of these proteins was
also identified as causing a concomitant decrease in protein synthesis. This suggested the
possible model that screen hits associated with DNA replication and repair are important
for maintaining genome stability at the replication fork (Figure 5-4). DNA replication at
highly transcribed loci can cause conflict and DNA double strand breaks. Thus,
maintaining genome stability during DNA replication and repair is important because
instability, particularly at the rDNA loci, has been associated with increased rates of
recombination, rDNA copy loss, and cancer (Lindstrom et al., 2018; Stults et al., 2009;
Xu et al., 2017a). Protective mechanisms, however, have evolved to deal with replication
stress (Lindstrom et al., 2018). For instance, the RNAPI transcription termination factor 1
(TTF-1) and a replisome component, TIMELESS (TIM), have been reported to regulate
replication fork activity during DNA replication (Akamatsu and Kobayashi, 2015). Thus,
I hypothesize that screen hits may encompass another protective mechanism to maintain
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genome stability during DNA replication through dynamic regulation of RNAPI at the
replication fork.
The proteins identified as screen hits have been localized to the replication fork
and nascent chromatin. A recent proteomic analysis using 5-ethynyl-2′-deoxyuridine (5EdU) labeling and enrichment followed by quantitative mass spectrometry, identified
proteins associated with nascent chromatin and the replication fork (Wessel et al., 2019).
Comparing the proteins identified in this experiment to the screen hits revealed that 9
screen hits are present at the replication fork (Table 5-4). These data would support a
putative role for screen hits in the regulation of RNAPI during DNA replication. Among
these hits were RFC1 and ATAD5, further supporting the hypothesis that these proteins
may be important for the repression of RNAPI transcription during DNA replication to
limit conflict. Furthermore, of the proteins enriched at the replication fork, 148 localize to
the nucleolus based on identification in at least one of the three datasets used in Chapter 2
[Appendix IX; (Ahmad et al., 2009; Jarboui et al., 2011; Leung et al., 2006; Thul et al.,
2017)]. Interestingly, of these hits, several have previously been reported to regulate
RNAPI transcription, including BLM, FANCI, ATM and ATR. ATM and ATR are
kinases that regulate the DNA damage response, which includes the transient inhibition
of RNAPI during DNA repair (Kruhlak et al., 2007). BLM and FANCI, on the other
hand, are reported to decrease RNAPI transcription when depleted. Together, these data
suggest not only the localization of screen hits at the replication fork, but also proteins
required for the regulation of RNAPI.
DNA repair is important for maintaining genome stability during DNA
replication, especially at highly transcribed loci like the rDNA. The existence of a

224

mechanism to transiently silence RNAPI transcription in response to DNA damage
validates this importance. An ATM- and ATR- mediated mechanism has been described
that results in the activation and recruitment of proteins required not only to silence
RNAPI, but to repair the DNA damage (Ciccia et al., 2014; Korsholm et al., 2019;
Kruhlak et al., 2007; Larsen and Stucki, 2016; Mooser et al., 2020). As such, several
substrates of ATM and ATR have been defined, and several others have been predicted.
In one study aimed at defining all the substrates of ATM and ATR in response to DNA
damage identified ~700 putative proteins (Matsuoka et al., 2007). I therefore asked
whether any of the screen hits were also identified among the putative ATM and ATR
substrates in response to DNA damage. Interestingly, 10 screen hits were identified and
included among these were RFC1 and ATAD5 (Table 5-4). TOPBP1 was also identified
and has already been reported as important for mediating the transcriptional silencing of
RNAPI upon DNA damage (Mooser et al., 2020). Finally, KIF11 was another hit
identified as a putative ATM or ATR substrate. KIF11 is primarily known for its role in
spindle assembly during mitosis (Blangy et al., 1995); however, I have also discovered
that depletion of KIF11 leads to a decrease in RNAPI transcription, which begs the
question, is KIF11 required for the regulation of RNAPI in response to DNA damage
rather than in a mitosis-specific role? These data thus suggest that a subset of screen hits
may regulate RNAPI transcription during DNA replication through the ATM- and ATRmediated response to DNA damage.
Moving forward, it will be important to establish whether DNA damage and
replication stress at the rDNA loci might be the cause for the increased numbers of
nucleoli that we observe. Furthermore, it will be interesting to ascertain whether other
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screen hits also regulate RNAPI transcription and if it is in response to DNA damage
during replication. Finally, to link the defects in RNAPI transcription to increased
nucleolar numbers, it will be critical to further define nucleoli from these cells.
Outstanding questions pertaining to this objective include: (1) Are these nucleoli
functional nucleoli with a defined tripartite substructure? And (2), are these nucleoli
mature nucleoli that contain multiple NORs or is there just a single NOR per nucleolus?
The latter might suggest the disassembly of nucleoli in response to a particular stressor,
like DNA damage, or a defect in S phase that manifests in mitosis as a failure in
reassembly and discussed in more detail in the next section. Taken together, the increased
number of nucleoli that we observe upon depletion of screen hits remains incomplete, but
several lines of evidence suggest the phenotype reflects changes in RNAPI transcription
and perhaps proteins required for maintaining genome stability at the rDNA loci during
replication.
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Figure 5-4. Screen hits may be required for maintaining genome stability at the
replication fork. Due to the high rate of transcription among the rDNA genes,
transcription by RNAPI presents a potential conflict. One hypothesis for the increase in
nucleolar number observed upon depletion of screen hits is that the screen hits are
required for dynamic regulation of RNAPI during replication to prevent conflict. In the
absence of this regulation, the rDNA loci would exhibit genome instability and nucleoli
would disassemble and could appear as an increase in nucleolar number.

227

Table 5-4. Screen hits identified at the replication fork and as substrates of ATM and
ATR kinases.
Screen hits at replication

Screen hits phosphorylated

fork and nascent chromatin

by ATM/ATR in response

(Wessel et al., 2019)

to DNA damage (Matsuoka
et al., 2007)

ATAD5

CASP8AP2

CUL1

GTF2IRD1

LDB1

KIF11

MCM6

MCM6

MDN1

RBBP8

PMM2

RFC1

RFC1

RIMS3

SKP1

STK24

XRCC5

TOPBP1
TPX2
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What mechanism underlies the increased nucleolar number observed when mitosis
factors are depleted?
Proteins required for mitosis were also among the most common proteins
identified in the screen for increased nucleolar number. Furthermore, depletion of a
subset of hits resulted in failures in G2/M phase progression (Chapter 2). The
mechanism, however, that underlies the connection between mitosis and increased
nucleolar number remains unknown. Yet, based on results obtained from depletion of
mitosis proteins in functional assays (Chapter 3), a possible model has emerged.
Depletion of KIF11, RACGAP1, TPX2, and INCENP all resulted in a significant
decrease in RNAPI transcription and concomitant decrease in protein synthesis. This
suggested the possible model that screen hits associated with mitosis are important for the
re-initiation of RNAPI transcription following metaphase (Figure 5-5). Nucleoli are
highly dynamic organelles during mitosis that not only require the coordinated
disassembly and relocalization of pre-rRNA and ribosome biogenesis factors, but also
require reassembly upon mitotic exit (Gautier et al., 1992; Hernandez-Verdun, 2011;
Savino et al., 2001). Furthermore, in early G1, nascent nucleoli fuse to form mature
nucleoli (Hernandez-Verdun, 2011), which might be a consequence of LLPS (Lafontaine
et al., 2020), although convincing evidence is still lacking. Failure of nucleoli to fuse
upon mitotic exit due to defects during mitosis could lead to the increased nucleolar
number observed.
Beyond the functional assays reported in this thesis, currently there is little
additional evidence to support a hypothesis for lack of nucleolar fusion upon mitotic exit.
Not only are the screen hits not enriched for proteins associated with LLPS, but screen
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hits are also not associated with proteins identified as localizing to the chromosomes
during mitosis. Proteins with intrinsically disordered regions (IDRs) are thought to be key
drivers of LLPS (Lafontaine et al., 2020); yet, in an analysis of proteins in the DisProt
database of proteins with IDRs (Hatos et al., 2020) only 4 hits were identified (HYPK,
MICA, SMG5, and XRCC5). Additionally, in the recent survey identifying nucleolar
proteins associated with the mitotic perichromosomal compartment, 65 proteins were
identified and 36 were not previously known to localize to chromosomes (Stenström et
al., 2020). A comparison of the screen hits with proteins that localize to mitotic
chromosomes reveal 0 overlapping proteins. Interestingly, this study also found that
proteins that localize to the perichromosomal compartment are enriched in proteins with
intrinsically disordered domains (IDRs). These data are consistent with the fact that few
proteins with IDRs were identified among the screen hits. Thus, the proteins identified in
this screen may represent a unique subset of proteins that are required for nucleolar form
and function.
Moving forward, it will be important to understand whether failure in the reinitiation of transcription during mitosis leads the increased numbers of nucleoli that we
observe. The identification of several mitosis-associated hits that when depleted lead to
decreased RNAPI transcription supports this putative link. Furthermore, it will be
important to ascertain whether the increased nucleolar numbers in fact represent nascent
nucleoli or mature nucleoli. A similar set of experiments as proposed in the prior section
can answer this question and include determining whether the nucleoli observed contain
the tripartite substructure consistent with mature functional nucleoli, and whether a single
or multiple NORs are present. Again, if the nucleoli contain only a single NOR, then
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these data would support failure in nascent nucleolar fusion. Taken together, the
mechanism underlying the increased nucleolar numbers that we observe in cells depleted
of screen hits remains incomplete; however, discoveries described herein suggest that the
regulation of RNAPI transcription in G2/M phase may be an important contributing
factor.
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Figure 5-5. Screen hits may be required for the re-initiation of RNAPI transcription
during mitosis. In every mitosis, the nucleolus disassembles in late prophase and
reassembles in telophase. In prophase, pre-rRNA and processing factors relocate to the
chromosomal periphery, also called the perichromosomal compartment. Activation of
CDK1-cyclin B inhibits RNAPI transcription by metaphase (red). Inhibition of CDK1cyclin B by PP1 phosphatases re-initiates RNAPI transcription by telophase (green). In
telophase, nucleolar proteins in the perichromosomal compartment condense into
prenucleolar bodies (PNB) from which ribosome biogenesis factors are recruited to the
competent nucleolar organizer regions (NORs) and, with early processing factors and
pre-rRNA, promote nascent nucleolar formation. In early G1, nascent nucleoli fuse to
from mature nucleoli. One hypothesis for the increase in nucleolar number observed upon
depletion of screen hits is that screen hits are required for re-initiation of transcription
during mitosis and when disrupted, results in the failure of nascent nucleoli to mature and
fuse. Failure to fuse upon mitotic exit could appear as an increase in nucleolar number.
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FC=fibrillar center (green); DFC=dense fibrillar component; GC=granular component.
Created with BioRender.com.
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Targeting the nucleolus for cancer therapy
The nucleolus holds promise as a target for the development of novel cancer
therapeutics. Not only has the nucleolus been associated with cancer for over two
hundred years, but an analysis of common cancer therapies has revealed that many
impact nucleolar form and function. The screen I performed of FDA-approved drugs for
regulators of nucleolar number revealed several drugs used in the treatment of cancer.
These results suggest that screening for changes in nucleolar number is an effective
strategy for identifying novel cancer therapies. As a result, I expanded the screen to test
~25,000 novel, synthetic compounds which uncovered an additional 234 compounds that
regulate nucleolar number. While we know that changes in nucleolar number reflect
changes in nucleolar function, this needs to be tested in order to identify a subset of lead
compounds with antineoplastic potential.
RNAPI is a promising target for the development of novel cancer therapeutics.
Several FDA-approved drugs target RNAPI through non-specific mechanisms, which
include drugs like AMD, oxaliplatin, doxorubicin and camptothecin (Ferreira et al.,
2020). Furthermore, in the past decade, specific RNAPI inhibitors have been developed
that not only show promising preclinical efficacy but have also had positive results in
Phase I trials for breast cancer and hematological malignancies. Indeed, the large subunit
of RNAPI, RPA194/POLR1A, is highly expressed among a range of cancers and is a
prognostic marker specifically in liver, ovarian, and thyroid cancer (Uhlen et al., 2017).
Survival analysis based on expression of RPA194/PORL1A, has revealed that patients
with tumors that exhibit high RPA194/POLR1A expression had a lower survival
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probability (Uhlen et al., 2017). Thus, identifying novel compounds that effectively target
RNAPI would be a good strategy for the treatment of cancer. Given that changes in
nucleolar number have been successful in identifying novel regulators of RNAPI, moving
forward, a secondary screen testing specifically for regulators of RNAPI transcription
from among the 185 high confidence compounds would be a good strategy moving
forward.
Pre-rRNA processing may also be a promising target for the development of
novel cancer therapeutics. While fewer FDA-approved drugs have been demonstrated to
regulate pre-rRNA processing, there are still several that have been used in the treatment
of cancer, including 5-fluorouracil, flavopiridol, roscovitine, and bortezomib (Burger et
al., 2010). These data suggest, that while drugs targeting pre-rRNA processing are not as
common, they still may be viable in the development of a novel cancer therapeutic. We
know from prior studies that regulators of nucleolar number can also reflect changes in
pre-rRNA processing; however, this observation was restricted primarily to proteins that
when depleted cause a decrease in nucleolar number. Furthermore, northern blots are the
best way to determine impact on pre-rRNA processing and therefore it would be difficult
to perform a high-throughput secondary assay to determine whether the screen hits are
regulators of pre-rRNA processing. Thus, a more low-throughput survey of a subset of
the novel synthetic compounds that cause a decrease in nucleolar number might be the
best approach to identify regulators of pre-rRNA processing. Cluster analysis was
performed to identify compounds with structural similarities, and based on a threshold of
50% similarity, 11 clusters were revealed among the novel synthetic compounds (Chapter
4). Thus, testing a single compound from each cluster for pre-rRNA processing defects
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might be the best approach. Taken together, while identifying regulators of RNAPI
transcription may be a highly effective strategy, targeting pre-rRNA may also hold
promise for the discovery of novel and effective cancer therapies.

In conclusion, the nucleolus is a fascinating nuclear domain that is integral to a
multitude of cellular functions. Screening for changes in nucleolar number has only
further highlighted the centrality of the nucleolus by uncovering several novel proteins
and small molecules that are associated with a wide range of cellular processes.
Furthermore, probing changes in nucleolar number has uncovered novel regulators of
nucleolar function, and has led to intriguing hypotheses for the role of these diverse
proteins in maintaining typical nucleolar form. Moving forward, however, it will be
critical to further validate screen hits through rescue experiments due the off-target
effects common among siRNA depletion methods like the siGENOME pools used here.
Furthermore, it will be important to develop the model used to study changes in nucleolar
number, perhaps through live cell imaging to observe changes in nucleolar number in real
time. Overall, the discoveries described herein broaden our understanding of nucleolar
biology in higher eukaryotes and provide a foundation for the development of novel and
more effective therapeutics for the treatment of cancer.
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Appendix I

166 DNA repair proteins localize to the nucleolus. Three nucleolar proteomes were
analyzed for the presence of DNA repair proteins based on Gene Ontology (GO)
Consortium categorization (GO: 0006281). The “Combined” column is the 166 total
unique DNA repair proteins identified. HGNC symbols are shown. Proteins in bold were
identified in more than one proteome.

260

NOPDB

Gautier

Human Protein

Combined

[n=136; (Ahmad et

[n=38; (Jarboui et

Atlas

(n=166)

al., 2009; Leung et

al., 2011)]

[n=40; (Thul et al.,

al., 2006)]

2017; Thul and
Lindskog, 2018)

ACTL6A

APEX1

APEX2

ACTL6A

APEX1

AQR

APTX

APEX1

APTX

BAZ1B

CDC5L

APEX2

AQR

BRCA2

CHAF1A

APTX

ASF1A

CDC5L

CSNK1D

AQR

ATM

CHD1L

DCLRE1A

ASF1A

ATR

DDB1

DTL

ATM

ATRIP

DDX1

FANCD2

ATR

ATRX

DEK

FANCG

ATRIP

BAZ1B

EXO1

FEN1

ATRX

BCCIP

FANCI

HMGA1

BAZ1B

BLM

FEN1

HMGA2

BCCIP

CDK1

HMGA1

HMGB2

BLM

CDK2

HMGB1

INO80C

BRCA2

CDK7

HMGB2

INO80E

CDC5L

CDK9

HUWE1

KDM2A

CDK1

CHAF1A

KDM2A

KDM4A

CDK2

COPS2

NONO

MAD2L2

CDK7
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COPS3

PARP1

MEIOB

CDK9

COPS7B

PCNA

MUS81

CHAF1A

COPS8

PRKDC

NPM1

CHD1L

CSNK1D

RAD21

NUDT16

COPS2

CSNK1E

RAD50

PARP2

COPS3

CUL4A

RBM14

PNKP

COPS7B

CUL4B

RFC1

POLR2F

COPS8

DDB1

RFC2

POLR2K

CSNK1D

DDX1

RFC4

PRMT6

CSNK1E

DEK

RFC5

RAD51

CUL4A

ERCC2

RPA1

RNF111

CUL4B

ERCC3

SETX

RPAIN

DCLRE1A

FANCD2

SFPQ

SETMAR

DDB1

FANCI

SMC1A

SFR1

DDX1

FEN1

SMC3

SMARCA5

DEK

GTF2H1

SSRP1

SUMO1

DTL

GTF2H2

SUMO3

SUPT16H

ERCC2

GTF2H2C

TERF2

UBE2N

ERCC3

GTF2H4

TRRAP

UBE2T

EXO1

H2AFX

UHRF1

USP28

FANCD2

HIST1H4A

WDR33

FANCG

HIST3H2A

YY1

FANCI

HIST3H3

FEN1

262

HLTF

GTF2H1

HMGA1

GTF2H2

HMGA2

GTF2H2C

HMGB1

GTF2H4

HMGB2

H2AFX

HSPA1A

HIST1H4A

HUS1B

HIST3H2A

HUWE1

HIST3H3

INTS3

HLTF

ISG15

HMGA1

KDM1A

HMGA2

KDM2A

HMGB1

KIN

HMGB2

KPNA2

HSPA1A

LIG1

HUS1B

LIG3

HUWE1

MC1R

INO80C

MDC1

INO80E

MLH1

INTS3

MMS19

ISG15

MNAT1

KDM1A

MORF4L1

KDM2A

MRE11A

KDM4A
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MSH2

KIN

MSH6

KPNA2

MUTYH

LIG1

NONO

LIG3

NPM1

MAD2L2

NSMCE1

MC1R

NSMCE4A

MDC1

OTUB1

MEIOB

PARG

MLH1

PARP1

MMS19

PCNA

MNAT1

PNKP

MORF4L1

POLR2E

MRE11A

POLR2H

MSH2

POLR2K

MSH6

POLR2L

MUS81

PPIE

MUTYH

PPP4C

NONO

PRKDC

NPM1

PRPF19

NSMCE1

PSMD14

NSMCE4A

PSME4

NUDT16

RAD21

OTUB1
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RAD50

PARG

RAD51AP1

PARP1

RBM14

PARP2

RBX1

PCNA

RECQL

PNKP

RFC1

POLR2E

RFC2

POLR2F

RFC3

POLR2H

RFC4

POLR2K

RFC5

POLR2L

RIF1

PPIE

RPA3

PPP4C

RPS27A

PRKDC

RPS27L

PRMT6

RPS3

PRPF19

RUVBL1

PSMD14

RUVBL2

PSME4

SFPQ

RAD21

SMARCA5

RAD50

SMC1A

RAD51

SMC3

RAD51AP1

SMC5

RBM14

SMC6

RBX1

265

SSRP1

RECQL

SUMO1

RFC1

SUMO2

RFC2

SUMO3

RFC3

SUPT16H

RFC4

TCEA1

RFC5

TOPBP1

RIF1

TRIM28

RNF111

TRIP12

RPA1

TRRAP

RPA3

UBA52

RPAIN

UBB

RPS27A

UBC

RPS27L

UBE2D3

RPS3

UBE2I

RUVBL1

UBE2N

RUVBL2

UBE2V2

SETMAR

UBR5

SETX

USP28

SFPQ

USP7

SFR1

VCP

SMARCA5

WHSC1

SMC1A

WRN

SMC3

266

XRCC1

SMC5

XRCC5

SMC6

XRCC6

SSRP1
SUMO1
SUMO2
SUMO3
SUPT16H
TCEA1
TERF2
TOPBP1
TRIM28
TRIP12
TRRAP
UBA52
UBB
UBC
UBE2D3
UBE2I
UBE2N
UBE2T
UBE2V2
UBR5
UHRF1
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USP28
USP7
VCP
WDR33
WHSC1
WRN
XRCC1
XRCC5
XRCC6
YY1
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Appendix II

The 113 high confidence screen hits that, when depleted, caused an increase in the
percentage of nuclei with ≥5 nucleoli. Yeast ortholog, ≥5 nucleoli per nucleus
normalized percent effect (NPE), percent viability, and nucleolar localization are
indicated. The positive control, KIF11, was the top hit.
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Screen hit

Yeast ortholog

(HGNC)
KIF11
CDCA8
ASIC1
CMPK2
WBP11
KRT222
MICA

Cin8/Kip1
Nbl1

ATAD5
RAP2C
SKP1
TPX2
CIAO2B
PRRT2
RFFL
C11orf63
ZER1
MAN1A1

Elg1

MFSD4
INCENP
SHC3
ENY2
CUL1
SHROOM2
CTF1
MDN1
ZDHHC17
CDCA5
CASP8AP2
HYPK
INKA1
NAT2
IRF2BP1

Cdc8

Skp1

Mnl2
Sli15
Sus1
Cdc53

Rea1
Akr1/2

≥5 nucleoli per Percent

Nucleolar

nucleus NPE

viability

(Y/N)

68.75
66.59
65.17
64.91
64.64
61.43
60.63

19.00
12.91
5.21
17.38
12.61
30.53
28.23

N
Y
N
N
Y
N
N

59.75
57.83
57.64
53.84
47.53
47.35
47.17
47.03
46.73
46.40

27.67
38.96
13.00
5.99
26.97
21.61
8.70
11.05
43.72
35.63

N
N
Y
Y
N
N
N
N
N
N

46.29
45.64
45.32
41.93
41.61
40.79
40.36
39.82
39.45

15.22
18.92
21.55
6.02
36.50
16.04
8.66
29.07
53.42

N
Y
N
N
Y
N
N
Y
N

39.33
39.14
38.87
38.64
38.52
37.62

9.55
13.82
15.80
14.41
27.49
38.21

N
Y
N
N
N
N
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PMM2
GLYATL2
TTC22
XRCC5
CYP4V2
RRM1
FAM221A
ECHDC2
RBBP8
CCDC81
KRBA1
PRUNE
SCRN3
AGR2
SMG5
LAPTM5
DBNDD1
RFC1
IFT88
C9orf142
SGOL1
EBF3
MCM6
OSBP2
PRAM1
GCNT2
ZNF219
LDB1
FAM58A
LIG3
SNX21
GLTP
GZF1
MAP4K5
SLC26A7

Sec53

Yku80
Rnr1/3

Ebs1/Est1

Mcm6
Hes1/Kes1

37.35

23.22

N

36.68
36.12
35.61
35.61
35.33
34.73
34.49
33.82
33.78

28.51
21.61
42.14
58.17
9.46
49.23
22.43
21.42
22.74

N
N
Y
N
N
N
N
N
N

32.89
32.76
32.28
31.52
31.03
30.61
30.51
30.18
30.16
29.86

29.14
19.24
63.05
25.80
27.66
32.18
10.27
46.61
57.16
29.73

N
N
N
N
N
N
N
Y
N
N

29.67
29.63
29.60
29.58
29.56
29.56
29.31
29.25
29.22

16.63
36.33
54.59
14.65
14.07
34.99
45.34
50.16
22.15

N
N
Y
N
N
N
N
N
N

29.07
29.02
28.95
28.93
28.92
28.77

40.91
25.45
20.74
47.20
27.53
61.21

Y
N
N
Y
N
N
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TARS2

Mst1

ABCE1
LCORL
TYMP
TYMP
MRPL52
RIMS3
WBSCR27
H1-10
ZNF678
RACGAP1

Rli1

STK24
SLC2A12
NGRN
LUC7L
YIPF7
WRAP53
DYNC1H1
GEN1
NR0B2
ANKEF1
KTN1
FGD4
MIA
CCN4
GOLGA8EP
TOPBP1
SMAP2
OXNAD1
HSD11B2
MARCH9
TM2D1
PCOLCE2
CAMK2N1
RAPH1
MPV17L2

28.66

36.20

N

28.57
28.28
28.06
27.86
Tcb3
27.82
27.79
Hho1
27.78
27.75
Bem2/Rga1/2/Rgd1 27.62

25.65
21.07
72.51
36.04
10.82
33.22
31.61
19.58
15.60

Y
N
N
N
Y
N
Y
Y
N

Kic1/Pbs2
Stl1
Rrg9
Luc7
Yip1
Swt21
Dyn1

27.53
27.49
27.47
27.15
27.11
27.10
26.87
26.82
26.79
26.73

13.92
71.34
25.68
25.86
5.29
9.48
19.67
51.87
37.50
22.43

Y
N
N
N
N
N
Y
N
N
Y

26.70
26.65
26.64
26.52
26.48
26.37
26.24
26.16
26.09

14.57
28.85
39.43
46.48
20.11
10.58
33.90
60.29
21.32

N
N
N
N
N
Y
N
N
N

26.06
26.04
26.02
25.99
25.95
25.65

68.46
19.78
19.56
26.33
6.16
13.92

N
N
N
N
N
N

Cdc24/Rom1/2

Dpb11
Glo3/Gts1
Aim33/Pga3
Ssm4

Mpv17

272

FAM98A

25.60

10.13

N

SUV39H1
TAF1D
NFYB
MASTL
GTF2IRD1
SCN2B
MLL3
DDAH1
NLRC5

25.56
25.54
25.50
25.41
25.38
25.29
25.28
25.27
25.12

32.30
27.66
41.60
32.46
24.82
15.56
73.70
55.36
46.44

N
Y
N
N
N
N
N
Y
N

25.00

61.84

N

SMAD5

Hap3
Pkh3/Rim15

Gip3/Her1
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Appendix III

Cell cycle analysis of screen hits selected for validation by oligonucleotide
deconvolution. Each siRNA in the pool of 4 was tested independently (n=3). Controls,
siRISC-free and the siKIF11 pool, were also assayed (n=48). The column with the
number (No.) of cells is the total sum of nuclei analyzed in all replicates and is number of
cells used to generate the cumulative histograms in Figure 2-5. Significance is listed in
parentheses below the mean ± SD and was determined by unpaired t-tests relative to
siRISC-free and a False Discovery Rate approach using the two-stage step-up method of
Benjamini, Krieger and Yekutieli (n=3 or 48; q<0.01=*; q<0.001=**; q<0.0001=***;
ns=not significant). A column that includes the ≥5 nucleoli per nucleus normalized
percent effect (NPE) is also included. NPE in black=validated; NPE in red=not validated.
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Screen Hit
(siRNA
HGNC, -last 2

No. of
cells
(sum)

% G0/G1

%S

% G2/M

% >4N

(mean ±

(mean ±

(mean ±

(mean ±

SD)

SD)

SD)

SD)

≥5
nucleoli
per
nucleus

digits of

NPE

product
number)
siRISC-free

498,155

48.3 ± 2.0

10.2 ± 1.1

20.3 ± 0.8

2.7 ± 0.5

0

siKIF11 (pool)

93,027

12.2 ± 1.2

7.5 ± 0.8

60.6 ± 1.7

12.1 ± 1.1

100

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siKIF11 -05

3426

)

)

)

)

16.5 ± 1.9

9.1 ± 1.2

56.1 ± 2.5

7.2 ± 1.8

(q<0.0001

(ns)

)
siKIF11 -06

6816

siKIF11 -07

2154

(q<0.0001 (q<0.0001
)

)
9.9 ± 0.3

15.8 ± 1.0

8.7 ± 0.3

56.7 ± 0.8

(q<0.0001

(q<0.01)

(q<0.0001 (q<0.0001

)
23.8 ± 4.5

10.8 ± 2.1

(q<0.0001

(ns)

)

)

)

42.1 ± 1.6

6.9 ± 2.4

(q<0.0001 (q<0.0001
)
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89.98

)

118.62

74.75

siKIF11 -08

2721

20.6 ± 2.3

10.5 ± 1.0

(q<0.0001

(ns)

)
siABCE1 -01

12653

30.6 ± 0.7

20.0 ± 0.3

50.7 ± 3.5

7.3 ± 0.4

116.70

(q<0.0001 (q<0.0001
)

)

33.6 ± 1.0

8.3 ± 0.6

50.71

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siABCE1 -02

22023

)

)

)

)

42.7 ± 1.0

15.4 ± 0.7

25.9 ± 0.6

5.8 ± 0.3

22.63

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siABCE1 -04

19958

)

)

)

)

49.9 ± 1.5

23.3 ± 0.4

15.9 ± 0.9

1.8 ± 0.2

(q<0.0001 (q<0.0001

(q<0.01)

(ns)

siABCE1 -17

21264

)

)

50.2 ± 2.9

12.9 ± 0.8

21.7 ± 1.6

1.9 ± 0.2

(ns)

(q<0.0001

(q<0.001)

(q<0.01)

24.1 ± 1.6

3.9 ± 2.4

(q<0.0001

(q<0.01)

26.31

9.86

)
siATAD5 -01

11302

32.3 ±

32.3 ±

14.3

11.6

(q<0.0001 (q<0.0001
)

)

276

)

55.60

siATAD5 -02

17992

49.9 ± 3.5
(ns)

siATAD5 -03

siATAD5 -04

21010

14337

19.4 ± 2.0

22.3 ± 1.2

1.5 ± 0.4

(q<0.0001 (q<0.0001

(q<0.001)

)

)

45.1 ± 1.9

17.2 ± 0.9

25.7 ± 1.1

(q<0.01)

(q<0.0001 (q<0.0001

37.0 ± 5.6

)

)

19.8 ± 3.9

27.8 ± 2.2

2.7 ± 0.2

16.49

25.01

(ns)

4.1 ± 0.5

22.60

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siCCN4 -01

siCCN4 -02

24641

4868

)

)

)

)

45.9 ± 0.9

20.3 ± 1.8

15.4 ± 0.4

2.6 ± 0.2

(q<0.01)

(q<0.0001 (q<0.0001

40.6 ± 4.3

)

)

14.6 ± 2.0

30.8 ± 3.3

(q<0.0001 (q<0.0001 (q<0.0001

siCCN4 -03

siCCN4 -17

7630

12550

)

)

)

44.5 ± 1.7

13.7 ± 1.0

27.8 ± 0.3

(q<0.01)

(q<0.0001 (q<0.0001

35.7 ± 2.2

)

)

24.5 ± 1.1

28.1 ± 0.3
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17.85

(ns)

2.5 ± 0.6

18.51

(ns)

2.0 ± 0.4

23.89

(ns)

3.3 ± 0.5

42.10

(q<0.0001 (q<0.0001 (q<0.0001

siCDCA8 -01

6261

)

)

)

10.6 ± 0.4

7.9 ± 0.8

26.6 ± 0.6

(q<0.0001

(q<0.001)

(q<0.0001 (q<0.0001

)
siCDCA8 -02

5595

10.4 ± 0.7

8.7 ± 0.3

(q<0.0001

(ns)

)
siCDCA8 -03

5073

(ns)

30.5 ± 1.0

14.6 ± 0.9

43.2 ± 0.5

)

)

23.8 ± 1.1

45.2 ± 1.5

82.17

60.19

(q<0.0001 (q<0.0001
)

)

27.0 ± 0.8

13.6 ± 1.3

23.40

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siCDCA8 -04

8186

)

)

)

)

23.7 ± 0.4

12.0 ± 0.8

28.7 ± 0.5

20.4 ± 0.1

(q<0.0001

(q<0.01)

(q<0.0001 (q<0.0001

)
siCIAO2B -01

siCIAO2B -03

16932

14686

)

)

16.3 ± 0.8

1.7 ± 0.0

(q<0.0001 (q<0.0001 (q<0.0001

(q<0.001)

42.3 ± 2.1

32.0 ± 4.2

)

)

)

38.2 ± 1.6

32.7 ± 1.7

17.1 ± 0.7

2.1 ± 0.2
(ns)

278

44.40

24.41

7.62

(q<0.0001 (q<0.0001 (q<0.0001

siCIAO2B -04

siCIAO2B -18

19264

14660

)

)

)

41.6 ± 1.5

24.0 ± 1.8

21.9 ± 0.8

4.8 ± 0.2

(q<0.0001 (q<0.0001

(q<0.001)

(q<0.0001

)

)

41.3 ± 3.7

37.7 ± 3.5

15.48

)
10.1 ± 0.3

0.9 ± 0.1

26.18

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siDYNC1H1 -

15255

01

siDYNC1H1 -

16855

02

siDYNC1H1 -

)

)

)

32.0 ± 0.3

25.3 ± 0.9

33.1 ± 1.0

4.0 ± 0.7

(q<0.0001 (q<0.0001 (q<0.0001

(q<0.001)

)

)

)

33.3 ± 0.2

21.1 ± 0.8

26.3 ± 0.2

7.1 ± 0.6

22.40

24.91

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

10371

03

siDYNC1H1 -

)

)

)

)

)

23.0 ± 0.7

22.4 ± 1.1

39.2 ± 0.1

6.9 ± 0.4

79.29

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

21012

)

)

)

)

37.7 ± 1.3

18.7 ± 1.3

23.3 ± 0.5

7.0 ± 0.3

04

279

9.05

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siENY2 -01

siENY2 -02

18169

10196

)

)

)

)

39.6 ± 0.7

25.0 ± 0.8

19.3 ± 0.3

5.3 ± 0.1

(q<0.0001 (q<0.0001

(q<0.01)

(q<0.0001

)

)

43.1 ± 1.4

15.5 ± 0.7

15.62

)
26.4 ± 1.3

7.0 ± 0.9

29.06

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siENY2 -03

21547

)

)

)

)

35.8 ± 0.5

24.5 ± 0.9

21.2 ± 0.9

5.7 ± 0.7

(ns)

(q<0.0001

(q<0.0001 (q<0.0001

siENY2 -04

14896

)

)

43.8 ± 1.6

28.6 ± 0.9

)
16.5 ± 0.4

(q<0.0001 (q<0.0001 (q<0.0001

siFAM98A -01

7481

)

)

)

38.5 ± 1.5

24.4 ± 1.0

23.8 ± 0.5

(q<0.0001 (q<0.0001 (q<0.0001

siFAM98A -02

9898

)

)

)

31.0 ± 3.6

32.0 ± 1.7

23.9 ± 1.2

280

24.64

2.1 ± 0.5

16.54

(ns)

3.1 ± 0.4

23.43

(ns)

5.1 ± 0.6

30.61

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siFAM98A -03

31999

)

)

)

)

47.9 ± 0.8

11.2 ± 0.6

20.0 ± 0.4

3.6 ± 0.2

(ns)

(ns)

(ns)

(q<0.0001

-1.10

)
siFAM98A -04

siH1-10 -01

12092

19495

33.1 ± 3.6

35.2 ± 3.1

18.8 ± 0.7

4.1 ± 0.4

(q<0.0001 (q<0.0001

(q<0.001)

(q<0.0001

)

)

40.2 ± 7.0

17.5 ± 5.7

37.85

)
27.4 ± 1.0

5.4 ± 0.3

19.98

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siH1-10 -02

3095

)

)

)

)

26.7 ± 1.4

10.9 ± 1.3

37.6 ± 4.7

5.7 ± 0.4

(q<0.0001

(ns)

)
siH1-10 -03

20063

38.30

(q<0.0001 (q<0.0001
)

)

54.2 ± 0.6

10.3 ± 1.4

19.8 ± 0.7

2.1 ± 0.2

(q<0.0001

(ns)

(ns)

(ns)

16.2 ± 5.3

9.0 ± 0.6

1.5 ± 0.5

16.89

)
siH1-10 -04

5378

64.3 ± 5.4

(q<0.001)
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10.30

(q<0.0001 (q<0.0001 (q<0.0001

siINCENP -01

5191

)

)

)

14.1 ± 0.5

9.3 ± 1.0

29.6 ± 0.7

(q<0.0001

(ns)

)
siINCENP -02

6073

5151

7989

8245

25.7 ± 0.9

(q<0.0001

(q<0.001)

(q<0.0001 (q<0.0001

9.5 ± 0.3

(q<0.0001

(ns)

19.9 ± 0.6

9.1 ± 0.3

(q<0.0001

(ns)

)
siINKA1 -01

)

43.1 ± 2.0

)
siINCENP -04

)
7.9 ± 0.3

14.6 ± 1.9

24.3 ± 0.6

13.0 ± 1.4

63.31

(q<0.0001 (q<0.0001

13.1 ± 1.2

)
siINCENP -03

28.0 ± 2.1

)

)

42.4 ± 2.7

19.4 ± 0.9

107.86

84.39

(q<0.0001 (q<0.0001
)

)

38.4 ± 0.4

20.0 ± 1.7

65.05

(q<0.0001 (q<0.0001
)

)

50.4 ± 0.5

5.7 ± 0.2

81.39

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siINKA1 -02

18874

)

)

)

)

33.1 ± 0.5

15.1 ± 0.7

28.0 ± 1.2

10.6 ± 0.9
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12.47

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siINKA1 -03

20994

)

)

)

)

56.5 ± 1.3

21.2 ± 1.2

14.5 ± 0.1

1.3 ± 0.2

17.64

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siINKA1 -04

7543

)

)

)

)

30.0 ± 3.2

16.8 ± 2.7

38.3 ± 1.2

6.9 ± 0.2

31.55

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siKTN1 -17

siKTN1 -18

15844

2762

)

)

)

)

43.6 ± 1.3

26.6 ± 1.7

16.9 ± 0.8

3.5 ± 0.4

(q<0.0001 (q<0.0001 (q<0.0001

(q<0.01)

)

)

)

22.7 ± 2.1

10.0 ± 0.7

47.8 ± 1.8

(q<0.0001

(ns)

)
siKTN1 -19

29473

4.2 ± 0.7

41.87

44.02

(q<0.0001 (q<0.0001
)

)

55.4 ± 2.1

10.9 ± 0.7

19.2 ± 0.9

2.7 ± 0.3

(q<0.0001

(ns)

(ns)

(ns)

18.1 ± 0.2

22.4 ± 0.6

3.9 ± 0.2

4.61

)
siKTN1 -20

22507

46.0 ± 0.4
(ns)

(q<0.001)
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16.93

(q<0.0001 (q<0.0001

siLUC7L -01

1855

)

)

30.5 ± 2.8

11.6 ± 1.4

34.1 ± 3.0

(q<0.0001

(q<0.01)

(q<0.0001 (q<0.0001

)
siLUC7L -02

9450

39.6 ± 2.7

30.3 ± 3.8

)

)

15.7 ± 0.2

2.4 ± 0.6

(q<0.0001 (q<0.0001 (q<0.0001

siLUC7L -03

siLUC7L -04

siMDN1 -03

24023

15445

22383

)

)

51.5 ± 0.7

25.4 ± 1.1

14.2 ± 0.6

1.6 ± 0.2

(q<0.01)

(q<0.0001 (q<0.0001

(q<0.001)

)

)

28.5 ± 2.5

21.1 ± 0.7

2.2 ± 0.0

(q<0.0001 (q<0.0001

(q<0.01)

(ns)

38.4 ± 1.5

10682

)

)

61.8 ± 4.5

17.6 ± 4.3

11.6 ± 0.5

1.5 ± 0.2

(q<0.0001

(ns)

(q<0.0001

(q<0.001)

64.0 ± 0.2

36.19

6.67

(ns)

)

)
siMDN1 -17

6.2 ± 2.2

7.84

22.01

16.23

)
10.7 ± 0.9
(ns)
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16.0 ± 0.3

1.4 ± 0.1

10.86

(q<0.0001

(q<0.0001 (q<0.0001

)
siMDN1 -18

siMDN1 -19

18302

16924

)

)

52.2 ± 0.9

24.3 ± 3.0

14.6 ± 0.6

1.4 ± 0.2

(q<0.001)

(q<0.0001 (q<0.0001

(q<0.001)

)

)

51.6 ± 1.8

15.7 ± 1.3

18.9 ± 1.2

2.1 ± 0.2

(q<0.01)

(q<0.0001

(q<0.001)

(ns)

31.1 ± 0.8

10.7 ± 0.9

8.92

28.03

)
siRACGAP1 -

10345

01

siRACGAP1 -

14099

51.56

)

)

)

)

33.4 ± 1.3

15.0 ± 0.3

27.8 ± 0.6

9.0 ± 1.3

34.13

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

9246

03

siRACGAP1 -

19.5 ± 1.6

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

02

siRACGAP1 -

28.6 ± 1.8

)

)

)

)

20.7 ± 2.0

14.2 ± 0.6

37.3 ± 1.6

17.2 ± 1.5

66.49

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

6630

)

)

)

)

15.1 ± 1.7

15.7 ± 1.0

34.3 ± 0.7

23.8 ± 2.4

04
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58.42

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siRFC1 -01

22242

)

)

)

)

36.7 ± 1.0

21.5 ± 1.7

28.7 ± 0.9

5.1 ± 0.2

12.31

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siRFC1 -02

siRFC1 -03

18739

18566

)

)

)

)

35.2 ± 2.3

24.5 ± 0.3

27.6 ± 0.9

3.7 ± 0.4

(q<0.0001 (q<0.0001 (q<0.0001

(q<0.01)

)

)

)

38.5 ± 2.1

24.6 ± 1.4

26.9 ± 0.6

(q<0.0001 (q<0.0001 (q<0.0001

siRFC1 -04

32219

2.6 ± 0.2

15.79

20.99

(ns)

)

)

)

46.9 ± 0.6

10.8 ± 1.0

21.8 ± 0.2

4.5 ± 0.1

(ns)

(ns)

(q<0.001)

(q<0.0001

0.60

)
siSTK24 -05

siSTK24 -21

13758

30865

41.3 ± 2.1

34.8 ± 1.9

15.0 ± 0.6

2.0 ± 0.3

(q<0.0001 (q<0.0001 (q<0.0001

(q<0.01)

)

)

)

52.6 ± 2.3

11.5 ± 1.7

19.3 ± 0.4

2.8 ± 0.2

(ns)

(q<0.01)

(ns)
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7.04

1.81

(q<0.0001
)
siSTK24 -22

siSTK24 -23

15617

11330

37.4 ± 3.9

25.7 ± 2.9

23.6 ± 0.6

3.6 ± 0.4

(q<0.0001 (q<0.0001 (q<0.0001

(q<0.01)

)

)

)

43.4 ± 3.4

37.5 ± 2.9

12.0 ± 0.8

1.4 ± 0.1

17.66

29.89

(q<0.0001 (q<0.0001 (q<0.0001 (q<0.0001

siTPX2 -01

3189

)

)

)

)

18.7 ± 2.6

12.4 ± 2.2

49.8 ± 2.8

9.0 ± 0.3

(q<0.0001

(q<0.001)

(q<0.0001 (q<0.0001

)
siTPX2 -02

6023

16.5 ± 1.3

10.6 ± 1.1

(q<0.0001

(ns)

)
siTPX2 -03

10750

47.2 ± 3.5
(ns)

siTPX2 -04

7667

34.5 ± 2.3

22.9 ± 2.6

)

)

50.9 ± 0.6

6.7 ± 0.7

)

)

15.9 ± 0.4

2.8 ± 0.4

)

)

18.3 ± 0.6

26.0 ± 1.3
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102.59

(q<0.0001 (q<0.0001

(q<0.0001 (q<0.0001

(ns)

38.82

39.05

(ns)

6.1 ± 0.9

31.55

(q<0.0001

(q<0.0001 (q<0.0001

)
siWRAP53 -19

31592

)

)

49.2 ± 1.4

12.6 ± 1.0

21.4 ± 0.9

4.2 ± 0.4

(ns)

(q<0.001)

(q<0.01)

(q<0.0001

2.90

)
siWRAP53 -20

17584

38.1 ± 1.9

33.2 ± 0.6

16.5 ± 1.4

(q<0.0001 (q<0.0001 (q<0.0001

siWRAP53 -21

18888

siXRCC5 -01

17244

24899

28.11

(ns)

)

)

)

41.2 ± 0.6

26.9 ± 0.5

20.9 ± 0.7

3.3 ± 0.3

(ns)

(ns)

(q<0.0001 (q<0.0001

siWRAP53 -22

2.4 ± 0.3

)

)

41.0 ± 1.0

29.8 ± 0.9

18.6 ± 0.2

2.4 ± 0.2

(q<0.0001 (q<0.0001

(q<0.001)

(ns)

)

)

50.9 ± 2.0

21.5 ± 1.4

18.8 ± 0.5

1.9 ± 0.3

(q<0.01)

(q<0.0001

(q<0.01)

(q<0.01)

23.2 ± 1.0

3.3 ± 0.3

18.45

38.53

8.08

)
siXRCC5 -02

25424

49.4 ± 1.2

13.2 ± 0.8

(ns)

(ns)
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6.89

(q<0.0001 (q<0.0001

siXRCC5 -03

24903

48.2 ± 2.0
(ns)

siXRCC5 -04

31137

)

)

15.0 ± 0.7

25.8 ± 0.8

(q<0.0001 (q<0.0001

2.2 ± 0.4

-1.50

(ns)

)

)

53.9 ± 0.8

10.2 ± 0.3

19.3 ± 0.2

2.7 ± 0.2

(ns)

(ns)

(q<0.01)

(ns)

-2.68

Effect on nucleolar number of 25 candidate compounds screened in positive control
search for a high-throughput screen. 25 compounds were tested at 8 different
concentrations. Mean percent effect (PE) from 3 replicates relative to DMSO (0.1%;
DMSO=100 PE), seeded at 2,000 cells per well and incubated for 48 hrs, are shown for
each phenotype. Percent viability relative to DMSO (0.1%) is also shown for each
condition.
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Appendix IV

Effect on nucleolar number of 25 candidate compounds screened in positive control
search for a high-throughput screen. 25 compounds were tested at 8 different
concentrations. Mean percent effect (PE) from 3 replicates relative to DMSO (0.1%;
DMSO=100 PE), seeded at 2,000 cells per well and incubated for 48 hrs, are shown for
each phenotype. Percent viability relative to DMSO (0.1%) is also shown for each
condition.
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Concentr-

One nucleolus

≥5 nucleoli per Percent

ation

per nucleus PE

nucleus PE

viability

(μM)

(mean ± SD)

(mean ± SD)

(mean ± SD)

5-Fluorouracil

20

106.7 ± 46.8

139.1 ± 103.5

20.2 ± 13.1

5-Fluorouracil

6.7

81.3 ± 12.7

292.7 ± 55.5

27.4 ± 0.8

5-Fluorouracil

2.2

80.3 ± 15.1

251.2 ± 19

29.1 ± 1.8

5-Fluorouracil

0.7

74 ± 6.5

219.7 ± 30.3

27 ± 8.5

5-Fluorouracil

0.2

73.1 ± 9.7

283.9 ± 7.3

41.3 ± 3.1

5-Fluorouracil

0.08

68.7 ± 8.1

222.5 ± 41.7

89.5 ± 2.5

5-Fluorouracil

0.03

77.4 ± 5.4

178.2 ± 28

109.3 ± 8.2

5-Fluorouracil

0.009

78 ± 7.7

177.3 ± 4.4

116.2 ± 6.4

Actinomycin D

20

13.5 ± 6.5

9.2 ± 8.3

3.4 ± 0.7

Actinomycin D

6.7

19.6 ± 12.4

69.3 ± 78.2

3.6 ± 2.3

Actinomycin D

2.2

18 ± 5.5

70.5 ± 96

2.5 ± 0.8

Actinomycin D

0.7

18 ± 9

32.7 ± 26.9

2.8 ± 0.8

Actinomycin D

0.2

22.1 ± 7.6

22.4 ± 19.7

4.2 ± 0.8

Actinomycin D

0.08

29.8 ± 5.6

156.2 ± 119

1.9 ± 0.4

Actinomycin D

0.03

48.9 ± 23.3

58.9 ± 62.6

2.3 ± 1.1

Actinomycin D

0.009

17.2 ± 13.8

10 ± 13.6

5.4 ± 2.6

Amperozide

20

86.2 ± 3.3

54.4 ± 10.5

66.1 ± 8.6

Amperozide

6.7

86.6 ± 7.6

86.1 ± 11.8

82 ± 5.5

Amperozide

2.2

87 ± 3.7

139.4 ± 4.4

86.1 ± 0.9

Amperozide

0.7

91.6 ± 4.6

106.2 ± 25.1

73.1 ± 1.6

Drug name
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Amperozide

0.2

70.5 ± 7.1

83.8 ± 8.4

77.8 ± 10.1

Amperozide

0.08

85.8 ± 4.9

124.2 ± 21.8

70 ± 1.5

Amperozide

0.03

92.7 ± 10.5

101.8 ± 21.6

77 ± 3.6

Amperozide

0.009

103.8 ± 4.8

100.5 ± 23.1

68.6 ± 2.9

BMH-21

20

26.8 ± 22.3

31 ± 23

5 ± 0.2

BMH-21

6.7

215.2 ± 135.6

40 ± 24.3

7.6 ± 3.5

BMH-21

2.2

331.1 ± 22.1

5.1 ± 1.1

15.8 ± 0.5

BMH-21

0.7

314.5 ± 34

7.6 ± 1.9

17.2 ± 3.2

BMH-21

0.2

89.6 ± 9.6

111.7 ± 46.2

50.8 ± 3

BMH-21

0.08

73.9 ± 7.1

155.2 ± 25

114.8 ± 17.1

BMH-21

0.03

76.5 ± 12.1

169.1 ± 12

120.1 ± 7.4

BMH-21

0.009

59.8 ± 15.4

153.9 ± 26.5

103.1 ± 19.2

C646

20

102.6 ± 11.5

127.4 ± 30.3

44.7 ± 23.8

C646

6.7

96.2 ± 22.8

107 ± 12.3

83.6 ± 6.2

C646

2.2

92.8 ± 22.1

104.1 ± 37.6

89.8 ± 5.8

C646

0.7

91.9 ± 10.1

115.2 ± 20.5

96.7 ± 9.5

C646

0.2

89.4 ± 3.5

124.2 ± 30

90.1 ± 1.6

C646

0.08

82.7 ± 9.3

99.4 ± 17

93.5 ± 4.3

C646

0.03

92.4 ± 2.5

123 ± 4.3

87.2 ± 10.8

C646

0.009

87.4 ± 15

108 ± 23.1

83.6 ± 5.1

CDK9 Inhibitor

20

70.2 ± 3.2

342.4 ± 16

47.5 ± 4.5

CDK9 Inhibitor

6.7

78.1 ± 13.5

179.1 ± 1.9

89.4 ± 10.2

CDK9 Inhibitor

2.2

88 ± 7.6

151.4 ± 15.4

94 ± 14.6
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CDK9 Inhibitor

0.7

75.8 ± 24.2

133.1 ± 38.7

97.6 ± 11.4

CDK9 Inhibitor

0.2

63.4 ± 48.5

96 ± 75.7

62.6 ± 52.1

CDK9 Inhibitor

0.08

73.9 ± 13.2

122.5 ± 11.4

96.4 ± 9.7

CDK9 Inhibitor

0.03

61.3 ± 19.8

78.6 ± 57.4

61.2 ± 49.2

CDK9 Inhibitor

0.009

81.5 ± 21

119.7 ± 31.8

90.1 ± 13.4

Cisplatin

20

77.2 ± 15.2

281.8 ± 47.1

23.9 ± 2.9

Cisplatin

6.7

53.6 ± 29.9

157.9 ± 71

40 ± 9.1

Cisplatin

2.2

92.7 ± 10.6

162.4 ± 15.1

69.1 ± 10.2

Cisplatin

0.7

116.4 ± 7.3

96.6 ± 16.3

101.4 ± 0.2

Cisplatin

0.2

75.7 ± 7.6

108.1 ± 5.4

95.3 ± 3.1

Cisplatin

0.08

77.3 ± 23.4

94.5 ± 34

97.5 ± 6

Cisplatin

0.03

108.8 ± 7.1

100.3 ± 14.7

81.9 ± 12.1

Cisplatin

0.009

100 ± 22.5

67.7 ± 53.5

57.7 ± 44.5

CX-5461

20

173.9 ± 6.4

91.2 ± 13

26.8 ± 2.6

CX-5461

6.7

133 ± 3.3

115 ± 14.2

26.2 ± 4.5

CX-5461

2.2

107.1 ± 11.8

164.5 ± 10.7

33.2 ± 7.9

CX-5461

0.7

92.2 ± 29.1

131.7 ± 42.5

25.5 ± 18.8

CX-5461

0.2

100.5 ± 5.5

182.1 ± 5.6

36.4 ± 11

CX-5461

0.08

75.9 ± 6.1

193.1 ± 29.9

60.7 ± 7.5

CX-5461

0.03

67.1 ± 13

186.2 ± 28.4

86.5 ± 4.2

CX-5461

0.009

79.1 ± 1.2

183.9 ± 22

113.3 ± 8.6

Doxorubicin

20

99.5 ± 19.1

36.3 ± 51.5

7.9 ± 1

Doxorubicin

6.7

91.5 ± 21.3

37.2 ± 32.5

10.1 ± 1
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Doxorubicin

2.2

91.2 ± 9.8

2.6 ± 2.7

9.8 ± 0.6

Doxorubicin

0.7

235.8 ± 58.8

42.3 ± 28.4

2.3 ± 1.2

Doxorubicin

0.2

300 ± 35.1

8.6 ± 7.6

7.6 ± 2.5

Doxorubicin

0.08

232.9 ± 28.3

22.9 ± 1.4

7.3 ± 1.5

Doxorubicin

0.03

121.6 ± 5.6

162.7 ± 46.6

10.4 ± 1.7

Doxorubicin

0.009

71.7 ± 25.5

88.3 ± 30

38.5 ± 5.4

Etoposide

20

173.7 ± 21.4

125.6 ± 20.2

14.7 ± 1.6

Etoposide

6.7

111.2 ± 15.5

275 ± 43.2

15.1 ± 0.8

Etoposide

2.2

88.1 ± 7

415.8 ± 36.8

15.9 ± 1.7

Etoposide

0.7

95.5 ± 4.3

365.2 ± 36.4

21.7 ± 2.3

Etoposide

0.2

89.1 ± 10.4

258.6 ± 26.5

46.3 ± 4.1

Etoposide

0.08

82.7 ± 23

185.1 ± 43.3

73.6 ± 5.3

Etoposide

0.03

85.7 ± 14.6

179.5 ± 19.4

96.6 ± 4.6

Etoposide

0.009

91.4 ± 10.2

138.6 ± 2.3

110.6 ± 12

Fenbendazole

20

143.1 ± 20.2

251.4 ± 45.7

4.8 ± 0.8

Fenbendazole

6.7

136.5 ± 12.7

185.8 ± 114.7

5 ± 0.4

Fenbendazole

2.2

113.2 ± 16.8

261.2 ± 35.4

5.2 ± 2.8

Fenbendazole

0.7

161.8 ± 17.4

138.2 ± 9.3

13.4 ± 1.8

Fenbendazole

0.2

89.7 ± 11.7

107 ± 5.7

86.4 ± 5.1

Fenbendazole

0.08

73.8 ± 22.9

85.8 ± 51.8

64 ± 49.8

Fenbendazole

0.03

89.2 ± 4.8

112.1 ± 19.7

85.2 ± 7.8

Fenbendazole

0.009

98.6 ± 18.5

94.4 ± 19.6

77.6 ± 6

Flavopiridol

20

133.5 ± 39

215.7 ± 50.6

1.9 ± 0.6
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Flavopiridol

6.7

125.3 ± 83.7

130 ± 65.6

2.2 ± 0.9

Flavopiridol

2.2

163.9 ± 44.5

104.7 ± 59.7

1.6 ± 0.9

Flavopiridol

0.7

87.1 ± 44.6

163 ± 115.8

1.4 ± 1

Flavopiridol

0.2

114.6 ± 74.2

88.7 ± 67

3.8 ± 1.6

Flavopiridol

0.08

97.5 ± 6.2

241.7 ± 80.6

7.9 ± 1.2

Flavopiridol

0.03

73.1 ± 8.9

194.3 ± 56.1

73.7 ± 4.7

Flavopiridol

0.009

79.3 ± 9.7

127.3 ± 13.1

93.5 ± 3.9

Hesperadin

20

230.3 ± 11.8

55.2 ± 25.1

3.2 ± 0.9

Hesperadin

6.7

211.3 ± 17.4

92.2 ± 29.1

9.4 ± 1

Hesperadin

2.2

200.4 ± 2.9

130.9 ± 16.4

10 ± 0.5

Hesperadin

0.7

152.1 ± 29.9

192.5 ± 45.4

10.4 ± 1.5

Hesperadin

0.2

120 ± 3.7

374 ± 37.6

12.4 ± 1.8

Hesperadin

0.08

96.9 ± 4.9

459.7 ± 38

16.1 ± 3.4

Hesperadin

0.03

73.3 ± 10.3

242.2 ± 52.5

44.3 ± 5.9

Hesperadin

0.009

90.5 ± 4.2

154.4 ± 28.4

89.9 ± 9.5

Ispinesib

20

6 ± 1.7

2 ± 3.5

5.8 ± 0.9

Ispinesib

6.7

201.6 ± 19.3

121.6 ± 24.2

3.2 ± 0.7

Ispinesib

2.2

93.4 ± 16.4

332.8 ± 51.2

3.7 ± 0.4

Ispinesib

0.7

94.6 ± 10.1

296.5 ± 58.2

3.6 ± 0.9

Ispinesib

0.2

105.7 ± 22.5

266.9 ± 80.4

4.7 ± 1.7

Ispinesib

0.08

114 ± 18.8

316.7 ± 12

4.1 ± 0.8

Ispinesib

0.03

83.5 ± 43.4

152 ± 130.3

5 ± 1.4

Ispinesib

0.009

79.7 ± 41.9

197.9 ± 159.6

6.6 ± 0.7
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IWP-2

20

77.9 ± 31.9

71.6 ± 44.7

48.3 ± 35

IWP-2

6.7

89.6 ± 14.4

96.9 ± 13.8

80.9 ± 2.8

IWP-2

2.2

80 ± 20

91.3 ± 21.6

72.5 ± 10

IWP-2

0.7

104.2 ± 9.6

85 ± 7

75.8 ± 1.1

IWP-2

0.2

87.5 ± 22.3

85 ± 30.8

53.8 ± 41.6

IWP-2

0.08

99.6 ± 9.1

89.4 ± 5.9

76.7 ± 3.6

IWP-2

0.03

97.3 ± 11.7

85.8 ± 16

54.3 ± 15.1

IWP-2

0.009

109.3 ± 11.6

74.2 ± 27

57.1 ± 18.9

LY411575

20

70.9 ± 4.2

121.7 ± 26.9

79.6 ± 3.8

LY411575

6.7

85.6 ± 10

123.7 ± 16.2

78.1 ± 5

LY411575

2.2

86.4 ± 7.9

139.1 ± 10.5

85.1 ± 1.8

LY411575

0.7

84.1 ± 2

143.8 ± 18.1

93.5 ± 6.8

LY411575

0.2

79.6 ± 7.2

127.1 ± 19.8

85.4 ± 2.6

LY411575

0.08

83.7 ± 13.6

136.9 ± 5.3

90.1 ± 1.8

LY411575

0.03

67.8 ± 18.3

112.3 ± 28.2

85.1 ± 6.3

LY411575

0.009

68.7 ± 18.3

124.9 ± 29.8

90.6 ± 6.8

Metarrestin

20

201.9 ± 35

12 ± 3.4

26.5 ± 3.3

Metarrestin

6.7

86.2 ± 26.9

46.4 ± 14

48.2 ± 36.1

Metarrestin

2.2

87.6 ± 4.6

83.9 ± 10.4

76.6 ± 5.8

Metarrestin

0.7

101 ± 7.9

74.5 ± 3.5

74 ± 20.8

Metarrestin

0.2

95.3 ± 3.7

125.8 ± 10.3

79.4 ± 6

Metarrestin

0.08

91.2 ± 3.4

105 ± 12.8

77.5 ± 9.9

Metarrestin

0.03

85.4 ± 22.9

66.8 ± 42.7

54.5 ± 40.2
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Metarrestin

0.009

97.2 ± 19.4

72.4 ± 4.4

Metformin

20

121.5 ± 8.5

78.3 ± 27.7

Metformin

6.7

111.9 ± 8

99.6 ± 5.1

85.7 ± 10.7

Metformin

2.2

104.1 ± 9.5

108 ± 11.4

92.5 ± 3.9

Metformin

0.7

93.4 ± 12.9

115.1 ± 16.3

98.2 ± 7.9

Metformin

0.2

82.1 ± 14.5

98.3 ± 24.2

95.5 ± 6.5

Metformin

0.08

85.1 ± 6.4

136.6 ± 12.3

87.8 ± 19.5

Metformin

0.03

67.1 ± 29.4

95.2 ± 59.2

60.4 ± 46

Metformin

0.009

80.9 ± 13.5

135.9 ± 22.8

96 ± 0.6

Mitomycin C

20

18.2 ± 16.2

1 ± 0.3

Mitomycin C

6.7

213.3 ± 142

13.1 ± 6.6

9.6 ± 2.8

Mitomycin C

2.2

155 ± 95.8

36.7 ± 14.4

10.4 ± 5.4

Mitomycin C

0.7

117.4 ± 5

219.2 ± 20.8

18 ± 1

Mitomycin C

0.2

78.4 ± 15.9

346 ± 65.7

26 ± 3.8

Mitomycin C

0.08

78.7 ± 11.1

297.5 ± 51.7

42.1 ± 8.6

Mitomycin C

0.03

77 ± 2.9

236.7 ± 11.7

67.7 ± 8.3

Mitomycin C

0.009

76.5 ± 8.9

180.2 ± 30.5

85.5 ± 2.2

Paclitaxel

20

123.7 ± 18.8

372 ± 49.3

3.2 ± 0.2

Paclitaxel

6.7

112.5 ± 65

171.7 ± 161.3

4.1 ± 3.5

Paclitaxel

2.2

121.5 ± 11.2

359.4 ± 60.8

2 ± 0.3

Paclitaxel

0.7

154.6 ± 4.7

306.7 ± 24

2.2 ± 0.5

Paclitaxel

0.2

90.1 ± 22.4

268.4 ± 55.3

1.8 ± 0.4

Paclitaxel

0.08

143.4 ± 6.3

227 ± 40.5

2.3 ± 1

237 ± 135.9
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69.4 ± 1.8
66.2 ± 51.4

Paclitaxel

0.03

113.2 ± 35.3

374.5 ± 88.2

2.3 ± 0.1

Paclitaxel

0.009

152.6 ± 15.9

250 ± 60.9

7.9 ± 1.4

SBE 13

20

54.6 ± 37.4

100.7 ± 73.9

69.7 ± 55.8

SBE 13

6.7

81 ± 7

163.5 ± 22.7

108 ± 2.9

SBE 13

2.2

79.6 ± 14.7

157.7 ± 13.4

106.3 ± 5.3

SBE 13

0.7

78.5 ± 9.6

160.3 ± 12.8

109.2 ± 1

SBE 13

0.2

82.8 ± 8.2

151.7 ± 10.5

105.2 ± 5.2

SBE 13

0.08

43.3 ± 28.9

47.6 ± 78.7

39 ± 56.9

SBE 13

0.03

78.8 ± 18.6

122.4 ± 21.3

84.7 ± 24.7

SBE 13

0.009

90.3 ± 4.1

114.8 ± 26.1

97.1 ± 8

Temsirolimus

20

116 ± 14.5

81 ± 24

25.5 ± 1.9

Temsirolimus

6.7

62 ± 9.9

159.6 ± 34.3

54.4 ± 4.6

Temsirolimus

2.2

77.4 ± 8.2

181 ± 9

54.4 ± 3.9

Temsirolimus

0.7

69.1 ± 8.2

213.4 ± 11.4

52.5 ± 3.8

Temsirolimus

0.2

57.6 ± 1.6

181.5 ± 53.6

43.1 ± 23.2

Temsirolimus

0.08

67.7 ± 3.1

198.5 ± 21.8

55.1 ± 6.6

Temsirolimus

0.03

65 ± 14.6

199 ± 31.9

58.1 ± 1.9

Temsirolimus

0.009

63 ± 7.6

206.3 ± 37.5

65.3 ± 2.6

Topotecan

20

263.1 ± 42.7

10.2 ± 17.7

1.2 ± 0.6

Topotecan

6.7

351.9 ± 31.8

3.4 ± 5.9

3.1 ± 0.3

Topotecan

2.2

247.9 ± 41.4

52.3 ± 10.7

8.1 ± 1.2

Topotecan

0.7

214.6 ± 24.3

69.3 ± 10.4

8.3 ± 1.5

Topotecan

0.2

156.7 ± 25.4

101 ± 9

11 ± 0.8
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Topotecan

0.08

129.3 ± 27.1

150.6 ± 26.2

12.2 ± 1.1

Topotecan

0.03

95.5 ± 16.1

223.4 ± 41.2

12.8 ± 0.5

Topotecan

0.009

87.9 ± 11.2

302.7 ± 37.4

17.6 ± 1.6

Trichostatin A

20

148.7 ± 37.2

10.3 ± 8

7.4 ± 1.5

Trichostatin A

6.7

136.6 ± 34.2

5.6 ± 1.7

7.4 ± 0.6

Trichostatin A

2.2

186.6 ± 86

26.7 ± 10.5

3.8 ± 3

Trichostatin A

0.7

187.9 ± 4

49.8 ± 11.2

9.4 ± 0.6

Trichostatin A

0.2

88.6 ± 7.5

129.9 ± 30

48.3 ± 3.1

Trichostatin A

0.08

96.7 ± 7.2

133.7 ± 33.5

56.1 ± 4.5

Trichostatin A

0.03

95.4 ± 5.3

126.5 ± 15.2

66.6 ± 3.5

Trichostatin A

0.009

99.4 ± 21.7

91 ± 26.7

67.7 ± 3.8

XAV939

20

92.4 ± 3.9

107.6 ± 28

78.7 ± 9.3

XAV939

6.7

64 ± 6.5

101.3 ± 14.3

80.6 ± 2.6

XAV939

2.2

80.7 ± 8.8

136.4 ± 21.2

83.2 ± 8.9

XAV939

0.7

74.4 ± 9.7

139.7 ± 21

89 ± 11.4

XAV939

0.2

78.8 ± 11.9

144 ± 12.8

84.1 ± 9.9

XAV939

0.08

81.5 ± 5.7

141 ± 6.1

100.4 ± 5

XAV939

0.03

79.1 ± 11.2

137.4 ± 29.5

91.6 ± 10.1

XAV939

0.009

83.6 ± 6

138.2 ± 22.1

96.1 ± 6.2
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Appendix V

The 110 FDA-approved drugs that caused a decrease in nucleolar number. Drug
name, Chemical Abstracts Service (CAS) registry number, the one nucleolus normalized
percent effect (NPE), percent (%) viability relative DMSO, medical use, and molecular
target are indicated.
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Drug Name

CAS No.

NPE

%

Medical use

Viab-

Molecular
target

ility
Viadent

5578-73-4

235.4 1.3

Antibacterial

(Sanguinarine

Plasma
membrane

sulfate)
Cetrimonium

57-09-0

208.9 1.1

Antiseptic

bromide
Mitoxantrone

Plasma
membrane

65271-80-9

188.7 5.9

Antineoplastic

Topoisomerase

Rubitecan

91421-42-0

146.6 8.4

Antineoplastic

Topoisomerase

Pixantrone

144675-97-8

142.3 11.7

Antineoplastic

dimaleate
GVS (gentian

Topoisomerase

548-62-9

139.2 4.2

Antiseptic

Unknown

Vindesine sulfate

59917-39-4

138.1 6.6

Antineoplastic

Tubulin

Mitoxantrone

70476-82-3

131.9 5.9

Antineoplastic

Topo-

violet)

hydrochloride
Lanoxin (digoxin)

Topotecan

isomerase
20830-75-5

119413-54-6

126.4 3.8

126.4 7.9

hydrochloride

Cardiovascular

Na+/K+

agent

ATPase

Antineoplastic

Topoisomerase
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Vinblastine

865-21-4

125.7 6.3

Antineoplastic

Tubulin

Lanatoside C

17575-22-3

125.6 3.8

Cardiovascular

Na+/K+

agent

ATPase

Antineoplastic

Kinesin

Ispinesib

336113-53-2

122.7 1.6

(KIF11)
Vincristine sulfate

2068-78-2

122.5 7.1

Antineoplastic

Tubulin

Povan (pyrvinium

3546-41-6

121.1 14.3

Antiparasitic

Unknown

17598-65-1

120.5 2.7

Cardiovascular

Na+/K+

agent

ATPase

Antineoplastic

Topo-

pamoate)
Deslanoside

Topotecan

123948-87-8

120.5 13.0

isomerase
Aclarubicin

57576-44-0

118.6 4.6

Antineoplastic

Topoisomerase

Vinblastine sulfate

143-67-9

117.6 6.7

Antineoplastic

Tubulin

Proscillaridin

466-06-8

116.3 1.9

Cardiovascular

Na+/K+

agent

ATPase

Antiseptic;

Plasma

Cetylpyridinium

6004-24-6

115.0 1.6

chloride

Pharmaceutical membrane
preservative

Vinorelbine

71486-22-1

114.8 6.5

Antineoplastic

Tubulin

Crystodigin

71-63-6

112.7 9.0

Cardiovascular

Na+/K+

agent

ATPase

(digitoxin)
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Velban (vinblastine

143-67-9

111.5 7.5

Antineoplastic

Tubulin

Vinorelbine

71486-22-1

111.4 7.4

Antineoplastic

Tubulin

Vincristine

57-22-7

109.8 6.3

Antineoplastic

Tubulin

Acetyldigitoxin

1111-39-3

106.4 2.9

Cardiovascular

Na+/K+

agent

ATPase

sulfate)

Oncovin

2068-78-2

105.8 6.3

Antineoplastic

Tubulin

404951-53-7

104.7 6.1

Antineoplastic

Histone

(vincristine sulfate)
Dacinostat

deacetylases
Vinleurosine

54081-68-4

104.4 8.2

Antineoplastic

Tubulin

Zinc omadine

13463-41-7

103.9 1.0

Antibacterial;

Plasma

Antifungal

membrane

(pyrithione zinc)
Mutamycin

50-07-7

103.5 15.7

Antineoplastic

DNA

1320-44-1

102.9 21.9

Antiseptic

Plasma

(mitomycin)
Methylbenzethonium

membrane

chloride
Digitoxin

71-63-6

102.3 4.0

Cardiovascular

Na+/K+

agent

ATPase

Plicamycin

18378-89-7

100.9 2.7

Antineoplastic

DNA

Maitansine

35846-53-8

100.5 6.8

Antineoplastic

Tubulin
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Ouabain

Mycophenolic acid

11018-89-6

24280-93-1

99.8

99.7

4.3

20.4

Cardiovascular

Na+/K+

agent

ATPase

Immuno-

IMPDH

modulator
Caradrin

466-06-8

99.1

2.6

(proscillaridin)
Miripirium

2748-88-1

99.0

18.2

Cardiovascular

Na+/K+

agent

ATPase

Antiseptic

Plasma
membrane

Dasatinib

863127-77-9

99.0

20.1

Antineoplastic

Tyrosine
kinases

Podophyllin

900-55-9

97.3

6.2

Antiviral

Tubulin

Velban

865-21-4

96.8

5.7

Antineoplastic

Tubulin

57576-44-0

96.8

1.0

Antineoplastic

Topo-

(vinblastine)
Aclarubicin

isomerase
Puromycin

58-58-2

96.7

13.7

dihydrochloride
Eldesine (vindesine

Antibacterial;

Ribosome

Antiparasitic
59917-39-4

96.5

6.2

Antineoplastic

Tubulin

11018-89-6

96.3

2.2

Cardiovascular

Na+/K+

agent

ATPase

Antifungal

Unknown

sulfate)
Ouabain

Octopirox

68890-66-4

94.1

(piroctone olamine)
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19.1

Piroctone

50650-76-5

94.0

17.3

Antifungal

Unknown

Cerivastatin

145599-86-6

93.0

14.2

Cardiovascular

HMG-CoA

agent

reductase

Navelbine

71486-22-1

91.7

6.6

Antineoplastic

Tubulin

Soblidotin

149606-27-9

91.3

6.7

Antineoplastic

Tubulin

Emetine

316-42-7

90.1

8.2

Antiparasitic

Ribosome

89.9

8.2

Antineoplastic

Topo-

(vinorelbine)

dihydrochloride
Vumon (teniposide) 29767-20-2

isomerase
Colchicine

64-86-8

88.1

8.9

Anti-

Tubulin

inflammatory
Taltobulin

228266-40-8

87.3

7.0

Antineoplastic

Tubulin

Anthelvet

5086-74-8

87.2

5.3

Antiparasitic;

Acetylcholine

(tetramizole

Antineoplastic;

receptors

hydrochloride)

Immunomodulator

Benzethonium

121-54-0

87.0

21.2

chloride

Antiseptic;

Plasma

Pharmaceutical membrane
preservative

Podofilox

518-28-5

86.2

7.0

Antineoplastic;
Antiviral
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Tubulin

Ciclopirox

41621-49-2

85.5

18.0

Antifungal

(ciclopirox

Plasma
membrane

olamine)
Plicamycin

18378-89-7

84.0

2.3

Antineoplastic

DNA

Ciclopirox

29342-05-0

83.7

15.3

Antifungal

Plasma
membrane

Azacitidine

320-67-2

83.0

10.8

Antineoplastic

DNA methyltransferase

Pranidipine

99522-79-9

83.0

23.8

Cardiovascular

Ca+ channels

agent
Mycophenolate

115007-34-6

82.9

20.5

mofetil

Immuno-

IMPDH

modulator

Vinformide

54022-49-0

82.6

6.8

Antineoplastic

Tubulin

Docusate sodium

577-11-7

81.6

2.5

Gastrointestina

Unknown

l agent
Mepacrine

83-89-6

81.1

24.5

Antiparasitic

DNA

Condylox

518-28-5

81.0

6.3

Antiviral

Tubulin

106516-24-9

80.1

22.0

Antipsychotic

Dopamine

(podofilox)
Sertindole

receptor
Halofuginone

55837-20-2

79.1

0.5

Antiparasitic

tRNA
synthetase
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Alexidine

22573-93-9

78.4

25.4

Antiseptic

hydrochloride

Plasma
membrane

Vinblastine

865-21-4

78.2

5.8

Antineoplastic

Tubulin

Mitomycin C

50-07-7

77.3

21.4

Antineoplastic

DNA

Albendazole

54965-21-8

76.4

15.5

Antiparasitic

Fumarate
reductase

Gemcitabine

95058-81-4

76.1

13.5

Antineoplastic

Ribonucleotide
reductase

Colchicine

64-86-8

75.3

7.9

Anti-

Tubulin

inflammatory
Roccal

8001-54-5

74.9

22.4

Antiseptic;

Plasma

(benzalkonium

Pharmaceutical membrane

chloride)

preservative

Mithracin

18378-89-7

73.6

2.1

Antineoplastic

DNA

70-30-4

73.1

20.9

Antiseptic

D-lactate

(plicamycin)
Hexachlorophene

dehydrogenase
BI-2536

755038-02-9

72.4

14.5

Antineoplastic

Polo-like
kinase

Mozavaptan

137975-06-5

72.0

20.5

Cardiovascular

Arginine

agent

vasopressin
receptor

307

Lestaurtinib

111358-88-4

71.6

6.7

Antineoplastic

Tyrosine
kinases

Nocodazole

31430-18-9

71.4

8.1

Antineoplastic

Tubulin

Gramicidin

1405-97-6

70.7

24.7

Antibacterial

Plasma
membrane

Albendazole

54965-21-8

70.4

19.4

Antiparasitic

Fumarate
reductase

Edoxudine

15176-29-1

68.8

28.3

Antiviral

DNA
polymerase

Idarubicin

58957-92-9

68.2

1.2

Antineoplastic

Topoisomerase

Ixabepilone

219989-84-1

68.2

2.9

Antineoplastic

Tubulin

Clofarabine 123318-82-1

68.0

18.3

Antineoplastic

Ribonucleotide
reductase

Cambendazole

26097-80-3

67.0

12.1

Antiparasitic

Fumarate
reductase

Parbendazole

14255-87-9

65.4

5.7

Antiparasitic

Tubulin

Mebendazole

31431-39-7

65.2

6.0

Antiparasitic

Tubulin

Flubendazole

31430-15-6

64.5

14.2

Antiparasitic

Tubulin

CellCept

128794-94-5

63.9

20.4

Immuno-

IMPDH

(mycophenolate

modulator

mofetil)
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Mycophenolic acid

24280-93-1

63.8

20.9

Immuno-

IMPDH

modulator
Riboprine

7724-76-7

62.3

16.4

Antineoplastic

Unknown

Daunorubicin

20830-81-3

62.2

1.4

Antineoplastic

Topoisomerase

Lasalocid

Bryamycin

25999-20-6

62.1

33.6

Antibacterial;

Plasma

Antiparasitic

membrane

1393-48-2

61.3

23.8

Antibacterial

Ribosome

184475-35-2

58.4

16.0

Antineoplastic

Tyrosine

(thiostrepton)
Gefitinib

kinases
Fenbendazole

43210-67-9

58.1

14.1

Antiparasitic

Tubulin

Oxyphenbutazone

7081-38-1

57.8

3.8

Analgesic;

Cyclo-

Anti-

oxygenase

inflammatory
Vorinostat

149647-78-9

57.7

16.9

Antineoplastic

Histone
deacetylases

Oxibendazole

20559-55-1

55.5

32.4

Antiparasitic

Tubulin

Cosmegen

50-76-0

55.4

1.3

Antineoplastic

DNA

31431-39-7

55.0

14.5

Antiparasitic

Tubulin

10331-57-4

54.5

20.1

Antiparasitic

Unknown

(Dactinomycin)
Vermox
(mebendazole)
Niclofolan
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Patupilone

152044-54-7

53.4

7.6

Antineoplastic

Tubulin

Cicloheximide

66-81-9

53.2

20.7

Antibacterial;

Ribosome

(cycloheximide)

Antifungal
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Appendix VI

The 30 FDA-approved drugs that caused an increase in nucleolar number. Drug
name, Chemical Abstracts Service (CAS) registry number, the ≥5 nucleoli normalized
percent effect (NPE), percent (%) viability relative DMSO, medical use, and molecular
targets are indicated.
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Drug Name

CAS No.

NPE

%

Medical Use

Viab-

Molecular
Target

ility
Monacrin

90-45-9

364.3

16.5

Antiseptic

DNA

Melphalan

148-82-3

353.1

29.9

Antineoplastic

DNA

Merimepodib

198821-22-6

271.6

24.7

Antiparasitic;

IMPDH

(aminacrine)

Antiviral
Docetaxel

114977-28-5

260.7

9.1

Antineoplastic

Tubulin

Acrisorcin

7527-91-5

236.6

18.6

Antifungal

DNA

Jevtana

183133-96-2

235.3

8.4

Antineoplastic

Tubulin

62-38-4

201.4

2.1

Pharmaceutical

Unknown

(cabazitaxel)
Agrosan
(phenylmercuric

preservative

acetate)
Taxol

33069-62-6

199.7

7.0

Antineoplastic

Tubulin

Fungizone

1397-89-3

183.6

6.2

Antifungal

Ergosterol

958227-46-8

174.4

28.7

Antineoplastic

Aurora B

(amphotericin B)
BI-831266

kinase
Taxotere

148408-66-6

173.3

(docetaxel)
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9.6

Antineoplastic

Tubulin

Alvocidib

131740-09-5

169.0

4.9

Antineoplastic

Cyclindependent
kianses

Oxiconazole

64211-46-7

155.2

86.9

Antifungal

Ergosterol

CellCept

128794-94-5

145.0

18.9

Immuno-

IMPDH

(mycophenolate

modulator

mofetil)
Chlormethine

55-86-7

140.8

19.9

Antineoplastic

DNA

Butoconazole

64872-77-1

135.2

72.6

Antifungal

Ergosterol

Piperacillin

61477-96-1

134.2

99.2

Antibacterial

Penicillin

(mechlorethamine)

binding
protein
Vepesid

33419-42-0

133.3

32.3

Antineoplastic

(etoposide)
Thiomersal

Topoisomerase

54-64-8

132.7

1.0

Pharmaceutical

Unknown

preservative;
Antiseptic
Panflavin

8063-24-9

129.1

20.5

(acriflavinium

Antiseptic;

DNA

Antiparasitic

hydrochloride)
Dalfopristin

112362-50-2

128.6
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53.0

Antibacterial

Ribosome

Actosin

362-74-3

126.6

44.3

(bucladesine)

Cardiovascular

Phospho-

agent; Anti-

diesterase

ulcerative
Bortezomib

179324-69-7

125.9

0.8

Antineoplastic

Proteasome

Tegafur

17902-23-7

124.5

66.7

Antineoplastic

Thymidylate
synthase

Sertaconazole

99592-32-2

124.2

90.0

Antifungal

Ergosterol

Mebendazole

31431-39-7

119.8

6.0

Antiparasitic

Tubulin

Tioconazole

65899-73-2

118.7

83.9

Antifungal

Ergosterol

Istaroxime

374559-48-5

117.5

34.3

Cardiovascular

Na+/K+

agent

ATPase

Anti-

Gluco-

inflammatory

corticoid

Clobetasol

25122-46-7

112.2

83.6

propionate

recceptor
Oxiconazole

64211-46-7

110.3
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90.0

Antifungal

Ergosterol

Appendix VII

The 234 synthetic, drug-like compounds that yielded either an increase or decrease
in nucleolar number. Unique compound ID, the designated phenotype (one nucleolus
per nucleus or ≥5 nucleoli per nucleus), the normalized percent effect (NPE) for each
phenotype, and percent viability relative to DMSO (0.1%) are shown.
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Compound ID

Pheno-

1 nucleolus per

≥5 nucleoli per

type

nucleus NPE

nucleus NPE

Percent viability

(1/≥5)
YU275173

1

82.1

-55.4

30.8

YU275624

1

79.5

-41.7

21.5

YU258006

1

78.8

-500.4

13.7

YU257337

1

74.0

-190.9

25.7

YU268831

1

73.0

-116.0

28.8

YU263255

1

68.4

-12.4

22.3

YU268218

1

67.4

-4.7

6.7

YU262883

1

62.1

-41.0

40.2

YU257828

1

61.1

-415.4

14.1

YU270835

1

61.1

18.7

6.3

YU271333

1

61.0

-40.2

36.2

YU258701

1

58.3

-114.4

7.2

YU256667

1

57.3

-61.7

10.0

YU256773

1

55.5

-189.4

30.1

YU270716

1

53.8

-22.4

22.2

YU256771

1

53.4

-91.2

8.1

YU265245

1

53.3

-45.3

19.9

YU269527

1

48.6

-170.4

215.2

YU275232

1

48.2

-29.5

56.2

YU256691

1

47.2

-213.2

17.8
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YU280992

1

47.1

-14.4

28.7

YU263854

1

46.8

-62.1

20.8

YU275534

1

46.8

52.3

38.3

YU256776

1

46.5

-229.8

6.2

YU265474

1

46.4

-458.2

354.7

YU263078

1

44.5

-27.0

51.7

YU276852

1

44.5

-58.5

41.7

YU276881

1

43.6

-43.5

55.4

YU277406

1

42.8

-38.1

63.1

YU276803

1

40.8

-51.7

67.9

YU262873

1

40.3

-34.1

61.6

YU276687

1

39.5

-28.6

76.5

YU276750

1

39.1

-45.7

68.2

YU267724

1

38.4

-86.9

253.4

YU276831

1

38.1

-47.0

60.7

YU271407

1

37.8

-37.9

26.3

YU257883

1

37.8

-20.3

22.9

YU257642

1

37.7

-246.5

26.7

YU257875

1

37.4

-384.4

35.0

YU276844

1

37.3

-40.0

74.6

YU275974

1

37.0

-41.4

56.2

YU258712

1

36.9

-208.1

27.1

YU279797

1

36.0

-34.0

53.4
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YU270641

1

35.9

-151.4

214.0

YU279821

1

35.9

-24.6

63.4

YU270819

1

35.0

-34.3

31.2

YU279801

1

34.9

-33.3

60.7

YU279798

1

34.5

-29.6

52.1

YU276816

1

34.3

-29.2

39.5

YU276861

1

34.2

-35.0

91.5

YU276806

1

33.8

-28.0

63.8

YU256505

1

33.6

-253.8

18.9

YU275610

1

33.1

-26.9

60.1

YU277605

1

33.0

-26.9

67.1

YU276867

1

32.9

-31.1

93.6

YU279851

1

32.6

-28.5

56.7

YU276814

1

32.4

-36.7

85.8

YU279858

1

32.3

-44.4

62.8

YU276856

1

32.2

-22.2

63.0

YU268641

1

31.8

-39.9

47.1

YU279803

1

31.7

-18.8

46.7

YU265485

1

31.3

-266.2

19.5

YU276596

1

31.2

-28.7

93.2

YU256775

1

31.1

-91.9

6.6

YU275397

1

31.0

-23.3

41.2

YU260066

1

30.9

-21.6

133.6
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YU276691

1

30.7

-36.2

57.4

YU258900

1

30.5

-210.9

19.9

YU266928

1

30.2

-52.6

58.2

YU276870

1

30.0

-13.3

86.6

YU276846

1

29.5

-27.0

74.0

YU279785

1

29.2

-24.7

55.1

YU279802

1

28.9

-26.9

55.2

YU275603

1

28.8

-23.3

33.2

YU270104

1

28.7

-33.9

56.9

YU276888

1

28.2

-29.4

118.1

YU276865

1

28.2

-27.5

72.7

YU276810

1

27.6

-27.1

76.2

YU277549

1

27.6

-15.8

43.1

YU275618

1

27.0

-22.6

49.7

YU276862

1

26.8

-18.6

100.4

YU263845

1

26.8

-50.8

21.2

YU278496

1

26.6

-21.9

63.9

YU277450

1

26.3

-23.3

70.7

YU275602

1

26.0

-21.0

36.1

YU268869

1

25.8

-57.5

31.3

YU279792

1

25.8

-46.3

57.1

YU274699

1

25.8

-35.2

111.2

YU258859

1

25.7

-245.0

46.4
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YU270744

1

25.4

-31.0

57.2

YU276833

1

25.4

-30.8

86.2

YU270748

1

25.3

-36.4

51.2

YU258715

1

25.3

-209.7

72.7

YU277932

1

25.1

-17.8

74.7

YU275374

1

24.8

-19.4

54.3

YU277614

1

24.8

-13.3

78.7

YU279789

1

24.8

-10.5

82.1

YU261429

1

24.6

-26.3

62.7

YU260850

1

24.5

-8.8

107.6

YU276808

1

24.3

-16.5

59.4

YU276595

1

24.2

-41.5

70.9

YU279799

1

24.2

-16.1

69.9

YU270752

1

24.1

-37.1

53.3

YU276618

1

23.8

-16.2

92.4

YU259823

1

23.8

-31.0

152.1

YU273348

1

23.6

-31.1

50.7

YU275607

1

23.5

-26.8

34.5

YU277613

1

23.1

-12.4

71.8

YU276837

1

22.9

-5.1

83.0

YU279819

1

22.6

-25.2

60.6

YU276738

1

22.6

-30.1

79.7

YU276901

1

22.5

2.0

94.0
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YU279793

1

22.5

-37.3

39.4

YU275612

1

22.5

-31.3

53.2

YU275775

1

22.4

-17.9

71.3

YU275402

1

22.4

-23.6

70.0

YU276727

1

22.3

-24.8

64.9

YU276807

1

22.2

-41.7

73.2

YU275398

1

22.2

-30.5

64.8

YU275243

1

22.2

-16.3

78.4

YU260480

1

22.1

-17.0

56.1

YU276764

1

22.0

-31.0

118.4

YU268679

1

22.0

-36.1

69.0

YU272087

1

21.9

-37.7

50.7

YU276879

1

21.6

-40.8

116.0

YU276305

1

21.6

-26.4

67.6

YU275286

1

21.6

-19.6

79.5

YU276871

1

21.5

-40.3

96.2

YU277943

1

21.4

-17.3

86.3

YU274118

1

21.4

-20.0

41.2

YU260026

1

21.1

-15.6

123.2

YU278495

1

21.1

-12.0

64.0

YU275632

1

21.1

-27.8

42.9

YU276809

1

20.9

-37.9

93.7

YU263335

1

20.9

-14.9

55.8
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YU276863

1

20.8

-25.1

111.0

YU276576

1

20.7

-16.5

37.9

YU271638

1

20.4

-38.7

54.2

YU271833

1

20.2

-27.6

58.0

YU276827

1

20.2

-28.8

114.5

YU278475

1

20.2

-24.6

71.7

YU274377

1

20.1

-19.3

121.0

YU276789

1

20.0

-29.5

120.5

YU258334

1

19.8

-132.3

52.9

YU276594

1

19.8

-25.4

60.2

YU276905

1

19.7

-26.0

104.8

YU273331

1

19.7

-26.0

40.1

YU276798

1

19.6

-27.8

112.0

YU279309

1

19.6

-24.7

101.4

YU268935

1

19.5

-129.5

68.3

YU276773

1

19.4

-23.2

119.4

YU275819

1

19.4

-26.7

60.5

YU259930

1

19.4

-10.5

110.6

YU276703

1

19.3

-14.4

102.0

YU273238

1

19.3

-29.2

40.1

YU275604

1

19.3

-18.1

39.2

YU268938

1

19.3

-151.8

57.0

YU275440

1

19.3

-16.9

54.8
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YU275570

1

19.2

-18.3

70.0

YU279838

1

19.2

-11.5

93.0

YU261750

1

19.2

-14.6

64.7

YU266010

1

19.0

-55.5

68.1

YU275588

1

19.0

-20.5

59.5

YU276699

1

18.9

-23.3

87.7

YU261190

1

18.8

-9.3

70.2

YU277461

1

18.8

-17.2

52.1

YU275987

1

18.7

-23.4

71.2

YU275628

1

18.7

-18.1

79.2

YU278050

1

18.6

-10.9

83.1

YU276848

1

18.6

-16.6

94.8

YU276689

1

18.6

-14.3

95.8

YU275300

1

18.5

-15.5

71.2

YU276836

1

18.5

-32.0

111.8

YU275609

1

18.5

-15.8

55.7

YU263612

1

18.5

-10.2

65.7

YU276568

1

18.4

-11.0

152.2

YU276712

1

18.4

-0.9

116.9

YU273533

1

18.3

-114.7

51.2

YU273745

1

18.3

-13.7

70.1

YU275623

1

18.3

-18.2

38.7

YU272308

1

18.3

-39.8

45.1
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YU276688

1

18.3

-9.1

95.1

YU276746

1

18.1

-17.8

79.2

YU260673

1

18.1

3.6

57.8

YU268759

1

17.9

-44.5

67.1

YU276740

1

17.8

-11.8

106.0

YU268672

1

17.8

-33.0

54.1

YU278492

1

17.8

-9.9

57.3

YU269499

1

17.8

-46.7

44.5

YU274537

1

17.7

-31.6

111.9

YU256863

1

17.7

-216.2

65.3

YU271635

1

17.4

-38.1

58.8

YU259866

1

17.3

-16.6

110.9

YU274162

1

17.3

-20.1

59.9

YU279413

1

17.2

-23.4

102.2

YU259962

1

17.1

-9.7

85.1

YU278301

1

17.1

-16.1

92.2

YU275406

1

17.1

-17.9

82.3

YU275611

1

17.0

-20.1

53.2

YU275294

1

17.0

-10.5

102.8

YU261389

1

16.9

-27.9

83.0

YU276885

1

16.8

-11.0

120.5

YU265558

≥5

-4.2

347.2

51.2

YU265327

≥5

-3.5

319.8

86.2
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YU265551

≥5

-3.1

315.9

55.9

YU258014

≥5

0.3

302.1

30.8

YU265571

≥5

-4.7

297.5

64.2

YU265323

≥5

-1.5

264.8

108.5

YU258011

≥5

-2.2

259.1

28.1

YU265585

≥5

-2.0

254.2

93.9

YU265315

≥5

0.9

250.4

77.7

YU265601

≥5

-6.1

243.1

86.7

YU265296

≥5

-4.2

240.8

122.7

YU258019

≥5

-6.2

240.7

24.3

YU258017

≥5

-4.6

236.2

39.4

YU265799

≥5

-0.7

228.0

133.0

YU266442

≥5

-0.3

225.3

155.0

YU265306

≥5

1.1

218.5

60.7

YU258013

≥5

-1.0

217.8

39.0

YU265301

≥5

2.2

210.2

98.7

YU258012

≥5

-4.7

208.9

39.8

YU265307

≥5

-3.2

208.6

42.4

YU265319

≥5

-3.9

188.2

88.9

YU265310

≥5

-8.4

178.8

85.6

YU265595

≥5

-0.2

174.5

88.0

YU265311

≥5

-2.9

161.9

83.3

YU265579

≥5

-0.9

156.3

74.6
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YU265560

≥5

-11.6

153.2

66.8

YU265484

≥5

1.0

152.0

120.9

YU265332

≥5

2.7

150.2

116.3

YU280559

≥5

-0.2

148.2

103.8

YU265475

≥5

3.2

146.5

115.2

YU265473

≥5

0.7

142.6

132.6

YU265303

≥5

1.1

140.9

88.4
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Appendix VIII

The 185 high confidence compounds that regulate nucleolar number from both the
FDA-approved drug screen and screen of synthetic, drug-like compounds. Drug
name or unique compound ID, the designated phenotype in initial screen (one nucleolus
per nucleus or ≥5 nucleoli per nucleus), percent effect for each phenotype relative to
DMSO, and the mean percent viability relative to DMSO are shown. The designated
cluster from the combined structure cluster analysis at ≥0.5 similarity are also shown.
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Compound ID or

Pheno- 1 nucleolus per

≥5 nucleoli per

Mean

Cluster

drug name

type

nucleus PE

nucleus PE

percent

No.

(1/≥5)

(Rep1, Rep2)

(Rep1, Rep2)

viability

≥5

-17.4, 1.3

150.3, 97

17.9

1

≥5

-10.9, -5

124.5, 100.9

43.0

2

Tegafur

≥5

-12.5, -8.4

61.6, 98.1

51.3

2

Docetaxel

≥5

4.2, -1.4

116.4, -8.6

59.9

2

Ouabain

1

54.4, 1.5

-53.7, 7.2

55.4

2

Mitomycin C

1

40.7, -4.4

-55.4, 26.4

62.4

2

Gemcitabine

1

21.6, 3.8

-11.4, 3.7

57.8

2

Clofarabine

1

30.5, 22.9

-23, 16.7

14.7

2

Taxol

≥5

37.5, 7.9

54.1, -26.2

56.3

2

Mutamycin

1

49.5, 107.9

-60.4, -97.8

11.6

2

Edoxudine

1

47.7, 47.7

13.3, -12.1

22.6

2

Vepesid (etoposide)

≥5

-13.1, 0.4

53.2, 89.2

32.4

2

Riboprine

1

22.5, 60.5

-22.6, -64.7

17.2

2

Lasalocid

1

46.6, 53.4

-64.4, -96

28.2

2

Vinorelbine

1

27.6, 50.4

-48.1, -91.8

25.8

3

Octopirox (piroctone 1

38.6, 94.1

-47.1, -94.9

15.9

3

Chlormethine
(mechlorethamine)
Actosin
(bucladesine)

(mitomycin)

olamine)
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Ciclopirox

1

64.7, 86.4

-64.1, -92.4

22.2

3

BI-2536

1

-8.8, 14.8

44.8, -35.8

12.4

3

Ciclopirox

1

53.2, 95.2

-66.2, -96.9

19.7

3

Piroctone

1

60.3, 98.9

-58, -78.7

24.0

3

BI-831266

≥5

8.4, 22.5

334, 180.9

30.4

3

YU256773

1

22.8, 45.8

82.7, 34.9

12.9

3

YU256863

1

18, 8.9

-38.7, -128.9

61.3

3

YU257337

1

71.4, 96.9

-63, -175.4

21.7

3

YU257828

1

1.5, 67.3

2.6, -153.7

53.1

3

YU257875

1

0.6, 44.9

4.7, -129.4

76.7

3

YU257883

1

36.4, 57.8

-43.5, -115.1

21.2

3

YU258006

1

-5.1, 104.8

-3.8, -170.9

70.1

3

YU258712

1

52.8, 68

-47.8, -149.1

20.7

3

YU258715

1

17.8, 10.5

-39.3, -110.2

46.6

3

YU258859

1

12.8, 13

-45.5, -111.3

51.1

3

YU260480

1

9.3, 11.2

-25.5, -92.5

58.3

3

YU260673

1

8.4, 10.7

-32.9, -100.3

64.2

3

YU261429

1

10.7, 10.1

-38.3, -100.8

73.0

3

YU261750

1

14.5, 13.4

-31.2, -119.1

63.0

3

YU262873

1

30.1, 34.2

-38.6, -115

82.9

3

YU262883

1

58.8, 74.2

-54, -174.9

31.8

3

YU263335

1

16.1, 18.4

-31.2, -106.1

43.4

3

(ciclopirox olamine)
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YU263845

1

42.2, 113.5

-61.1, -176.2

21.1

3

YU263912

1

12.3, 13.2

-30, -116.2

48.2

3

YU264306

1

15.5, 18.1

-26.1, -77.8

84.9

3

YU265142

1

12.3, 15

-43.8, -113.5

60.9

3

YU265245

1

62.3, 64.8

-42.4, -129.6

30.6

3

YU266010

1

20.9, 13.7

-32.9, -116.3

52.4

3

YU266138

1

2.8, 10.3

-9.8, -21.7

60.5

3

YU266595

1

16.4, 8.4

-12, -26.5

77.8

3

YU266868

1

17.4, 20.4

-31.9, -99.1

77.2

3

YU266926

1

14.9, 6.2

-35.7, -110.5

64.6

3

YU268257

1

15.3, 4.2

-34.2, -137.8

62.8

3

YU268641

1

17.1, 30.4

-27.2, -149.3

41.7

3

YU268672

1

25.7, 16.5

-52.1, -127.4

55.9

3

YU268679

1

14, 17.9

-36.2, -121.6

62.2

3

YU268680

1

18.4, 11.4

-43, -108

48.9

3

YU268831

1

70.3, 107.2

-56.4, -125.1

22.9

3

YU268869

1

43, 74.7

-56.5, -165.9

30.5

3

YU268935

1

20, 18.3

-35.4, -70.7

41.5

3

YU268938

1

15.6, 18.8

-36.8, -78.5

51.1

3

YU270716

1

55, 64.5

-41.4, -128.8

24.9

3

YU270744

1

18, 8

-45.1, -132.8

77.8

3

YU270748

1

17.8, 7.9

-39.4, -123

69.9

3

YU270751

1

22.3, 9.1

-36.4, -96

84.2

3
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YU270819

1

23.9, 66.2

-55.9, -169.6

30.8

3

YU271407

1

34.3, 26.8

-33.3, -103.9

62.6

3

YU272087

1

13.6, 13.1

-47.6, -93

64.7

3

YU272289

1

13.4, 14.3

-36.6, -63.5

63.4

3

YU272308

1

38.8, 13.5

-46.5, -98.8

39.1

3

YU273466

1

23.6, 22.2

-42.6, -75.3

56.2

3

YU273533

1

10.6, 13.7

-20.3, -56

62.6

3

YU273668

1

-6.7, 18.8

-40.7, -82.8

52.8

3

YU273758

1

27, 19.6

-32.6, -69

62.4

3

YU274118

1

17.4, 15.8

-27.6, -68.4

57.0

3

YU275232

1

19.9, 14.6

-34.8, -60.6

61.8

3

YU275243

1

13.2, 11.2

-16.4, -53.6

88.0

3

YU275374

1

8.2, 14.4

-23.2, -91.9

52.6

3

YU275397

1

14.8, 10.1

-35.9, -73.3

57.3

3

YU275398

1

13.9, 10.9

-25.4, -63.9

63.1

3

YU275402

1

7, 15

-28.6, -59.6

75.9

3

YU275534

1

24.4, 36.8

76.7, 48.4

10.4

3

YU275602

1

36.1, 15.5

-49.9, -105.8

30.9

3

YU275603

1

21.5, 46.6

-42.4, -118.2

34.2

3

YU275607

1

12.6, 22.9

-37.4, -81.3

67.3

3

YU275610

1

16.3, 17.5

-34.6, -76.2

39.4

3

YU275612

1

12.3, 12.9

-34.9, -77.4

46.3

3

YU275618

1

8.9, 16.3

-33.7, -72

62.9

3
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YU275624

1

51.2, 105.2

-56.4, -125.2

25.5

3

YU275632

1

0.7, 12.2

-39.5, -65.4

63.4

3

YU276576

1

8.4, 20.1

-36.1, -73

58.8

3

YU276595

1

13.6, 22.7

-33.7, -76

60.8

3

YU276618

1

18, 9.7

-21.6, -45

65.7

3

YU276691

1

14.3, 14.4

-29.4, -58.3

50.6

3

YU276750

1

23.8, 18.4

-35.7, -68.4

62.8

3

YU277549

1

5.5, 14.7

-31.1, -96.3

47.2

3

YU277605

1

16.3, 18.5

-23, -66.8

63.0

3

YU280408

1

18.5, 26.2

-30.3, -80.8

69.4

3

Monacrin

≥5

27.8, 5.2

65.1, 243.1

16.9

4

1

14.3, 15.6

-31.3, 12.5

18.2

5

YU264477

1

0.5, 17.9

-44.7, -112.9

53.7

5

YU277406

1

12.2, 19.9

-42.5, -77

43.8

5

YU277450

1

7.6, 12.3

-35.2, -76.1

75.3

5

YU280992

1

63, 51.5

-3.3, -73.9

26.5

5

Albendazole

1

48.7, 52

-29.1, -53.9

15.5

6

YU256419

1

18.6, 8.9

-32.1, -84.2

64.6

7

YU266928

1

15.2, 17.9

-34.6, -108.5

61.4

7

YU268759

1

13.3, 13.5

-35.4, -88.2

77.2

7

YU269011

1

13, 14.2

-30.4, -91.7

78.0

7

(aminacrine)
Zinc omadine
(pyrithione zinc)
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YU269499

1

13.1, 11.9

-34.1, -85.1

33.4

7

YU270104

1

12.7, 15.2

-29.7, -92.3

68.0

7

YU270941

1

21.7, 11.3

-36.9, -103.6

72.2

7

YU275775

1

10.3, 12.5

-39.3, -58.5

78.8

7

Melphalan

≥5

-20.5, -11.6

243.3, 222.6

27.7

8

Vorinostat

1

22.8, 0.5

-30, -43.2

17.5

9

YU263612

1

16.4, 17.3

-39.3, -109.5

63.2

10

YU265745

1

9.9, 16.3

-37.1, -98.6

60.6

10

YU273238

1

14.3, 12.1

-33.5, -71.6

58.8

10

YU273331

1

22.7, 12.8

-29.7, -74.7

49.2

10

YU275173

1

56.4, 103

-53.6, -117

19.3

10

YU275974

1

17.9, 16.2

-24.6, -61

59.3

10

Cicloheximide

1

17.8, 42.4

-30, -71.5

22.5

11

YU268779

1

3.5, 15.3

-29, -73.4

57.2

11

YU273745

1

14.7, 11.2

-25.2, -52.4

78.0

11

YU278496

1

9.1, 15.4

-38.2, -60

55.8

11

Hexachlorophene

1

49.2, 71.9

-50.5, -87

13.1

12

YU258334

1

11.5, 21.1

-8.9, -67.7

46.6

13

Roccal

1

51.6, 65.6

-56.1, -92.1

19.8

14

(cycloheximide)

(benzalkonium
chloride)
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Cetrimonium

1

5.4, 130.5

-7.1, -97.8

57.8

14

YU261190

1

17.4, 16.3

-34.7, -93.3

81.3

15

YU271333

1

44.1, 64.4

-55.6, -170.9

31.3

15

YU271635

1

13.2, 18.4

-33.7, -100.6

78.1

15

YU271638

1

10, 17.2

-43.9, -108.8

69.6

15

Miripirium

1

62.1, 66.5

-54.1, -88

18.5

16

Niclofolan

1

17.8, 25

-29.1, -75

56.3

17

Mycophenolic acid

1

85.3, 111.4

-45.4, -88.1

21.1

18

Mycophenolic acid

1

80.6, 0.4

-52.1, 8

56.6

18

Mycophenolate

1

80, 96.6

-44.6, -74.1

24.2

18

1

90.6, 119.1

-64.8, -92.6

22.4

18

YU276687

1

17.3, 18.6

-30.7, -60

59.1

19

YU276803

1

22.2, 15.9

-31.5, -66.1

62.2

19

YU276806

1

16.1, 10.7

-32.3, -72.2

65.8

19

YU276814

1

23, 19.2

-32.8, -74.3

66.0

19

YU276816

1

1.8, 9.1

-28, -61.2

63.1

19

YU276831

1

13.1, 13.1

-34, -68.6

58.2

19

YU276833

1

18.4, 13.1

-23.3, -53.7

54.0

19

YU276844

1

13.9, 12

-35, -63.7

51.2

19

bromide

mofetil
CellCept
(mycophenolate
mofetil)
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YU276846

1

17.7, 11.6

-26.9, -54.6

62.4

19

YU276852

1

15, 13.8

-31.2, -62.5

51.0

19

YU276856

1

4.5, 19.1

-32.8, -62.8

68.7

19

YU276862

1

16.7, 11.7

-28.3, -66.8

63.3

19

YU276865

1

31.6, 18.4

-38.4, -83.2

50.7

19

YU276867

1

10.8, 18.7

-34.5, -77.5

68.4

19

YU276870

1

15.6, 12.2

-46.3, -73.6

58.4

19

YU276881

1

20, 16.4

-38.6, -74.8

41.7

19

YU279785

1

18.5, 16.8

-29, -69.3

61.4

19

YU279789

1

18, 3

-22.8, -54.9

66.0

19

YU279792

1

11.4, 17.6

-28.3, -66.9

53.9

19

YU279793

1

7.2, 18.3

-38, -86.4

55.2

19

YU279797

1

23.7, 12.2

-37.5, -64.4

51.9

19

YU279798

1

17.6, 2.1

-46.2, -87.1

45.0

19

YU279799

1

18.8, 13.5

-32.9, -75.5

54.6

19

YU279801

1

20.7, 12.1

-31.1, -63.4

57.4

19

YU279802

1

16, 18.9

-34.9, -74.4

55.3

19

YU279803

1

20.7, 5.1

-36.3, -77.1

57.4

19

YU279821

1

2.4, 15.9

-16.4, -74.4

58.8

19

YU279851

1

15.3, 12.8

-31.5, -80.3

60.2

19

Mitoxantrone

1

76.8, 141

-48.3, -97.8

10.4

20

hydrochloride
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Pixantrone

1

90.7, 149.1

-64, -96.3

12.9

20

YU271832

1

21.4, 19.6

-39.4, -109.6

42.3

21

YU271833

1

13.3, 18.1

-34.9, -106.7

65.1

21

Gefitinib

1

53.9, 78.1

-57.5, -88.3

25.8

22

Methylbenzetho-

1

45.3, 37.7

-49.5, -92.8

27.5

22

YU256505

1

27.5, 69.1

-46.3, -163.6

20.4

22

Istaroxime

≥5

-6.6, -10.1

57.4, 6.8

70.9

23

YU256254

1

15, 8.7

-50, -119.5

49.8

24

YU257642

1

34.2, 45.1

-37.1, -133.9

23.7

24

YU258900

1

44.5, 32.4

-28.2, -119.4

17.7

24

YU273265

1

19.5, 10.6

-21.8, -58.8

58.0

24

YU273348

1

21.2, 10.8

-33.6, -58.7

71.7

24

YU279858

1

21.2, 20

-32.3, -84.7

56.5

24

Mepacrine

1

63.1, 117.2

-58.5, -97

26.3

25

Sertindole

1

35.6, 50.2

-56.5, -84.7

29.2

26

YU263078

1

31.1, 52.8

-54, -156.6

34.7

26

Cerivastatin

1

48.3, -5

-47.9, 6.6

52.1

29

Pranidipine

1

70.3, 78.7

-66.6, -97.8

25.0

30

Alexidine

1

46, 52

-50.7, -87.1

30.5

31

dimaleate

nium chloride

hydrochloride
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Povan (pyrvinium

1

36.7, 84.8

-55.6, -89.1

13.1

32

1

10.2, 16.1

-13, -37.5

80.5

33

pamoate)
Bryamycin
(thiostrepton)
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Appendix IX

Nucleolar proteins enriched on nascent chromatin at the replication fork

338

Nucleolar proteins at the
replication fork and
nascent chromatin (HGNC)
ANLN
ANXA1
APEX2
APTX
AQR
ATM
ATR
ATRIP
BAZ1B
BLM
BOLA2
BUB3
BUD31
CAND1
CBX1
CBX3
CBX5
CDC73
CDK1
CDK2
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CDK5
CDK6
CDK7
CDK9
CHD1
CHD4
CHD8
CLIC1
CLIC4
CUL1
CUL4A
CUL4B
DDB1
DDX23
DDX41
DDX42
DDX46
DHX15
DHX16
DNMT1
DTL
DUT
EP400
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ERCC2
ERCC3
FANCG
FANCI
FEN1
FKBP5
FOXK1
GLRX3
GSTP1
GTF2I
HAT1
HDAC1
HDAC2
HLTF
JADE3
KDM1A
KDM3B
KIF2A
KIFC1
LARP7
MCM10
MCM2
MCM3

341

MCM4
MCM5
MCM6
MCM7
MDN1
MED20
MED23
MLH1
MORC2
MSH2
MSH6
MTBP
MUTYH
NACC2
NASP
NCOR2
NFIC
NOSIP
ORC4
ORC6
OTUB1
PARG
PARP1
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PARP2
PCBP1
PCNA
PDS5A
PGK1
PNKP
PPID
PPIH
PRKDC
PSME3
RAD21
RAD50
RBBP4
RBBP7
RBM12
RBM27
RBM4
RFC1
RFC2
RFC3
RFC4
RFC5
RPP30
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RREB1
SAE1
SART3
SBNO1
SCML2
SET
SF3B2
SIMC1
SKP1
SLFN5
SMC1A
SMC2
SMC3
SMC4
SMC5
SMC6
SMU1
SR140
SRP14
SSRP1
STAT1
SUMO2
TCEA1
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TKT
TOP2A
TOP2B
TRRAP
UBA1
UBE2T
UBR5
WDR82
WIZ
XPO5
XRCC1
XRCC5
XRCC6
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